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RÉSUMÉ
La régulation de la transcription est un processus complexe qui a évolué pendant des millions
d’années permettant ainsi aux cellules de s’adapter aux changements environnementaux. Notre
laboratoire étudie le  rôle de la rapamycine,  un agent immunosuppresseur et anticancéreux, qui
mime la carence nutritionelle. Afin de comprendre les mécanismes impliqués dans la réponse a
la rapamycine,  nous recherchons des mutants de la levure  Saccaromyces cerevisiae qui ont un
phenotype  altérée  envers  cette  drogue. Nous avons  identifié  le  gène  RRD1,  qui  encode une
peptidyl prolyl isomérase et dont la mutation rend les levures très résistantes à la rapamycine et il
semble  que se soit associé à une réponse transcriptionelle  alterée. Mon projet de recherche de
doctorat est  d’identifier  le  rôle  de Rrd1 dans la  réponse à la  rapamycine.  Tout d’abord nous
avons trouvé que Rrd1 interagit avec l’ARN polymérase II (RNAPII), plus spécifiquement avec
son  domaine  C-terminal.  En  réponse  à  la  rapamycine,  Rrd1  induit  un  changement  dans  la
conformation du domaine C-terminal in vivo permettant la régulation de l’association de RNAPII
avec certains gènes. Des analyses  in vitro ont également  montré que cette action est directe et
probablement liée à l’activité isomérase de Rrd1 suggérant un rôle pour Rrd1 dans la régulation
de la transcription. Nous avons utilisé la technologie de ChIP sur micropuce pour localiser Rrd1
sur la  majorité  des gènes  transcrits  par  RNAPII et  montre que Rrd1 agit  en tant  que facteur
d’élongation  de  RNAPII.  Pour  finir,  des  résultats  suggèrent  que  Rrd1  n’est  pas  seulement
impliqué dans la réponse à la rapamycine mais aussi à differents stress environnementaux, nous
permettant ainsi d’établir  que Rrd1 est un facteur d’élongation de la transcription requis pour la
régulation de la transcription via RNAPII en réponse au stress. 
Mots clés: ARN polymérase II, rapamycine, peptidyl-prolyl isomérase, Immuno-precipitiation de
chromatine sur micropuce, régulation transcriptionelle, élongation
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ABSTRACT
Transcriptional  regulation  is  a  complex  process  that  has  evolved  over  millions  of  years  of
evolution. Cells  have  to  sense  environmental  conditions  and  adapt  to  them by  altering  their
transcription.  Herein,  we study the role  of rapamycin,  an immunosuppressant  and anticancer
molecule  that  mimics  cellular  starvation.  To  understand  how  the  action  of  rapamycin  is
mediated, we analyzed gene deletion mutants in the yeast Saccharomyces cerevisiae that have an
altered response to this drug. Deletion of  RRD1, a gene encoding a peptidyl prolyl isomerase,
causes  strong  resistance  to  rapamycin  and  this  was  associated  with  a  role  of  Rrd1  in  the
transcriptional response towards rapamycin. The main focus of my PhD was therefore to unravel
the role of Rrd1 in  response to rapamycin.  First, we discovered that Rrd1 interacts with RNA
polymerase II (RNAPII), more specifically  with its C-terminal domain and we showed that in
response to rapamycin,  Rrd1 alters the structure of this C-terminal domain. This phenomenon
was confirmed to be directly mediated by Rrd1 in vitro, presumably through its peptidyl prolyl
isomerase activity.  Further, we demonstrated that Rrd1 is capable of altering the occupancy of
RNAPII on genes  in vivo and in vitro. With the use of ChIP on chip technology, we show that
Rrd1 is  actually  a  transcription elongation factor that  is  associated with  RNAPII on actively
transcribed  genes.  In  addition,  we  demonstrate  that  Rrd1  is  indeed  required  to  regulate  the
expression of a large subset of genes in response to rapamycin.  This data let us propose a novel
mechanism  by  which  Rrd1  regulates  RNAPII  during  transcription  elongation.  Finally,  we
provide evidence that Rrd1 is not only required for an efficient response towards rapamycin but
to a larger variety of environmental stress conditions, thus establishing Rrd1 as a transcriptional
elongation factor required to fine tune the transcriptional stress response of RNAPII. 
Keywords: RNA polymerase II, transcriptional regulation, peptidyl prolyl isomerase, Chromatin
immunoprecipitation and chip analyis, elongation, rapamycin
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11 INTRODUCTION 
The transcription of mRNA encoding for proteins from template DNA is a phenomenon
that is required for the most basic forms of life, from simple to complex organisms. Transcription
has to be regulated, meaning that the right mRNA has to be produced in the right amount, at the
right moment and if possible without mistakes. Thus, in response to every possible condition, a
cell  must  precisely  control the production of specific  mRNAs.  To perform such an enormous
task, various levels of transcriptional regulation have evolved, where multiple factors influence
transcription at virtually every step of the process. One can imagine that a failure of this highly
regulated process is not compatible  with life  and can lead to a multitude of diseases including
different  forms  of  cancer.  Therefore,  studying  this  fundamental  process  will  lead  to  further
understanding of life as well as pathologies and disease treatment. 
 An outline  of the basic  steps of transcription,  its general regulation as well as more specific
regulatory mechanisms  in  response  to  different  cellular  conditions  will  be  described  in  this
section. The second part of this article  will  then focus on the functions of the peptidyl prolyl
isomerase Rrd1, which we have now shown to play a role in transcription.  
1.1 Transcription
1.1.1 Gene conservation during evolution 
During  the long  evolutionary process from yeast  to man,  the signaling  pathways  that
mediate transcription and other relevant processes described here, have undergone some changes
and as genes evolved, some were replaced or new genes with additional functions were created.
Since the thesis focuses only on work in yeast, a table detailing the conservation of the genes
(comparison of the  S.cerevisiae and human genome)  that are described in  the introduction is
provided below. 
 If the gene is not found in one or the other genome it is labeled as not determined (N.D.), which
could mean that this gene is not (yet) discovered, that it  is  not conserved, or it  was created in
later stages of evolution and is not present in S.cerevisiae.  
1
Class
Mammalian
gene Yeast gene brief description 
RNAPII   RNA polymerase II consists of 12 subunits 
 hRpb1 Rpb1 yeast major subunit of RNAPII contains the C-terminal domain 
 hRpb2 Rpb2 yeast second larbest subunit of RNAP II , is also part of the active site 
 hRpb3 Rpb3 orthologue of the alpha factor of the bacterial RNAP together with Rpb11
 hRpb4 Rpb4 forms a subcomplex with Rpb7 and is involved in the stress response
 hRpb5 Rpb5 shared subunit of RNAPI, II and III is required for transcription activation
 hRpb6 Rpb6 shared subunit of RNAPI, II and III is required for assembly and stability of the complex
 hRpb7 Rpb7 form a subcomplex with Rpb4
 hRpb8 Rpb8 shared subuit of RNAPI, II and III, binds to oligonucleotides
 hRpb9 Rpb9 contains a zinc binding motif, supposed to be involved in elongation and start site selection
 hRpb10 Rpb10 shared subunit of RNAPI, II and III 
 hRpb11 Rpb11 orthologue of the alpha factor of the bacterial RNAP together with Rpb3
 hRpb12 Rpb12 shared subunit of RNAPI, II and III 
GTFs    
TFIID TBP Spt15 TATA-binding protein
 TAFII250 TAFII145/130 Involved in promoter binding, G1/S progression; histone acetyltransferase; kinase (human)
 CIF150 Tsm1 Involved in promoter binding; mutations arrest in G2/M of cell cycle (yeast)
 TAFII130/135 N.D. Involved in interaction with activators
 TAFII100 TAFII90 Mutations can cause arrest in G2/M of cell cycle (yeast)
 TAFII70/80 TAFII60 Similar to histone H4; binds downstream promoter elements (DPEs) (Drosophila)
 TAFII31/32 TAFII17 Similar to histone H3; interacts with p53
 TAFII20 TAFII68/61 Similar to histone H2A
 TAFII15 N.D. Similar to histone H2A; highly similar to TAFII20
 TAFII28 TAFII40 Similar to histone H3; contains atypical histone fold motif seen in Spt3-like transcription factors
 TAFII68 N.D. Contains consensus RNA binding domain; can bind RNA and ssDNA;
 TAFII55 TAFII67 Interacts with numerous activators
 TAFII30 TAFII23/25 Mutations can cause arrest in G1/S of cell cycle (human)
 N.D. TAFII47 No homologous subunit identified in metazoans
 N.D. TAFII30 Shared with TFIIF (yeast), no homologous subunit identified in metazoans
 TAFII18 TAFII19 Similar to histone H4; contains atypical histone fold motif seen in Spt3-like transcription factors
 TAFII105 N.D. B-cell specific; related to TAFII130; co-activator for NF-kappaB
TFIIA TFIIAα Toa1 Involved in transcriptional coactivation; involved in stabilizing TBP-DNA interactions
 TFIIAβ N.D. TFIIAα and TFIIAβ result from processing of a single peptide that is homologous to Toal.
 TFIIAγ Toa2
Involved in activator interactions, TFIIA-mediated antirepression, stabilizing TBP-DNA
interactions
TFIIB TFIIB Sua7 Involved in start site selection, promoter binding and promoter bending during initiation
TFIIF RAP74 Ssu1 Makes extensive contacts with DNA to position the template during initiation
 RAP30 Tfg2 Binds RNA polymerase II and suppresses non-specific DNA binding
 N.D. Anc1 Common component of yeast TFIID, TFIIF, and Swi/Snf; similar to ENL and AF-9 proteins
TFIIE TFIIEa Tfa1 Interacts with TFIIH; involved in recruitment, stimulation of TFIIH and promoter opening
 TFIIEb Tfa2 Double strand DNA binding activity
TFIIH p62 Tfb1 Required for nucleotide excision repair; target for activators
 p52 Tfb2 Required for nucleotide excision repair
 MAT1 Tfb3 Required for nucleotide excision repair; MAT1/Cdk7/cyclin H form the CAK subcomplex (human)
 p34 Tfb4 Required for nucleotide excision repair
 XPD/ERCC2 Rad3 5′–3′ DNA helicase; ATPase; required for DNA repair
 p44 Ssl1 Required for nucleotide excision repair; involved in DNA binding and stimulation of XPD activity
 XPB/ERCC3 Ssl2 3′–5′ DNA helicase; ATPase; essential for promoter opening and promoter escape
 Cdk7 Kin28 Kinase subunit of cyclin-dependent CTD kinase; Kin28 & Cell form the TFIIK subcomplex (yeast)
 CyclinH Ccl1 Cyclin subunit of cyclin-dependent CTD kinase
SAGA PCAF Gcn5 histone acetyl transferase catalytic unit, acetylates histone H2B and H3
 ADA1 Ada1 adaptor protein required for structure of SAGA
 ADA2b Ada2 component of SAGA
 ADA3 Ada3 transcriptional regulator of SAGA
2
2
 ND Spt8 component of SAGA
 SPT20 Spt20 component of SAGA
 SPT7/ Spt7 component of SAGA, required for assembly 
 SPT3 Spt3 component of SAGA required for transcriptonal activation
 TAFII70/80 TAFII60 TBP associated factor present in SAGA and TFIID
 TAFII100 TAFII90 TBP associated factor present in SAGA and TFIID
 TAFII32 TAFII17 TBP associated factor present in SAGA and TFIID
 TAFII30 TAFII23/25 TBP associated factor present in SAGA and TFIID
 TAFII20 TAFII61 TBP associated factor present in SAGA and TFIID
 TRRAP Tra1 coactivator protein of SAGA and NuA4 histone acetylase complex
 SGF29 Sgf29 component of SAGA
 USP22 Ubp8 ubiquitin protease required for deubiquitination of histone H2B
 ATXN7L3 Sgf11 associates Ubp8 to SAGA
 ENY2 Sus1 required for mRNA export and transcription elongation component of SAGA
 ATXN7 Sgf73 component of SAGA required for PIC assembly
 ND Chd1 chromatin remodeling factor associated with SAGA
TFIIS TFIIS Dst1 Transcription elongation factor, restarts RNAPII after arrests, mRNA cleavage stimulatory activity
DSIF DSIF Spt4, Spt5 elongation factor composed of Spt4 and Spt5
 NELF N.D. negative tanscription elongation factor 
FACT SSRP1 Spt16 facilitates chromatin transcription , heterodimer, remodels chromatin during transcription
 SUPTH16 Pob3 facilitates chromatin transcription , heterodimer, remodels chromatin during transcription
 Paf1 Paf1 RNAP II associated factor, assists in transcription elongation 
  Def1 RNAP II degradation factor 
CTD   kinases and phosphatases of the RNAPII CTD
 Cdk7 Kin28 RNAPII CTD kinase phosphorylates serine 5 and serine 7 , part of TFIIH 
 PTEFb Ctk1 RNAPII CTD kinase phosphorylates serine 2  
 Fcp1 Fcp1 RNAPII CTD phosphatase that dephosphorylates serine 2  
 Ssu72 Ssu72 RNAPII CTD phosphatase that dephosphorylates serine 5 
DNA
repair    
 CSA Rad28 cocayne syndrome factor A 
 CSB Rad26 cocayne syndrome factor B 
 XPA Rad14 NER factor recognizes and binds damaged DNA
 XPF Rad1 NER factor single strand endonuclease
 XPG Rad2 NER factor single strand endonuclease
PP2A    
 α4 Tap42 PP2A associated protein involved in Tor1 signalling (yeast)
 PPP4C Pph3 PP2A like phosphatase involved in DNA repair
 PTPA Rrd1 PP2A phosphotase activator
 PPP6C Sit4 PP2A related phosphatase
 Pin1 Ess1 PPIase in yeast homologue of Pin1
 N.D. Rrd2 resistant to rapamycin deletion 2 paralogue of Rrd1 in yeast
 PPP2CA Pph21 PP2A catalytic subunit redundant with PPH22
 PPP2CA Pph22 PP2A catalytic subunit redundant with PPH21
 N.D. Ppg1 PP2A like phosphatase involved in glycogen metabolism
PPiases    
 Pin1 Ess1 Parvulin family member, isomerizes phospho-prolines, involved in multiples diseases
 PTPA Rrd1 the new familiy of PPIases, so far known to regulate PP2A phosphatase complexes 
 FKBP1A Fpr1 FKBP binding protein, binds to FK506 and Rapamycin , involved in protein folding
 CypA Cpr3 Cyclophilin family member, binds to cyclosporin, involved in protein folding 
TOR   TOR signaling pathway
Torc1 mTOR Tor1 PI3like kinase that controls growth in response to nutrient , is inhibited by rapamycin
 N.D. Tco89 part of Torc1 complex
 MLST8 Lst8 part of Torc1 and 2 complex
 Raptor Kog1 controler of growth protein 1 part of the Torc1 complex
Torc2 mTOR Tor2 PI3like kinase that controls spatial growth is not inhibited by rapamycin
 hSin1 Avo1 Torc2 associated factor
3
3
 N.D. Avo2 Torc2 associated factor
 rictor Avo3 Torc2 associated factor
 mLST8 Lst8 part of Torc1 and 2 complex
 N.D. Bit61 binding partner of Tor2
Npr1 N.D. Npr1 kinase that prevents nitrogen permease degradation
Mep2 N.D. Mep2 ammonium permease induced by NCR
TFs   Transcription factors 
 N.D. Msn2/Msn4 Stress response transcription factors , binds to STRE elements
 N.D. Rtg1/2 retrograde signaling transcription factors
 N.D. Gal4 Galactose regulation transcription factor
 N.D. Gln3 Nitrogen discrimination transcription factor
 N.D. Fhl1 binds to ribosomal genes and activates transcription 
 N.D.  Ifh1 transcriptional activator for ribosomal gene expression
 N.D. Crf1 transcriptional repressor for ribosomal gene expression
1.1.2 The transcriptional machinery 
Transcription is the process by which RNA is synthesized in a DNA-dependent manner.
It  is  similar  to  the  replication  of  DNA,  as  it  makes  use  of  a  polymerase,  synthesis  is
unidirectional and DNA is used as a template.  The process can be divided into three distinct
phases: initiation, elongation and termination. Unlike DNA replication, the polymerase does not
need a primer but binds to specific sequences called promoters. These promoters will then drive
the transcription of the gene downstream of the promoter [1].
The RNA polymerase dissociates the DNA duplex and forms a transcription bubble in which one
of the separated DNA strands becomes the template for the RNA strand, forming a short DNA-
RNA  hybrid.  This  hybrid  dissociates  as  the  polymerase  advances  and  the  DNA  strands
reassociate, closing the bubble.   In eukaryotes three different  RNA polymerases (RNAP) have
been identified and were named RNAPI, RNAPII and RNAPIII. Each RNAP produces specific
types of RNAs: RNAPI drives the expression of only rRNA, namely 5.8S, 28S and 18S rRNA,
which  is  required for  the synthesis  of the large  and  small  subunit  of the ribosome  [1].  The
eukaryotic  rRNA genes  are  arranged  in  tandem repeats  and  form a  few clusters  within  the
genome. rRNA transcription accounts for about 50% of the total RNA produced in  a cell  [2].
RNAPIII transcribes tRNA and 5S rRNA. tRNAs are cruciform transfer RNAs which become
covalently linked to a specific amino acid.  They enter the ribosome and add this amino acid to a
growing chain of polypeptides in a sequence specific  manner during the translation of mRNA.
The 5S rRNA is another part of the ribosomal complex [1].  RNAPII transcribes mRNA as well
as different small RNAs including spliceosomal small nuclear RNAs (snRNA), small nucleolar
RNAs (snoRNA), microRNA precursors and cryptic unstable transcripts (CUT) [3]. mRNAs  are
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processed  and  driven  to  a  ribosome  to  be  translated  into  a  protein,  whereas  snRNAs  have
multiple  functions in mRNA maturation, formation of heterogenous nuclear ribonucleoproteins
(hnRNP), ribozymal activity, transcriptional regulation and telomere maintenance [1]. 
1.1.2.1 RNAPII structure 
 Eukaryotic  RNAPII is  a holoenzyme  consisting  of 12 individual  proteins.  It  is  highly
conserved  among  eukaryotes  and the crystallization of the yeast  RNAPII has  provided deep
insights into the structure and function of this enzyme [4-6].
The largest subunit in yeast is called Rpb1, is homologous to the bacterial RNA polymerase and
with Rpb2, the second largest unit, forms the central core of RNAPII. Within this core is located
the active  center,  surrounded by a mobile  clamp  and the inner  structure termed the cleft.  In
addition, a pore provides access from the outside to the active center [4-6].  
During transcription initiation, the double stranded DNA is separated and the template strand is
inserted into the cleft  of RNAPII. In the active center the ribonucleotide complementary to the
open DNA strand is  then linked to the growing mRNA chain  [4-6]. The resulting DNA-RNA
hybrid leaves the active center through the pore, where it is then separated. The two loose DNA
strands reform a duplex and the mRNA strand will  be  processed by additional factors  [4-6].
Additionally,  Rpb1  contains  a  mobile  structure  called  the  jaw  that  is  required  for  efficient
binding  to the DNA strands.  Finally,  Rpb1 also contains  a unique C-terminal  domain  (CTD)
which consists of a highly conserved heptapeptide (YSPTSPS) that is repeated 26 times in yeast
and up to 52 times in  mammalian  cells  [4, 7-9]. This  CTD has multiple  roles throughout the
transcriptional process which will be discussed in detail in section 1.1.6.
It is  noteworthy that, overall,  the three different  RNAPs have a similar  structure within their
catalytic  center  as  was  revealed  by  structural  experiments  [10,  11].  However,  they  acquire
different transcriptional properties because they associate with different subunits attached to their
core enzyme. Notably, RNAPIII and RNAPI have additional subunits that are required for their
transcriptional  initiation  and  recruitment  to  the  specific  promoters  [10,  11].  These  different
compositions also allows for the specificity of the type of RNA transcribed by each RNAP. The
transcription factors (specific  for each type of RNA) recruit only the RNAP which is associated
with its unique subunits that recognize these transcription factors [10, 11]. 
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1.1.2.2 Transcription factors 
RNAPII  itself  does  not  recognize  promoters  and  is  instead  recruited  by  a  series  of
accessory proteins called transcription factors during transcription initiation [12].  Transcription
factors  are  proteins  that  modulate  the  transcriptional  process.  One  can  distinguish  between
general  transcription  factors  (GTFs),  positive  transcription  factors  (activators)  and  negative
transcription factors (repressors). GTFs are required for the assembly and recruitment of RNAPII
at  the  promoter  as  well  as  for  transcription  initiation.  Stemming  from 30 years  of  in  vitro
transcriptional studies, a model for the stepwise recruitment of the RNAPII machinery has been
established. The first step is the formation of the pre-initiation complex (PIC), in which a GTF
called the TATA box binding protein (TBP) binds to the promoter (Figure 1). TBP specifically
recognizes  the  TATA  box,  a  sequence  rich  in  thymine  and  adenine  upstream  of  the
transcriptional start site (TSS) of the gene. Around 20 % of genes contain a TATA box, but the
position of this box with respect to the TSS varies. The consensus sequence of the TATA box in
yeast  is  TATA(A/T)A(A/T)(A/G) [13]. However,  TBP also binds  to promoters which do not
contain a TATA box. TBP is part of a multiprotein complex composed of TBP associated factors
(TAFs) collectively termed TFIID. This DNA-protein complex recruits TFIIA, which stabilizes
the complex and recruits TFIIB, which is required for the recognition of the TSS. TFIIF, TFIIE
and TFIIH are then recruited [12, 14] (Figure 1). TFIIE reorganizes the structure of RNAPII by
modifying  the jaw-like structure from a closed to an open position. TFIIH has three important
functions: (i) its helicase activity unwinds and separates the DNA duplex; (ii) it ensures that the
correct DNA strand is transcribed, and (iii) it phosphorylates the CTD of RNAPII on serine 5 of
heptapeptide repeats. This forms the complete PIC, which is ready to initiate transcription [12,
14] (Figure 1).
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Figure 1 Pre-initiation complex formation at the promoter 
(Molecular Biology of the Cell)
Activators and repressors regulate the recruitment of the PIC complex. Most activators are DNA
binding  proteins  that  recognize  specific  sequences  within  the  promoter  or  within  upstream
activation sequences  (UAS),  which  are located distantly  from the promoter.  These activators
recruit  large  co-activator  complexes  as  well  as  ATP  dependent  nucleosome  remodeling
complexes,  both of which remodel and render the local DNA accessible.  This can be done by
two mechanisms, one by weakening the nucleosome-DNA interactions through acetylation of the
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histone tails, and second by actively removing the histones from the DNA. As a consequence the
TATA box and the transcriptional start site become more accessible to GTFs, allowing assembly
of the PIC [15].  Activators can also directly bind to GTFs to promote PIC assembly,  although
both mechanisms of GTF recruitment are probably interrelated [12, 14]. 
Transcriptional repressors can inhibit  the PIC formation in different  ways,  by competing with
activators  for  the  same  sequence,  by  directly  inhibiting  GTF  recruitment,  or  by  recruiting
chromatin  modifying  enzymes  such as histone deacetylases  (HDAC)  to the promoter region.
These HDAC complexes deacetylate histones, resulting in a more compact and less accessible
form of chromatin.
In  addition,  the  mediator,  a  large  complex  of  20  polypeptides,  mediates  the  interaction  of
activators  with  RNAPII.  It  bridges  distant  activator  sites  with  the  PIC at  the  promoter  and
stimulates transcription. More precisely,  it  interacts directly with the CTD of RNAPII and can
therefore mediate  signaling  from the activator directly to RNAPII.  It  is  composed of several
modules, which can vary depending on the cellular conditions and can provide an interface for
integration with additional signaling pathways. Thus, the mediator provides an additional target
for transcriptional regulation [12, 14]. The balance between activators and repressors allows for
the integration of different signaling pathways towards the decision of PIC assembly.  Once the
PIC has been assembled successfully, transcription initation can take place [12, 14]. 
1.1.3 Transcription initiation 
Once the PIC is  assembled, TFIIH, with the help of TFIIE, recruits RNAPII onto the
DNA template. This conformation is termed the open complex and once it  is formed, RNAPII
becomes ready to initiate  transcription.  Upon phosphorylation of serine  5, RNAPII clears the
promoter. During transcription of the first  2-15 nucleotides,  the process is  often abortive and
RNAPII restarts a new round of initiation. However, once the first 15 nucleotides are transcribed,
RNAPII escapes the promoter and enters the processive phase of transcription elongation.
In addition, RNAPII dissociates from the GTFs TFIID, TFIIA, TFIIB and the mediator, which
remain bound to the promoter. These GTFs then allow for formation of a new PIC, leading to
rapid subsequent rounds of transcription [12, 14]. Elongation factors (EFs) then associate with
RNAPII to regulate transcription elongation [12, 14]. 
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1.2.4 Transcription elongation 
The elongation process is  complex and involves multiple  factors, which are exchanged
during elongation. For simplicity, the role of each elongation factor will be described separately.
1.1.3.1 SAGA 
SAGA stands for Spt–Ada–Gcn5 acetyltransferase and is a multiprotein complex which has
multiple  roles during  transcription.  First,  like  TFIID, it  can bind  to TBP and be recruited to
promoters [16-18]. Also, like TFIID it contains histone acetyl transferase activity and is able to
recruit RNAPII and initiate transcription. Both complexes contain shared subunits necessary to
associate with TBP, the TAFs [17]. TFIID and SAGA together are essential for gene expression
of RNAPII but each of them is required for different gene sets. Notably, TFIID expresses house
keeping genes and dominates up to 90% of all genes expressed whereas SAGA is required for
stress regulated genes and is important for only 10% of the genes [16]. Interestingly,  SAGA has
additional roles which include regulating transcriptional elongation and linking transcription to
mRNA nuclear export. It is thought that SAGA associates through the serine 5 phosphorylated
CTD of RNAPII, remains associated during elongation and enhances this step through different
mechanisms,  notably  by  acetylating  histones  and  deubiquitinating  histone  H2B  [18].
Furthermore,  SAGA is  thought  to  assist  in  mRNA export  through some  of its  subunits  that
recruit mRNA export factors and bring the transcription site close to nuclear pores, favoring a
rapid export [18]. 
1.1.3.2 TFIIS
TFIIS is the first elongation factor that was found to interact with elongating RNAPII and
is  thought  to promote elongation.  TFIIS co-localizes  with elongating RNAPII  throughout the
gene and  can stimulate the intrinsic  mRNA cleavage activity of RNAPII by reaching  into its
active center and altering its structure  [19-21]. This activity is important when RNAPII stalls.
RNAPII may arrest at each step of nucleotide addition. The time of arrest is variable and depends
on nucleotide availability and the sequence of the DNA template. Drugs that diminish the overall
nucleotide  pool,  such as  mycophenolic  acid  (MPA)  and 6-Aza  uracil  (6AU)  (both of which
inhibit  GTP synthesis,)  increase RNAPII arrests. If GTP synthesis is inhibited,  the nucleotides
UTP  and  GTP  are  depleted  and  RNAPII  cannot  insert  the  complementary  nucleotides  and
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therefore  stops transcribing  the  genes  [22,  23].  In  addition,  the  sequence  context  influences
RNAPII  arrest  by  affecting  the  stability  of  the  RNA-DNA  hybrid.  AT-rich  sequences  are
particularly  weak  and  cause  RNAPII  arrest[22].  Upon  arrest,  RNAPII  may  backtrack  2-4
nucleotides. When RNAPII backtracks more then 7-15 nucleotides, it typically stalls irreversibly,
unless TFIIS stimulates the restart of RNAPII by cleaving the mRNA [20-22] 
1.1.3.3 TFIIF, Elongin, Ell and Csb
TFIIF,  Elongin,  Ell  and  CSb  are  additional  factors  that  also  influence  the  rate  of
transcription elongation by regulating  the pausing  of RNAPII  during  elongation  [12].  These
factors will be discussed in more detail in section 1.1.7.
1.1.3.4 PTEFb
PTEFb is a cyclin  dependent  kinase (named Ctk1 in  yeast).  It is  a positive elongation
factor  that  phosphorylates  RNAPII  during  elongation  on  serine  2  of  the  CTD.  PTEFb
phosphorylates serine 2 after RNAPII enters the processive  phase of elongation and, serine  2
remains  phosphorylated  until  termination  [7-9].  Serine  2  phosphorylation  has  several
consequences which will be described in more detail in section 1.1.6. 
1.1.3.5 The Paf1 complex 
The Paf1 complex is  another positive elongation complex associated with RNAPII that
was initially found as being essential for the expression of some genes. It is present in yeast and
higher eukaryotes including  mammalians.  Paf1 physically  and genetically  interacts with other
elongation  factors  such  as  FACT  and  DSIF,  and  has  multiple  roles  including  chromatin
modifications during elongation and mRNA processing [24]. It was proposed that Paf1 acts as a
platform for the recruitment of other elongation factors to RNAPII [25].
1.1.3.6 DSIF and NELF
In higher eukaryotes, DSIF consists of a heterodimer of Spt4 and Spt5, and is thought to
negatively regulate elongation. NELF is a multiprotein complex that interacts with DSIF and is
also  required  for  DSIF  function.  Together,  they  slow  down  the  elongation  rate  in  vitro,
counteracting the positive elongation effect of PTEFb [26]. In addition, they inhibit  the mRNA
cleavage activity of TFIIS when RNAPII stalls. In yeast, DSIF is named and composed of Spt4
and  Spt5 and they positively  influence  transcription.   However,  NELF is  not found  in  yeast
suggesting that it has evolved later during evolution [26].
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1.1.3.7 Elongator and FACT
DNA is wrapped around nucleosomes and this inhibits transcription elongation, since it
acts as a physical barrier for RNAPII processivity.  To overcome this nucleosome barrier,  the
evolutionarily conserved complexes Elongator and FACT promote elongation by remodeling the
chromatin as RNAPII slides along the DNA. Elongator contains a histone acetyltransferase that
co-transcriptionally acetylates histones H3 and H4, which in turn diminishes  the histone-DNA
interaction and opens the chromatin [27].
FACT  is  a  chromatin  remodeling  complex  which  removes  the  H2A-H2B  dimers  of  the
nucleosomes  ahead  of  RNAPII  in  order  to  facilitate  RNAPII  movement.  After  passage  of
RNAPII, the nucleosomes are then restored by FACT [28]. 
1.1.3.8 CTD-phosphatases 
During  transcriptional  initiation  at  the  promoter,  the  CTD  of  RNAPII  is  highly
phosphorylated on serine 5 by Kin28 which is part of TFIIH (see section 1.1.2.2), but serine 5
becomes progressively dephosphorylated in the body and end of the gene. In contrast, PTEFb
phosphorylates serine 2 progressively after RNAPII leaves the promoter and until it reaches the
end  of  the  gene  (see  section  1.1.4.4).  After  the  round  of  transcription  RNAPII  becomes
dephosphorylated  on  serine  2.  Several  phosphatases  mediate  these  dephosphorylations.  The
Ssu72 phosphatase is  a component of the mRNA processing machinery that dephosphorylates
serine 5 once RNAPII is processively elongating [7-9, 26]. More recently, another phosphatase,
Rtr1, was shown to be required to dephosphosphorylate the serine 5-phosphorylated form and
thus favor the serine 2-phosphorylated form of the CTD.
 Finally,  to  restore  the  unphosphorylated  form of  the  CTD at  the  end  of  the  gene,  Fcp1
phosphatase dephosphorylates serine 2 during transcription termination. This allows RNAPII to
reinitiate a new round of transcription [7-9]. 
It was long thought that transcription elongation was a simple processive step regulated only by
PIC assembly.  However,  during the last  decade, research in  this  field  has clearly  shown that
multiple  factors regulate  the transcription elongation process at  multiple  levels.  Most  studies
have  been  performed  in  vitro,  and  only  recently  has  chromatin  immunopreciptiation  (ChIP)
allowed gene-specific  analysis  in vivo.  The precise  mechanisms  underlying  how these factors
interact together  in vivo remains to be elucidated [29]. However, it  seems that their concerted
action regulates at least two crucial events during elongation: 
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a) mRNA processing 
The  processing  and  maturation  of  nascent  mRNA  occurs  cotranscriptionally.  For
example,  the  capping  enzyme  is  recruited  to  the  CTD upon serine  5  phosphorylation  and
mediates  the  cotranscriptional  capping  of  the  5’  end  of  the  mRNA  chain  [30].  3’  mRNA
processing also takes place during transcription and is regulated by proteins which are recruited
to the CTD, such as the PAF complex [24]. In addition, the spliceosome, a ribonucleoprotein
complex, is recruited during the elongation process to mediate alternative splicing of the mRNA
[30]. Finally,  it  has even been shown that mRNA export from the nucleus and translation are
regulated during elongation [31, 32]. Taken together, it  seems that all  known mechanisms  of
mRNA processing are linked to active transcription. 
b)  Cotranscriptional chromatin modification  
As discussed above, the positive elongation factors FACT and Elongator facilitate  the
passage  of RNAPII  through the chromatin.  However,  once  RNAPII has  moved through the
gene, the initial chromatin state must be restored; otherwise, the transcriptional machinery can
be inappropriately recruited to “open chromatin” within the body of the gene. This is referred to
as cryptic  initiation [33].  To restore the initial  chromatin  state and to protect against  cryptic
initiation,  an  HDAC  complex  is  recruited  to  de-acetylate  the  nucleosomes  after  passage  of
RNAPII. To accomplish this, the histone methyltransferase Set2 is recruited by phosphorylated
serine  2  on the CTD and methylates  histone  H3 on lysine  36. This  methylation allows  the
recruitment of the Rpd3 HDAC complex, which then deacetylates histones to restore a closed
chromatin state [34, 35]. 
Chromatin modifications during transcription are also important for the recruitment of mRNA
processing factors during transcriptional initiation. At every actively transcribed gene, lysine 4
of histone H3 is  heavily  methylated  at  the promoter by the histone  methyltransferase  Set1,
which  is  recruited by  phosphorylated serine  5  on the CTD. This  mark  is  thought  to  recruit
mRNA processing factors to the initiating RNAPII. [34].  
1.1.4 Transcription termination and polyadenylation 
The  end  of  a  gene  is  marked  by  a  transcription  termination  site  (TTS),  which  is
specifically recognized by the ribosomal machinery [1]. However, at this site, RNAPII continues
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transcribing  the  template  strand  and  since  there  is  no  conserved  signal  for  transcription
termination,  it  can  occur  variably  anywhere  ranging  from  a  mere  few  to  thousands  of
nucleotides after the 3’ end of the mature mRNA [3, 36]. As well,  shortly after the TTS lies a
specific polyadenylation element (AAUAAA). This and a second (GU rich) element, determine
where the mRNA is cleaved off from RNAPII and where the poly(A) tail will be added [37]. For
this, the cleavage specificity and polyadenylation factor (CSPF) travels along with elongating
RNAPII. At the end of the gene a large polyadenylation complex is recruited, that contains the
poly(A)  polymerase (PAP), the poly(A)  binding  protein (PABP) as well as additional factors
required  for  efficient  cleavage   (CstF,  CFI  and  CFII)  [37,  38].  This  complex  mediates  the
cleavage of the pre-mRNA from the still transcribing RNAPII. PAP, then, extends the poly(A)
tail by adding adenines to it. PABP binds to this elongating poly(A) tail.  This poly(A) tail and
the associated factors have the important function of regulating mRNA stability by inhibiting 3’
exonucleases that chew off the tail in the cytoplasm [37-39]. 
The RNAPII  continues  transcribing  after  the mRNA has  been  cleaved  off  and  needs  to  be
released from the DNA. For this, two models  of termination have been proposed and current
evidence suggests that termination might  occur through a combination of both. First, the anti-
terminator or allosteric model postulates that transcription of the polyadenylation signal induces
a structural change  in  RNAPII  and  the  elongation complex,  causing  them to dissociate  and
recruit termination factors. The second model is called the torpedo model and is based on the
observation that the 3’ mRNA is  rapidly degraded after cleavage of the polyadenylation site
from the mRNA. The cleavage recruits a 5’-3’ exonuclease which degrades the 5’ end of the
uncapped mRNA associated with  RNAPII,  and when it  rejoins  the elongating  RNAPII,  this
exonuclease dissociates the complex from the DNA and terminates transcription [3, 36].  
A different termination mechanism occurs during snoRNA and snRNA transcription, since these
RNAs are not polyadenylated. This mechanism involves Nrd1, a protein complex that binds to
the serine 5-phosphorylated form of the CTD. Nrd1 regulates recruitment of termination factors
as well as the exosome, an mRNA processing complex [3]. 
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1.1.5 A central role of the RNAPII CTD during transcription 
As discussed previously,  the CTD is phosphorylated differentially along the transcription
cycle.  The  CTD  phosphorylation  pattern  distinguishes  between  the  different  states  of
transcription. A hypophosphorylated form of RNAPII is recruited to the promoter and is found
during  PIC assembly  (figure  2).  Then,  during  open complex  formation,  the  CTD becomes
hyperphosphorylated on serine 5 and RNAPII enters initiation. Once processive elongation is
underway, serine 2 becomes phosphorylated and serine 5 becomes dephosphorylated. Finally,
when  termination  occurs,  serine  2  is  then  also  dephosphorylated  to  regenerate  the
hypophosphorylated form and prepare for a new round of transcription (figure 2) [7-9, 14, 26]. 
More  recently,  it  was  shown  that  the  CTD  is  also  phosphorylated  on  serine  7.  This
phosphorylation was found to be enriched within the promoter region as well as towards the 3’
end of the gene, following  a pattern similar  to that of serine 2 [40, 41].  Recent  publications
suggest  that  this  phosphorylation is  mediated by TFIIH and  by components of the mediator
complex [42, 43]. A precise role has not yet been characterized; however, enrichment towards
the end of the gene suggests a role in 3’ mRNA processing. Additional research will be required
to understand the precise function of this phosphorylation. 
The CTD has also been shown to be isomerized by peptidyl prolyl isomerases (PPIases). These
enzymes catalyze the cis-trans isomerization of proline residues (see section 1.2.5 and figure 4).
Since the CTD is rich in prolines, their isomerization might affect the binding of proteins to the
CTD and  alter  the  ability  to  phosphorylate  or  dephosphorylate  the  CTD  [7-9,  44,  45].  As
discussed  above,  numerous proteins  have  been shown to bind  to the CTD and any of these
interactions might be regulated by PPIases.  Since the heptapeptide is repeated multiple  times,
this  allows  for  a  high  number  of  different  structural  possibilities.  Therefore  it  has  been
postulated that the RNAPII regulates transcription through a ‘CTD-code’ that is  dynamic  and
changes  as  elongation  goes  on.  This  also  allows  for  tight  regulation  of  the  transcription
elongation process as well as integration of the multiple events, such as mRNA processing and
chromatin remodelling, taking place during mRNA production [7-9]. 
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Figure 2 Transcription cycle of RNAPII
Modified from [8]. RNAPII is recruited as an unphosphorylated form during initation, becomes phosphorylated on
serine 5 during the early elongation phase, then phosphorylated on serine 2 and dephosphorylated on serine 5 during
the late elongation phase. The last step is the transcription termination where RNAPII is dephosphorylated on serine
2.  
1.1.6 RNAPII arrest during transcription 
As RNAPII transcribes the gene, various obstacles can slow down or arrest it. Several
phenomena  may cause RNAPII blockage:  the intrinsic  DNA sequence can cause slippage of
RNAPII, which then backtracks and ultimately arrests [22]. Also, if the chromatin structure in
front of elongating RNAPII is in a repressive state, RNAPII progression can be slowed or even
blocked  [28].  Finally  a  variety  of DNA lesions  can cause  an irreversible  block of RNAPII
progression, such as cyclo butane pyrimide dimers or 6-4 photoproducts generated by UV light
(see also section 1.2.1) [46]. 
A blocked polymerase on a crucial gene can have deleterious effects, if this gene product has
vital cellular  roles.  Cells  have therefore developed multiple  mechanisms  to assist  RNAPII in
overcoming  these  blocks.  To  counter  those  blockages  and  continue  transcription,  RNAPII
recruits  different  factors,  depending  on the specific  situation  [47]. As  mentioned earlier,  the
elongation factor TFIIS is  very important  for  restarting  backtracked and  stalled  RNAPII  by
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stimulating its intrinsic mRNA cleavage activity. Once this mRNA end is clipped off, RNAPII
can restart elongation where it stopped. The importance of TFIIS is emphasized when cells are
challenged with the drug 6-azauracil (6AU). This uracil analog inhibits GTP and UTP synthesis,
decreases their cellular concentration and causes RNAPII to slow down during elongation [48,
49]. TFIIS mutants are highly sensitive to 6AU because TFIIS is crucial for RNAPII to restart
after stalling. In fact, 6AU was used to discover a variety of elongation factors that are required
for RNAPII progression, as mutants of these factors are hypersensitive to this drug [22, 23]. 
Besides TFIIS, there are other elongation factors such as Elongin, TFIIF and ELL that stimulate
the restart of paused RNAPII as shown by in vitro transcriptional systems [12, 47].  
1.1.6.1 Transcriptional blocks caused by DNA lesions
DNA integrity is constantly challenged by lesions caused by endogenous and exogenous
factors, including reactive oxygen species (ROS) generated during normal cellular metabolism,
UV light from the sun, radiation or genotoxic agents. Besides causing gene mutations, deletions
and single strand or double strand breaks that are a major threat to cellular survival, certain types
of lesions also block the progression of RNAPII during transcription. Throughout evolution, cells
have  developed  mechanisms  to  protect  themselves  against  these  deleterious  lesions.  These
include a variety of DNA repair pathways as well as induction of apoptosis when the damage is
not reparable [46, 50] . As mentioned earlier, several lesions can cause a RNAPII blockage, for
example, UV can create cyclobutane pyrimidine dimers (CPD) as well as 6-4 photoproducts (6-
4PP) in DNA, which block RNAPII progression  [51].  Also, bulky adducts in  DNA can cause
RNAPII arrest as they block the active center of RNAPII. Even byproducts of ROS: for example,
malondialdehyde  generated  through  lipid  peroxidation  can  form guanine  adducts  that  block
elongation [46, 50]. In addition, abasic sites are known to block transcription. Abasic sites are
produced  during  a  step  of  the  base  excision  repair  pathway [52].  Some  lesions  that  cause
RNAPII arrest  may simply be bypassed by RNAPII,  although this  can lead to transcriptional
errors [46, 50]. To protect against lesions that cause the stalling of RNAPII during transcription,
a specific  DNA repair pathway is activated. This pathway is called transcription coupled repair
(TCR), and is a sub-pathway of nucleotide excision repair (NER). TCR is one way to recruit the
NER, which alternatively can be recruited by global genomic repair (GGR). In fact GGR and
TCR are two separate mechanisms  of lesion recognition which then use the NER pathway to
repair the lesion [46, 50]. TCR is initiated when CSB (Rad26 in yeast) recognizes and binds to
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stalled  RNAPII  at  the lesion.  CSB is  loosely  associated  with  elongating  RNAPII,  and  upon
stalling, this association becomes tighter and a second TCR factor, CSA, is recruited. Then, the
NER factors that excise  the lesion, XPF, XPG and XPA, are recruited. More precisely,  these
factors  incise  the  lesion  at  the  5’end,  then  the  intact  DNA strand  is  replicated  by  a  DNA
polymerase while the 3’ end of the DNA strand containing the lesion is cleaved off. Finally,  the
newly synthesized strand is ligated and the intact double stranded DNA is repaired [46, 50]. 
1.1.6.2 RNAPII ubiquitylation during transcriptional arrest
 If RNAPII restart fails, an ultimate mechanism is activated that consists of ubiquitylation
and  subsequent  proteasomal  degradation  of  RNAPII.  Ubiquitin  (Ub)  is  a  highly  conserved
polypeptide of 76 amino acids that is covalently linked to lysine residues of the target protein.
The process of ubiquitylation is highly regulated via three factors, the Ub-activating enzyme that
associates to Ub (E1), the Ub-conjugating enzyme E2 that recieves Ub from E1 and adds the Ub
to the substrate, and finally, the Ub ligase E3, which provides substrate specificity and ligates Ub
to the substrate [53]. The substrate often becomes polyubiquitylated, meaning that additional Ubs
are linked to the first, eventually forming an Ub chain. This Ub chain is then recognized by the
proteasome, a large complex responsible  for protein degradation. RNAPII contains two lysine
residues  in  its  major  subunit  Rpb1  that  can  be  ubiquitylated:  K330  and  K695  [54].  The
ubiquitylation process originally  observed in response  to DNA damage seems to be a general
mechanism in response to RNAPII stalling  [53]. For example,  mutant  cells  lacking the TFIIS
gene accumulate high levels  of ubiquitylated RNAPII  when treated with 6AU  [53]. One key
factor required for efficient  RNAPII ubiquitylation is Def1 [55]. The double deletion of DEF1
and  TFIIS is  lethal,  suggesting  that  both  mechanisms--  RNAPII-Ubiquitylation  and  TFIIS-
mediated mRNA cleavage-- are essential for clearing RNAPII arrest. This is further confirmed
by the fact  that the K330R mutation of  RPB1 is  also synthetic  lethal with  TFIIS, and indeed
strains  containing  the  single  deletion  of  DEF1 or  the  K330R  mutation  of  RPB1 are
hypersensitive to 6AU [47]. 
During  TCR, RNAPII is also ubiquitylated by Def1. Interestingly,  CSB inhibits  ubiquitylation
when engaging  the NER pathway.  RNAPII  becomes  ubiquitylated  and  degraded only if  this
repair fails  [55]. Taken together, data suggests that RNAPII ubiquitylation and degradation is a
“last chance” mechanism that is only used when other RNAPII release mechanisms fail [46, 47].
17
17
1.1.7 Transcriptional regulation of RNAPII
Cells  constantly  need  to  sense  and  adapt  to  environmental  changes  so  that  they  can
modify their transcriptional program accordingly. Multiple signaling pathways sense the external
conditions  and  signal  the  nucleus  to  induce  transcription  of the appropriate  genes  for  each
condition.  To achieve  this,  specific  transcription factors  (TFs)  are required  to  regulate  gene
expression. Genes belonging to a similar  pathway are generally regulated by the same TF, and
these  groups  of  genes  are  called  regulons.  For example,  the  galactose  regulon  consists  of
multiple genes regulated by the Gal4 TF in response to galactose. This regulon is then expressed
and allows the cell to produce proteins required for galactose metabolism [56]. 
1.1.7.1 The target of rapamycin (TOR) signaling pathway 
Cells must constantly adapt to the availability of nutrients in the environment.  Nutrient
levels are critical for the decision to grow and multiply or to limit  consumption and metabolism.
A signaling pathway conserved from yeast to human senses nutrients availability  via  the TOR
protein  kinases.  When  nutrients  are  readily  available,  TOR  becomes  active  and  stimulates
transcription of genes involved in anabolic processes, including translation, ribosome biogenesis
and  gene  transcription.  Additionally,  catabolic  processes  such  as  protein  degradation  and
autophagy  are  inhibited. When  nutrients  are  limited,  TOR  becomes  inactive  and  catabolic
processes, stress response genes, and G1 cell cycle arrest is activated whereas anabolic processes
are repressed [57-59]. The TOR kinases are PI3K like kinases and two isoforms (Tor1 and Tor2)
have  been  identified  in  yeast.  Tor1  was  originally  discovered  as  being  inactivated  by  the
immunosuppressant  rapamycin,  a  macrocyclic  lactone  that  was  isolated  from  the  bacteria
Streptomyces hygrocopicus on the Rapa Nui islands.  Tor1 is  associated with several cofactors
including  Kog1,  Tco89,  and  Lst8,  and  together  they  form the  rapamycin-sensitive  TORC1
complex. Tor2 is found in another complex, where it is associated with additional factors Avo1,
Avo2, Avo3, Bit61 and Bit2.  Together they form the rapamycin-insensitive  TORC2 complex
[57, 59]. It  is  thought that the TORC1 complex regulates growth temporally  (i.e. it  makes the
decision of whether the cell should grow and divide),  whereas TORC2 regulates growth in  a
spatial context, meaning that it decides in which direction the cell will grow [57, 59]. 
In yeast, TOR signaling is controlled by amino acid levels, such as the nitrogen rich amino acid
glutamine. In multicellular organisms, additional upstream signals include the insulin  signaling
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pathway and the platelet  derived growth factor [58]. There are several downstream targets of
Tor1, which  will  be  discussed  in  detail  below.  In yeast,  Tor1 signaling,  like  most  signaling
pathways, results in translocation of TFs into the nucleus to alter gene expression. 
1.1.7.1.1 TORC1 regulates transcription of specific regulons 
The first pathway, downstream of TORC1 signaling that was characterized includes the
PP2A-like phosphatase Sit4  and its  regulator Tap42. Under  high nutrient  conditions,  TORC1
maintains Tap42 in a phosphorylated state. Upon amino acid depletion or rapamycin treatment,
TORC1 becomes inactivated and Tap42 is dephosphorylated by PP2A, activating several classes
of genes including stress-regulated (STRE) genes, nitrogen catabolite repressed (NCR) genes and
retrograde signaling (RTG) genes [59, 60] (see figure 3). For example,  Tap42 dissociates from
the Sit4 phosphatase, which in turn becomes activated and dephosphorylates the cytoplasmic TF
Gln3. Gln3 is retained in the cytoplasm in a phosphorylated state when TOR is active.  When
Gln3 becomes de-phosphorylated,  it  moves  into the nucleus  and activates NCR genes,  which
generate nitrogen from proline or urea [61] (see figure 3).
 Similarly,  the TFs Rtg1 and Rtg3 are retained in the cytoplasm in a phosphorylated form and
upon activation of the Sit4 phosphatase; they are dephosphorylated and move into the nucleus to
activate  the  RTG  genes  (see  figure  3) [59,  60].  RTG  genes  are  important  for  the  TCA
(tricarboxylic  acid) cycle, which in turn is crucial for respiration and to mediate the conversion
of nutrients into energy in the mitochondria. In addition, it provides molecules that are important
for  biosynthetic  pathways.  For  example,  α-ketoglutarate  is  a  precursor  of  glutamate  and
glutamine, which in turn are used for nucleotide biosynthesis as well as for nitrogen containing
molecules including NAD+ [62]. 
Finally,  Tap42 is  also  implicated  in  the  transcription  of the  STRE  genes  by  regulating  the
translocation of the TFs Msn2 and Msn4. When Tap42 is active, it inhibits Sit4 and the Msn2/4
TFs  are  exported  from the  nucleus.  When  Tap42  is  inactivated,  the  Sit4  phosphatase  can
dephosphorylate Msn2/4, causing them to stay in the nucleus [60] (see figure 3).  
Msn2/4  binds  to  specific  DNA  sequences  called  stress  response  elements  (STRE).  STRE-
containing  genes are divided of several sub-classes including  carbohydrate metabolism,  genes
required to scavenge reactive oxygen species, protein chaperones such as heat shock proteins and
DNA repair  proteins.  Additionally  in  response  to  stress,  genes  are induced  that  regulate  the
transcriptional  stress  response  with  negative  or  positive  feedback  loops.  For  example,  upon
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induction of stress, transcripton of the Msn4 gene is activated, thus contributing to a faster and
stronger stress response [63].   
Tor1 is  implicated through its regulation of Tap42 in the nuclear retention of Msn2/4, which
keeps STRE gene  transcription active.  However,  Tor1 does not  regulate  the translocation of
Msn2/4 from the cytoplasm to the nucleus,  as has been shown for other transcription factors.
Therefore, additional upstream signaling pathways are required to first mediate the translocation
of Msn2/4 from the cytoplasm to the nucleus in order to activate the STRE response induction
[60]. Next, Tor1 may keep this STRE response active by retaining Msn2/4 in the nucleus. 
Figure 3 regulation of transcription by Tor1 signaling
Transcription factors are regulated by translocation from the cytoplasm to the nucleus in yeast.
1.1.7.1.2 TORC1 regulates ribosome biogenesis
Ribosome  biogenesis  is  crucial  for  cellular  anabolism  and  growth,  which  is  in  turn  a
prerequisite for cell cycle progression. At least 100 protein-coding genes are required as well as
the combined action of the three RNA polymerases. This requires tight regulation, as the process
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expends a large amount of energy [57, 59]. Upon TORC1 inactivation, via rapamycin treatment
or in  response  to  nutrient  limitation,  Tor1 moves  into  the  nucleus  and  inhibits  RNAPI  and
RNAPIII by binding to the promoter of the rDNA genes [64]. To regulate RNAPII ribosomal
gene expression, Tor1 controls the nuclear translocation of Ifh1, a transcriptional activator, and
Crf1,  a  transcriptional  repressor [65-67].  When  Tor1 is  active,  Ifh1  is  associated  to Fhl1,  a
ribosomal gene TF, and together they are bound to ribosomal gene promoters and stimulate their
transcription. When Tor1 becomes inactive, Crf1 is dephosphorylated and enters the nucleus to
compete with  Ifh1  for  binding  to  Fhl1  (see  figure  3).  Once  Crf1 binds  to Fhl1,  it  represses
transcription of the ribosomal genes [67].  This mechanism seems to be specific  to some strain
backgrounds since it  has been demonstrated that in a  crf1Δ  mutant from a W303 background,
ribosomal  genes  are  still  repressed  upon  rapamycin  treatment,  suggesting  that  alternative
mechanisms of ribosomal repression via the Tor signaling pathway must exist [68].
1.1.7.1.3 Differences between mammalian and yeast cells
In  mammalian  cells,  anabolism  is  regulated  through translation  initiation  rather  than
transcription. The S6K kinase and 4EBP-1 are regulated by TORC1 and are responsible for the
regulation of translation initiation and mRNA production [58]. In yeast, there is no homologue of
4EBP-1 and the majority of Tor signaling is regulated through transcription [60]. Only recently
has Sch9, the homologue of the S6K kinase, been identified [69]. Sch9 is required for optimal
ribosomal gene expression and translation of mRNA [70].   
1.1.7.2 The environmental stress response (ESR) 
Yeast  cells  must  constantly adapt to various extracellular  conditions,  which can cause
cellular  stress.  Such  conditions  include  heatshock,  pH variations,  changes  in  osmolarity,  an
increase in reactive oxygen species as well as toxins.  To adapt to these conditions, yeast have
developed  a  rapid  response  termed  the  ESR [63].  Within  this  ESR,  various  sensors  signal
changes to an intracellular signaling pathway, resulting in changes to the transcriptional program.
Around 300 genes are upregulated in response to stress and 600 are repressed [71]. There is a
correlation between the ESR and the severity of the stress, indicating  that the ESR is tightly
regulated [63, 71]. Downregulated genes include those associated with cellular  anabolism and
cell cycle progression as well as genes required for ribosome biogenesis. In contrast, upregulated
genes include the STRE genes induced by the Msn2/4 transcription factors. Interestingly,  not
every  condition  induces  exactly  the  same  response,  and  not  every  branch  of  the  signaling
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pathway is required for every condition [63, 71]. For example,  Sko1 is  only activated during
osmotic  changes  via  the  Hog1  signaling  branch,  and  induces  genes  required  for  osmotic
regulation. Alternatively,  upon oxidative stress, the Yap1 TF is activated to regulate oxidative
stress genes [63, 71]. For DNA damage response, the Mec1 kinase is  activated which in turn
activates  Dun1  to  trigger  the  ESR  [63].  Together  this  suggests  a  network  of  overlapping
signaling pathways that allow for a precise response to each condition [63, 71]. 
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 1.2 Rrd1 and its biological role
1.2.1 Introduction
Our laboratory is  interested in  the cellular  responses  to exogenous stresses caused by
drugs used in clinical therapies. These drugs include various DNA damaging agents as well as
agents  causing  oxidative  stress  or the starvation mimicking  drug rapamycin.  It  is  crucial  to
understand  how  cells  respond  to  drug  treatment  in  order  to  understand  drug  resistance
mechanisms  of cancer  cells.  In addition,  a  better understanding  of cellular  responses to drug
treatment might provide insights into new drug targets and prevent inappropriate treatments. To
study these cellular  responses, yeast is an ideal model as genes can be easily deleted, allowing
the analysis of their functions. Through yeast genetics, major cell activities such as transcription,
cell cycle regulation, replication and DNA repair have been studied [72]. Throughout evolution,
these  pathways have been conserved from yeast to man, which validates the use of yeast as a
model system in current molecular  biology research. The yeast  strain library harbouring each
viable gene deletion (approx. 4800 genes of a total of 6125 genes) which is now available for the
research  community,  allows  for  genome  wide  identification  of  genes  important  for  cellular
responses  to  stresses  [73-76].  In  order  to  study  these  responses,  several  ‘model’  drugs  are
commonly used and will be briefly described in this section:
4-nitroquinoline 1-oxide (4NQO)
This  carcinogen is not used as a chemotherapeutic agent in clinics but widely in research. It is
thought to cause cellular damage through two different modes of action. After entering the cell,
4NQO is  activated via  chemical  modifications and becomes 4-hydroxyaminoquinoline,  which
reacts with purines and forms stable bulky adducts [77]. These bulky adducts resemble lesions
caused by 254 nm UV radiation, namely cyclobutane pyrimidine dimers and 6-4 photoproducts
[51, 74, 77]. Similarly to UV lesions, 4NQO-dependent bulky adducts are also recognized and
repaired via the NER pathway. 
The second mode of action by which 4NQO causes cellular damage is thought to be through the
generation of reactive oxygen species (ROS), thereby causing intracellular oxidative stress [74,
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77].  ROS cause cellular  damage  by altering  DNA as well  as through lipid  peroxidation and
protein oxidation [78].  
Ultraviolet radiations 
UV radiations have wavelengths ranging from 400 nm to 100 nm. They are divided into UVA
(400-315 nm), UVB (315-280 nm) and UVC (280-100 nm); their toxicity differing depending on
the wavelength. UVC radiation is mostly used at a wavelength of 254 nm for research purposes
as a standard and it mainly induces cyclobutane pyrimidine dimers as well as 6-4 photoproducts,
whereas  UVA  generates  reactive  oxygen  species.  UVB  causes  both  types  of  stress,  ROS
becoming more prominent as the wavelength increases [51]. 
Gamma rays 
Gamma irradiation is used in clinical oncology to treat several types of cancer. It is also used in
molecular  biology as it  is  known to induce double-strand breaks (DSB) as well  as oxidative
stress [79]. DSB are of high interest in research as they are very toxic to the cells and their repair
is highly regulated and complex [79, 80]. 
Hydrogen peroxide
Hydrogen peroxide (H2O2) reacts with metal ions and generates ROS in vivo, such as superoxide
anions,  which  are  known to  react  with  lipids,  proteins  and  DNA [81].  It  is  widely  used  in
research to induce oxidative stress in cells. 
 
1.2.2 Discovery of the RRD1 gene in yeast 
RRD1 (rapamycin resistant deletion 1) was originally identified in a genome-wide screen
for mutants hypersensitive to 4NQO but not to UVC, suggesting that this gene product might be
important for the response to increased ROS but not to lesions repaired by the NER pathway.
This hypothesis was further confirmed since rrd1Δ mutants showed sensitivity towards UVA and
diamide, which both cause oxidative stress but showed no increased sensitivity to γ-radiations,
MMS, UVB or UVC [74]. Taken together, these phenotypes suggest that the function of Rrd1
would be in the cellular response to oxidative stress but not to other stresses such as those caused
by  DNA  lesions  [74].  Subsequently,  rrd1Δ  mutants  were  shown  to  be  highly  resistant  to
rapamycin  as  well  as  to  caffeine  but  sensitive  to  vanadate,  Ca2+,  ketokonazole  and
cycloheximide. Both caffeine and vanadate are also thought to influence cellular oxidative stress,
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though,  through  different  mechanisms.  It  is  believed  that  caffeine  directly  inhibits  cellular
signalling  pathways  including  oxidative  stress  response  pathways,  but  does  not  generate
intracellular reactive oxygen species [82]. Vanadate also stimulates the stress response pathways
but does so by increasing the ROS levels [83]. The difference in the resistance could therefore be
explained by the hypothesis that rrd1Δ mutants do not adequately respond to stresses. In the case
of caffeine, rrd1Δ mutants grow better then wild type cells since they don’t activate the ESR (see
section 1.1.8.2). In contrast, in response to vanadate, rrd1Δ mutants still do not activate the ESR
but  in  this  case,  ROS will  lead  to  cellular  damage  and  ultimatively  to  cell  death [82,  83].
Ketokonazole is  an anti-fungal agent that interferes with ergosterol biosynthesis [84], whereas
cycloheximide inhibits protein biosynthesis by interfering with ribosomal function.  
1.2.3 Discovery of PTPA, the human homologue of Rrd1 
The  RRD1 gene is  evolutionary conserved and its  human  homologue is  called  PTPA.
PTPA  was  originally  identified  as  being  an  Activator  of  the  in  vitro Phospho-Tyrosyl
Phosphatase  activity  of  PP2A  phosphatases  without  affecting  their  serine/  threonine
dephosphorylation activity [85, 86]. PP2A phosphatases are a class of phosphatases which have
multiple  cellular roles and will be described in more detail in the next section. To date, the  in
vitro phospho-tyrosyl phosphatase activity was not shown to be relevant in vivo [87, 88]. Rather,
it was found that PTPA is crucial for the reactivation of inactive phosphatase complexes as well
as for their substrate specificity and holo-enzyme assembly in vivo (see next section). PTPA was
therefore renamed PP Two A Phosphatase Activator [89, 90] .
1.2.4 Structure and function of PP2A phosphatase complexes
PP2A phosphatases  complexes  (PP2A) are serine/  threonine  phosphatases involved  in
numerous  cellular  pathways  including  cell  cycle,  cellular  morphology,  DNA  repair  and
transcription [91, 92]. PP2A is  constituted of three distinct  subunits,  the structural A subunit
which is bound to the catalytic C subunit to form a core dimer that associates with the third and
regulatory B subunit [91, 92]. 
The structural A subunit exists in two isoforms, α and β, which share high sequence similarity.
Subunit A binds tightly to the catalytic C subunit and serves as a scaffold for the recruitment of
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the regulatory B subunit.  Subunit  C also has two isoforms (α and β) which are differentially
expressed within the cell and are highly conserved throughout evolution. There are at least  4
different families of B subunits that can mutually exclusively bind to the core A-C dimer. They
are  named  according  to  their  molecular  size:  PR55,  PR61,  PR72  and  PR93,  all  expressing
various isoforms within their family and the different isoforms contribute to substrate specificity.
The  various  associations  between  A,  B  and  C  subunits  give  rise  to  multiple  different
compositions of PP2A which allow for specific  cellular  localisation, phosphatase activity  and
most  importantly,  substrate specificity  [91, 92]. Besides holo-enzyme  composition, PP2A can
also be regulated by post-translational modifications such as phosphorylation or methylation [91,
92]. In addition, it has been shown that although PP2A is a serine/ threonine phosphatase in vivo,
PTPA can stimulate the low phosphotyrosyl phosphatase activity of AC dimers but not of ABC
trimers in vitro  [85, 86].  This activity requires Mg2+ and ATP, but it  is  not known wether the
phosphotyrosyl stimulating activity of PTPA plays a role in vivo [87, 88, 91]. 
Subsequently, it was shown that PTPA is required to activate PP2A in vivo and contributes to its
substrate specificity in yeast cells  [89]. In addition, when PTPA is not present, the catalytic  C
unit is less stable and its in vitro phosphatase activity becomes dependent on bivalent metal ions.
This suggests that PTPA might alter the structure of PP2A catalytic units [89]. 
1.2.5 Rrd1 is a peptidyl prolyl isomerase 
Rrd1 was recently shown to posess peptidyl prolyl isomerase (PPIase) activity [93]. As
mentioned above, PPIases are enzymes that catalyze the conversion of proline residues from the
cis to the trans conformation. Proline isomerisation can occur spontaneously (albeit slowly) and
is often a rate-limiting step during protein folding. However it can be stimulated by a PPIase [94,
95]. In addition, PPIases can switch the proline conformation when the target protein is already
in a folded form. This induces a conformational change which may alter the activity or function
of the target protein (see figure 4).
The molecular basis of proline isomerization 
The extreme rigidity of prolines  compared to other amino  acids has  several structural
implications.  Notably,  prolines  are  normally  excluded  from secondary  structures  like  alpha
helices and beta strands but are found in turns. Also, most amino acid bonds are form in a trans
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position, because of steric hindrance of the cis conformation. However, for an aa-Pro bond, both
the cis and the trans conformations are possible. Thus both conformations are possible and each
will result in a distinct structure of the same peptide. It is thought that 5 % of these bonds are in
cis form when the protein is folded [96]. Since prolines are positioned mostly within turns, they
are often exposed to solvent and a switch from cis to trans will result in a drastic change of the
structural conformation with consequences like alteration of activity and function [96]. This has
been termed a molecular switch, where cis conformation can change to trans and vice-a-versa,
thereby altering the protein structure. This switch has a high energy barrier. It can occur slowly
and  spontaneously,  or rapidly  with  PPIase catalysis.  How exactly  does PPIases  mediate  this
switch is not yet known [96]. It has been postulated that PPIases might act as a molecular timer
whereby they rapidly promote one conformation of prolines with a timely effect on the activity
of this target protein. Due to conformational restriction this proline will slowly switch back to the
alternate conformation causing the target protein to stop its activity [96].
To date, three classes of PPIases are known; cyclophylins, FKBP’s and parvulins (see figure 5). 
Figure 4 Model of proline cis- trans isomerisation by PPIases [96]
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Cyclophilins
These  are present  in  all  living  organisms.  Members  of this  family  share  a  conserved
domain of 109 amino acids called cyclophilin like domain (CLD) [97]. Originally,  cyclophilin A
was identified as binding the immunosuppressant cyclosporine A from the fungi Tolyplocadium
inflatum.  In  mammals  this  binding  leads  to  inhibition  of  calcineurin,  a  serine  /threonine
phosphatase,  which  is  required  to  translocate  the  NF-AT  transcription  factor  in  T-cells  and
induces  transcription  of  interleukins  including  IL2  [97,  98].  Interestingly,  the  binding  of
cyclosporine  A to cyclophilins  is  conserved  throughout  evolution.  For  example,  in  the yeast
S.cerevisiae, the homologue of cyclophilin A (Cpr1) binds cyclosporine A and this is thought to
inhibit  growth from alpha-factor arrested cells  [98]. Besides this role, cyclophilins are localized
mainly in the cytoplasm and in the endoplasmatic reticulum where they are thought to assist in
protein folding by isomerizing prolines. In yeast, a simultaneous knockout of all cyclophilins is
still viable, suggesting that their function in protein folding is not essential [99]. Additional roles
for this family have also been described; for example, Cpr1 is found in the nucleus and regulates
meiosis [100]. 
In mammalian cells, cyclophilins are required for proper protein folding, and this is also crucial
for  the formation and infectivity  of HIV-1 virions  [101].  In addition,  cyclophilins  have been
found  to  be  associated  with  transcriptional  regulators  such  as  YY1  and  steroid  receptors,
suggesting that besides protein folding, cyclophilins may also be involved in regulatory functions
of signaling pathways [97].
FK506 Binding Proteins 
These  proteins  were initially  discovered because  they bind  to the immunosupressants
FK506  isolated  from  Streptomyces  tsukubaensis and  rapamycin  from  Streptomyces
hygroscopicus. Whereas binding  of FKBP with rapamycin  results  in  the inhibition of the Tor
signaling pathway, the binding of FKBP to FK506 leads (similar to cyclophilin and cyclosporine
binding) to the inactivation of calcineurin and inhibition of T-cell activation [102, 103]. Similar
to cyclophilins, they isomerize proline residues during protein folding. FKBPs are characterized
by a 108 amino acid long FK506 binding domain but vary in their other domains. Some FKBPs
are additionally thought to act as chaperones, binding and sequestering misfolded proteins [104]. 
The  fact  that  both the  cyclophilins  and  FKBPs  are involved  in  immunosuppressive  activity
--through binding of exogenous factors-- has lead to their common appelation of immunophilins
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[104]. This also suggests that their evolutionary conservation is maintained, thus underscoring
their  importance  in  cellular  function.  The  yeast  FKBPs  and  cyclophilins  are,  however,
dispensable  for  survival  [99].  Both families  are  under  investigation  for  their  role  in  disease
treatment  as  they  can  be  easily  inhibited  by  drug  treatments  [104].  Thus  cyclophylins  and
FKBP’s are PPIases required for proper protein folding and can isomerize a broad spectrum of
peptides [93, 94].
Parvulins
Parvulins have high substrate specificity as they only isomerize prolines that are preceded
by a phosphorylated serine or threonine residue [93, 94, 96, 105]. The prototype of the parvulin
PPIase family is Pin1 in mammalian cells and Ess1 in S.cerevisiae. Numerous cellular targets of
Pin1 have been identified so far, and Pin1 is thought to regulate a number of important cellular
pathways,  including  transcription,  cell  cycle,  DNA  damage  stress  responses  and  immune
responses  as  well  as  developmental  roles  such  as  germ  cell  maturation  and  neuronal
differentiation [96]. In the yeast  S.cerevisiae, Ess1 was found to isomerize the CTD of RNAPII
and  influence  its  phosphorylation  status (see also  section 1.1.6) [44,  45, 95,  106-108].  This
mechanism  is  conserved  during  evolution  and  Pin1  overexpression  leads  to
hyperphosphorylation  of  the  serine  5  of  RNAPII,  its  dissociation  from  the  chromatin  and
accumulation into speckle like structures [95]. More recently, it was discovered that Ess1 is also
involved in transcriptional termination of snoRNAs by altering the phosphorylation status of the
RNAPII  CTD and  thereby  promoting  the  recruitment  of the  NRD complex  which,  in  turn,
terminates transcription (see section 1.1.5) [44]. Interestingly an Ess1 knockout deletion is lethal
and suggests that besides these roles, Ess1 might  perform additional functions as well,  as was
found for Pin1 in mammalian cells [44]. 
The  importance  of  Pin1  is  further  underscored  by  its  involvement  in  numerous  diseases,
including cancer, asthma and Alzheimer’s disease [96, 105]. 
The exact role of Pin1 in cancer is not clear yet but Pin1 is known to interact with transcription
factors Jun and Fos which are both involved in  cellular  proliferation. It stabilizes  the tumour
suppressor P53 and P73 during checkpoint arrest in response to DNA damage and Pin1 knockout
mice are less prone to certain types of cancer [109]. For asthma, aberrant expression or activity
of Pin1 is  thought to increase cytokine release,  by enhancing  the stability of mRNA of these
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cytokines [109]. In Alzheimer’s disease Pin1 plays a role by interacting with and regulating Tau
and amyloid precursor protein, both of which are important in this disease occurrence [109]. 
RRD1 
Rrd1  can  isomerize  prolines  and  has  substrate  specificity  similar  to  FKBP12  and
cyclophilin (Cpr7 in yeast).  This PPIase activity is stimulated by ATP and Mg2+ [93]. Rrd1 does
not isomerize substrates preceded by a phosphorylated residue, suggesting that it  has different
substrate specificity than Pin1 and might belong to a different family (see figure 5). Originally
Rrd1 was found to isomerize  a specific  proline  residue in  PP2A (186-LQEVPHEGAMCDL-
198), which induces a conformational change, thereby affecting its activity [93]. 
Figure 5 Phylogram of peptidyl prolyl isomerase family 
The sequence alignment was generated by clustal W 2.0.  s.c indicates that the gene is from S.cerevisiae, if not gene
it is from H.sapiens. 
1.2.6 RRD2 
RRD2 is the yeast paralogue of RRD1 (figure 5) and it shares 40 % of sequence identity
with Rrd1 [74, 110].  rrd2Δ mutants are also resistant to caffeine and rapamycin (although to a
lesser  extend)  but  display  no  phenotype  towards  4NQO,  MMS  and  UVA  [74,  110].  Rrd2
interacts with different PP2A phosphatases then Rrd1, notably Pph21 and Pph22 but might also
share some overlapping function with Rrd1 [87, 93, 111]. However, when our lab performed the
genome wide screen for 4NQO hypersensitive mutants that are resistant to UV radiation, rrd2Δ
mutants were not identified  and it  was subsequently shown that  RRD2 is  not required for the
response to 4NQO [74].  Since  our lab only found  RRD1 to be sensitive  towards 4NQO,  the
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RRD2 gene was not further investigated. Interestingly,  rrd1Δ- rrd2Δ double mutants are lethal, a
phenotype which can be rescued with the overexpression of PTPA [90, 110, 112]. This suggests
that they both have important cellular functions and the fact that PTPA can rescue this phenotype
suggests that these functions are conserved throughout evolution. Since Rrd1 and Rrd2 both are
activators  of  a  variety  of  phosphatases  (Sit4,  Pph3,  Ppg1,  Pph21  and  Pph22)  loss  of  both
isomerases could lead to inactivation of all these phosphatases and ultimately  to cell death, a
phenotype which might be suppressed if only one of these genes is deleted, as one Rrd protein
might  take over some of the functions of the other missing protein. This is consistent with the
fact  that  they have  some  overlapping  functions  notably  in  the reactivation of inactive  PP2A
complexes and substrate specificity [74, 87, 93, 111].  
1.2.7 Structure of Rrd1
In 2006, two research groups independently published the characterization of the crystal
structure of PTPA [87,  88].  These  analyses  revealed  important  cues  about  the structure and
function of this enzyme. Although there are some structural differences in the crystals analyzed,
similar  general  conclusions  were  drawn  from both publications.  The  PTPA structures  were
described differently by the two groups and only one will be elaborated here. PTPA contains 17
alpha  helices  and  4 beta strands.  These  secondary structures were further  divided  into  three
distinct subunits, the core, lid  and linker (figure 6); the linker connecting the core to the lid. A
large cleft is found between the lid and the core and a deep pocket is formed between the core
and the linker  (figure 6). This  deep pocket is  important  for the catalytic  activity of PTPA as
shown  by  the  high  evolutionary  conservation  of the  residues  as  well  as  through mutational
analysis  of these residues  (figure  6 and 7) [87, 88].  To analyze  the previously characterized
ATPase activity of PTPA, Chao and coworkers co-crystallized ATP with PTPA and showed that
ATP binds within the deep pocket and is maintained there by the highly conserved residues of
the pocket (eg. D205G). They further showed that the ATP binding of PTPA is required for its in
vitro phosphotyrosil phosphatase activity.  Finally,  they demonstrated that binding  of PTPA to
PP2A is required for PTPA’s ATPase activity which is mediated by a surface patch of conserved
residues at the lid-linker border [88]. Taken together, their results suggest that PP2A and PTPA
form a composite ATPase that is required to modulate the substrate specificity of PP2A for the
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dephosphorylation of phosphotyrosyl peptides [88]. The modulation of substrate specificity by
Rrd1 is further confirmed by the fact that Rrd1 binding to PP2A inhibited the serine/threonine
phosphatase activity of PP2A in vitro [88].
Leulliot  and  coworkers  additionally  demonstrated  that  PTPA,  Rrd1  and  Rrd2  have  nearly
identical  structures  [87].  They  also  described  the  deep  pocket,  which  contains  the  highly
conserved residues but, surprisingly,  they demonstrated that this pocket is  required to bind a
peptide from PP2A that was previously shown to be isomerized by PTPA [87, 93]. The crystal
structure further revealed that when PTPA binds this peptide, it  forms a homodimer that binds
two molecules of the peptide. 
Finally,  they concluded similarly to Chao et al., that the conserved residues in the deep pocket
are required for the tyrosyl phosphatase activity of PP2A and, additionally,  that this domain is
also required for the resistance to rapamycin in vivo.  
  No structural homologue of PTPA has been identified to date. Interestingly,  the structure of
PTPA is distinct  from all  characterized peptidyl  prolyl  isomerases (see figure 5). Although it
seems surprising that the same pocket binds ATP in one case and peptides in the other it clearly
suggest that the highly  conserved pocket is  essential for PTPA catalytic  activity,  whether this
activity is ATP hydrolysis or proline isomerisation [87, 88]. 
Both publications concluded that PTPA has a highly conserved and unique structure which puts
it into a novel class of peptidyl prolyl isomerases [93] (figure 5).
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Figure 6 crystal structure PTPA, conserved residues are painted green, showing the deep pocket, the linker core
and lid [88].
Figure 7 Sequence alignments of PTPA homologues
Mutational  analysis  was  performed  and analyzed  for  two  distinict  functions:  1.  Binding of  Rrd1  to  PP2A as
indicated by squares below the alignment if it is affected by mutation of the residue. 2. Catalytic activity of the
PPIase as indicated by circles if it is affected by mutation. Colour indicates the severity ,  green= mild, orange=
severe and red = completely abolished [88].
 
1.2.8 Rrd1 interacts with phosphatases in vivo
In yeast, it has been shown that Rrd1 interacts with different phosphatases, such as Pph3,
Ppg1 and Sit4 [111-114]. The yeast PP2A catalytic C subunit is encoded by PPH21 and PPH22
genes whereas the catalytic A subunit  is encoded by TPD3. Only two families  of regulatory B
subunits are found in yeast; PR55, that is encoded by CDC55 and Pr61, encoded by RTS1 [91].
There  are  three  PP2A  like  phosphatases  in  yeast,  namely  Pph3  which  is  known  to
dephosphorylate H2AX [115], Ppg1, which is involved in glycogen metabolism and Sit4, which
is known to be involved in the rapamycin response [113, 114, 116, 117].  
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Rrd1  was  found  to  form  a  ternary  complex  with  Tap42  and  Sit4,  and  this  complex
dephosphorylates  the TF Gln3  as part  of the Tor signaling  pathway [117, 118].  This  would
explain  why  rrd1Δ  mutants  are resistant  to rapamycin;  in  the absence  of Rrd1,  Sit4  cannot
dephosphorylate  Gln3;  therefore,  the  NDG signaling  pathway  is  not  activated.  Since  gln3Δ
mutants  are  resistant  to  rapamycin,  the  lack  of  Gln3  activation  might  confer  resistance  to
rapamycin  to  rrd1Δ mutant  cells.  However,  it  was  found  that  Gln3  can  be  activated
independently of the Sit4 phosphatase [119, 120]. In addition, we have shown that expression of
a target gene of Gln3, MEP2 was still induced in response to rapamycin in rrd1Δ mutants [113].
Moreover, Sit4 was able to dephosphorylate the kinase Npr1 independently of rrd1Δ deletion in
response to rapamycin.  [113].  It  was previously shown that  Pph3 and Rrd1 interact  together
[111]; however, we showed that  pph3Δ mutant are resistant to rapamycin  and that the  rrd1Δ-
pph3Δ double  mutant  is  synergistically  resistant,  suggesting  that  they  function  in  different
signaling  pathways  to mediate  the response to rapamycin  [113].  These findings  indicate that
Rrd1 might have additional functions that are required for the response to rapamycin. 
1.2.9 Rrd1 is involved in transcriptional regulation in response to rapamycin 
We  have  shown  that  Rrd1  is  required  to  modulate  gene  expression  in  response  to
rapamycin.  More precisely,  it  was demonstrated that Rrd1 is required to not only activate gene
expression of the diauxic shift  genes  CPA2 and  PYC2, but also to inhibit  the expression of at
least  two ribosomal genes,  RPL26A and  RPL9A, in  response to rapamycin.  This  suggests that
more than these four  genes  are regulated by Rrd1. This  is  the case especially  for  ribosomal
genes,  since  ribosome  biogenesis  is  a  coordinated  and  highly  regulatored  network  which
involves all three RNAPs [121]. Therefore it is likely that more then a couple of ribosomal genes
are influenced by Rrd1. Further, if Rrd1 plays a role in transcriptional regulation of ribosomal
genes,  Rrd1 would  have  additional  roles  since  it  has  been  shown  that  the  Tap42-Sit4-Rrd1
complex is not involved in regulation of ribosomal genes  [60]. Most interestingly,  and for the
first  time, it  was shown that RNAPII was degraded in response to rapamycin over time. This
could  be  a  mechanism  to  drastically  reduce  excess  RNAPII  and  reduce  metabolic  gene
expression. However, when Rrd1 was deleted, RNAPII was not degraded anymore, suggesting
that Rrd1 may play a direct role in RNAPII transcriptional regulation [113].
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1.2.10 Role of Rrd1 in rapamycin resistance
To date Rrd1 has been shown to interact with phosphatases, an interaction that requires
biochemical  isomerase  activity.  Notably,  Rrd1 associates with Sit4 and Tap42, which form a
complex crucial for TORC1 signaling. Rapamycin inactivates TORC1, causing the dissociation
of Tap42 from Sit4-Rrd1 and the activation of Sit4 phosphatase, which then dephosphorylates
Gln3 or Npr1 kinases [113, 118]. Deletion of Rrd1 could cause aberrant activation and/or loss of
Sit4  substrate  specificity;  therefore,  causing  rapamycin  resistance.  However,  several  data
indicate  that  Gln3  can  be  activated  independently  of  Sit4  and,  even  more  interestingly,
independently  of Rrd1 [113, 119, 120]. This clearly suggests that Rrd1 might  have additional
regulatory roles  in  the rapamycin  response.  Indeed,  we have  shown that  Rrd1 is  required to
regulate the expression of rapamycin responsive genes [113]. This clearly indicates that Rrd1 has
a role independent of its Sit4 phosphatase activator function, since ribosomal genes are regulated
independently of the Tap42- Sit4 complex [60]. Since the catalytically inactive mutant of Rrd1 is
also resistant to rapamycin and this resistance does not seem to depend on the interaction of Rrd1
with Sit4, it is very possible that Rrd1 has additional targets for its isomerase activity, and those
could be important for the response to rapamycin. 
Consistent with this notion, the PPIase Pin1 also has multiple cellular targets and is involved in
various different cellular activities, including the isomerisation of RNAPII and its transcriptional
regulation [94].  
The  fact  that  Rrd1  is  required  to  modulate  gene  expression  in  response  to  rapamycin,
independently of its Sit4 associated function, led us to the hypothesis for my Ph.D project: 
Rrd1 regulates RNAPII transcription in response to rapamycin through its peptidyl prolyl
isomerase activity.
The two subsequent articles will describe, in the form of manuscripts for publication, how
the project developed, the methods that were used and the results that were obtained during my
Ph.D. 
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2 ARTICLES
2.1 Rrd1 isomerizes RNA polymerase II in response to rapamycin
Nathalie Jouvetψ, Jeremie Poschmannψ, Julie Douville,  Lisa Bulet, Xiaoming Yang, and Dindial
Ramotar
My contribution to this article:
I would evaluate my contribution to the experimental data to about 35 %. I produced figure 1,
figure 3A, figure 7, figure 8 and supplemental figure S1. NJ produced figure 2 and figure 3B.
Figure 3C was done by LB. Figure 4, 5 and 6 were produced by NJ and JD. Protein purification
for assays was done by XY. 
The entire manuscript has been written by NJ, DR and myself. 
This article has been rejected by the reviewers for NAR submission.
However, based on their comments, we believe that we can do the required experiments and re-
submit to NAR soon. 
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Abstract
In  Saccharomyces  cerevisiae,  the  immunosuppressant  rapamycin  engenders  a  profound
modification in the transcriptional profile  leading to growth arrest.  Mutants devoid of Rrd1, a
protein possessing in vitro peptidyl prolyl cis/trans isomerase activity, display striking resistance
to  the  drug,  although  how Rrd1  activity  is  linked  to  the biological  responses  has  not  been
elucidated.  We now provide evidence that Rrd1 is associated with the chromatin and it interacts
with RNA pol II.  Circular  dichroism reveals that Rrd1 mediated structural changes of the C-
terminal  domain (CTD) of the large subunit  of RNA pol II (Rpb1) in response to rapamycin,
although this appears to be independent of the overall phosphorylation status of the CTD.  In
vitro experiments,  revealed that recombinant  Rrd1 directly isomerizes  purified GST-CTD and
that it  releases  RNA pol II  from the chromatin.   Consistent  with  this,  we show that  Rrd1 is
required  to  alter  RNA pol  II  occupancy  on rapamycin  responsive  genes.   We  propose as a
mechanism, that upon rapamycin exposure Rrd1 isomerizes Rpb1 to modulate transcription.  
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Introduction
Rapamycin is an immunosuppressant that was recently approved for treating kidney carcinomas
[122]. It is known to inhibit the Tor1 (Target of Rapamycin) kinase signalling pathway leading to
growth inhibition [123].  In S. cerevisiae, several factors have been identified through genome-
wide screens that when deleted cause resistance to rapamycin  [124].  One of these proteins is
Rrd1 (Rapamycin Resistance Deletion 1) that was first reported to play a role in protecting cells
against oxidative DNA damage caused by the carcinogen 4-nitroquinoline-1-oxide (4-NQO) and
by UVA [74].  Mutants deficient in Rrd1 are also unable to undergo rapamycin-induced growth
arrest and therefore exhibit marked resistance to the drug [110].  Rrd1 is conserved in eukaryotes
and shares 35% identity with the human phosphotyrosyl phosphatase activator, hPTPA, which
was initially isolated as a protein that stimulated the weak phosphotyrosyl phosphatase activity
of the type 2A Ser/Thr phosphatase PP2A [125, 126].  We and others reported that Rrd1 can
physically interact with the Ser/Thr phosphatase Sit4, a PP2A like phosphatase [111, 114, 127].
In S. cerevisiae, rapamycin binds to the peptidyl-prolyl cis/trans isomerase Fpr1 and this drug-
protein  complex  inactivates  the  Tor1  kinase  causing  a  profound  modification  in  the
transcriptional profile,  and culminating in G1 growth arrest [57, 128, 129].  Inhibition of Tor1
leads to the activation of Sit4, by virtue of its dissociation from the inhibitor complex Tap42-
Sit4,  which  in  turn  dephosphorylates  several  targets  including  the  nutrient-responsive
transcriptional  activator  Gln3  that  translocates  to  the  nucleus  to  activate  GLN1 and  MEP2
expression [57, 61, 130].  However, these Sit4-dependent processes do not require the function
of Rrd1, suggesting that  the latter  protein might  execute a  function downstream in  the Tor1
signaling pathway [113, 129, 131, 132].  
Recent data indicate that Rrd1 exerts an effect at the transcriptional level [113].  Genes known to
be  upregulated (e.g.,  the diauxic  shift  genes  CPA2 and  PYC1) and down-regulated (e.g.,  the
ribosomal protein genes including  RPS26A, RPL30, and  RPL9) following rapamycin exposure
showed an altered transcription pattern in rrd1Δ mutants [113, 129, 131, 132].  To date, the exact
function executed by Rrd1 causing alteration in transcription has not been investigated.  Rrd1
and its mammalian  counterpart PTPA have been shown to possess an in  vitro peptidyl prolyl
cis/trans isomerase (PPIase) activity on model substrates [133].  PPIases are ubiquitous proteins
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that  catalytically  facilitate  the cis/trans  isomerization of peptide bonds  N-terminal  to proline
residues within polypeptide chains [134, 135].  Both Rrd1 and PTPA can independently change
the  structure of short  peptides  including  the synthetic  substrate  (186LQEPHEGPMCDL198)
representing  a  conserved  sequence  amongst  PP2A phosphatases  [133].  As  such,  it  has  been
suggested that Rrd1/PTPA could activate PP2As via this PPIase activity [133].  So far, neither
the in vivo target nor the biological function of the PPIase activity of Rrd1 has been elucidated,
although this is not the case for other PPIases.  For example, the PPIases Ess1 and Pin1 from S.
cerevisiae and mammalian cells, respectively, possess the ability to associate with the C-terminal
domain (CTD) of Rpb1 [95, 108].  In yeast, the CTD consists of 26  repeats of the YS2PTS5PS7
heptad  sequence  and  Ess1  has  been  shown  to  stimulate  the  dephosphorylation  of  Ser-5  to
efficiently terminate transcription of a subset of genes [44].  
In this study, we show that Rrd1 is associated with RNA pol II and isomerizes the CTD of Rpb1
in  vivo  and  in  vitro.   Our  data  suggest  a  model  whereby  this  isomerization  leads  to  the
dissociation of RNA pol II from the chromatin resulting in transcriptional changes.  This study
provides insight into a possible new mechanism by which RNA pol II could rapidly respond to
transcriptional changes.  
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MATERIALS AND METHODS
Strains, media and plasmids 
The strains used in this study were the parents BY4741 (Mat a, his3-1, leu2-0, met15-0, ura3-0),
YDL401 (MATa his3-200 leu2-1 trp1 ura3-52 gal2 gal-108), and the isogenic mutants rrd1∆ and
gln3∆.  Strains were endogenously and independently tag at the following loci APN1,  RAD52,
RRD1, SWE1 and YAP8 as previously described [136].  Strains bearing Rpb1-TAP was provided
by Tom Begley (Albany,  USA).  Strains  were grown in  either  rich (YPD) or selective  (SD)
media.   Construction of pGFP-SIT4, pGFP-RAD52, pGFP-RRD1, GST-APN1 was previously
described  [114].   pGST-CTD was constructed  by amplifying  the murine  CTD from plasmid
pGCTD  [137] and  subcloned  into  pTW340  (provided  by  Tom  Wilson,  Michigan,  USA).
Construction of the plasmid pGAL-HIS-RRD1 and purification of HIS-Rrd1 fusion protein were
done as previously reported for pHIS-BLH1 [138].  
Spot test analysis
The assay was done as previously described, except for plates containing rapamycin [139].  
Extraction of chromatin-associated proteins
Extraction of proteins bound to chromatin was done as previously described [139]. Exponentially
growing cultures (50 ml) were spun down, resuspended in 6.25 ml of 100 mM PIPES/KOH, pH
9.4, 10 mM DTT, and incubated at 30oC for 10 min with agitation. Cells were spun down and
resuspended in 2.5 ml of YPD containing 0.6 M sorbitol, 25 mM Tris-HCl pH 7.5 and 100 µl of
25 mg/ml lyticase.  Cells  were incubated at 30oC for 30 min with agitation, spheroplasts were
spun down, resuspended in 2.5 ml YPD containing 0.7 M sorbitol, 25 mM Tris-HCl pH 7.5 and
incubated at 30oC for 20 min with agitation. The spheroplasts were washed 3 times with 1 ml of
lysis buffer (0.4 M sorbitol, 150 mM KoAc, 2 mM MgCl2, 20 mM PIPES/KOH pH 6.8, and the
protease  inhibitor  cocktail  (Roche,  1  tablet  per  10  ml).  The  washed  spheroplasts  were
resuspended in 300 µl of lysis buffer containing 1% Triton X-100. To a 90 µl aliquot of the lysed
spheroplasts was added 45 µl of 2X protein loading buffer and used as the “whole cell extract”.
Another 100 µl of the lysed spheroplasts was spun at 14,000 rpm for 5 min in a microcentrifuge
at 4oC. To the supernatant was added 45 µl of 2X protein loading buffer and labelled the “SOL”
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fraction, while the pellet was resuspended in 90 µl of lysis buffer and 45 µl of 2X protein loading
buffer and labelled the “CHR” fraction.  
Co-Immunoprecipitation experiments
Co-immunopreciptation  was  done  as  previously  described  [114],  except  using  8WG16
covalently  coupled to AminoLink  matrix (Pierce) and total extracts  [140]  prepared from cells
expressing  either  MYC- or GFP-tagged form of the indicated proteins  or from the untagged
parent  or  rrd1Δ cells.   The matrix  with bound proteins was washed four times with a buffer
containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% NP40. The input (5%) used in
the co-immunoprecipitation experiment  as well as half the volume of the matrix were assessed
by  Western  blost  using  either  anti-MYC,  -GFP  (Clonetech),  or  -ubiquitin  (Rockland).   The
remaining  half  of the matrix  was  analyzed  separately  by Western blot  probed  with  8WG16
antibody. 
Western blot analysis of GST, GST-CTD and Rpb1-TAP
BY4741 parent  or  rrd1Δ mutant  cells  expressing  the  GST-CTD or carrying  the endogenous
Rpb1-TAP tag were subcultured in the appropriate media and treated with rapamycin (200 ng/ml
for 30 min). Whole cell extracts or where indicated affinity purified proteins (GST, GST-CTD or
Rpb1-TAP using  manufacturer’s protocol (Stratagene,  USA)) were analyzed  by Western blot
with  anti-GST  (Sigma),  H5  (anti-Ser2  phosphorylated)  and  H14  (anti-Ser5  phosphorylated)
antibodies  (Covance)  or  anti-PAP  (Sigma).   For  purification of GST-CTD,  500 ml  cultures
grown in selective media to an OD600 of ~ 1.0 were used, which yielded ~1 to 2 mg of purified
protein which was stored in phosphate buffer.
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Interaction between Rrd1-MYC and GST-CTD
Total protein extracts derived from parent cells (100 ml) expressing GST-
CTD or GST-Apn1, untreated or treated with rapamycin  (200 ng/ml for
2h) were allowed to bind to 1 ml GST affinity matrix slurry as described
for the purification, except samples were not eluted from the columns.  A
second protein extract (1 mg) derived from a strain expressing Rrd1-MYC
or  Yap8-MYC  was  applied  and  allowed  to  bind  for  1  h  at  room
temperature on a rotating platform.  The columns were then washed with
20 bed volumes of PBS and an aliquot of the beads (30 µl) was loaded
onto an 8% SDS-PAGE and processed for Western blot.  The presence of
GST-CTD  on  both  columns  was  detected  using  polyclonal  anti-GST
(Sigma)  and the bound Rrd1-MYC was revealed anti-MYC monoclonal
antibody (SantaCruz).
Circular dichroism spectroscopy
Continuous  far-UV circular  dichroism spectra  (197-250 nm)  of the GST and  the GST-CTD
fusion protein (2.0 µg and 4.32 µg, respectively, in 100 µl of 10 mM phosphate buffer pH 7.0, 50
mM  NaCl)  were  collected  using  a  Jasco-810  spectropolarimeter.   The  measurements  were
carried  out  at  room temperature  using  a  1  mm  path-length  cuvette  (Hellma) and a  1  nm
bandwidth.   Three  spectra  were  collected  for  each  sample  and  averaged.  The  spectral
contribution of the buffer was corrected for by subtraction. Relative ellipticity was converted to
mean residue molar ellipticity [] according to Fasman [141].
Limited chymotrypsin digestion assay
The purified GST-CTD (~100 ng) derived from parent cells untreated or treated with rapamycin
(200 ng/ml for 2h) was subjected to digestion with 5 ng chymotrypsin (Roche) in the presence of
1 mM  CaCl2,  and  incubated  at  37oC for  the indicated  time.   Digestion was  stopped by  the
addition of SDS-PAGE loading buffer and boiling of the samples. Processing of the GST-CTD
was analyzed using 8% SDS-PAGE followed by staining with silver.
In vitro isomerase assay
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Purified  HIS-Rrd1 was added to the purified  GST-CTD in sodium phosphate buffer  (10 mM
NaPO4 pH 7.0, 50 mM NaCl) without or with 1 mM MgCl2, and 1 mM ATP in a final volume of
200  µl.  The proteins  were incubated for  1 h at  30oC the GST-CTD was recovered by GST-
affinity purification and then subjected to CD analysis. 
In Vitro Rpb1 release assay
Exponentially  growing culture (200ml)  of the BY4741  rrd1∆  Apn1-MYC strain was prepared
and  lysed  as  above  for  the  extraction  of  chromatin  associated  proteins.  Supernatant  was
discarded and the pellet was washed once in 1 ml of isomerization buffer (10 mM NaPO4 pH 7.0,
50 mM NaCl, 1 mM MgCl2, and 1 mM ATP). Supernatant was discarded again and pellet was
resuspended in  600  µl of isomerization buffer  and  equally  divided  in  three tubes.  Increasing
amounts of purified HIS-Rrd1 were added and samples were rocked for 1 h at 30ºC. Samples
were  then  spun  down  and  supernatant  was  kept  for  subsequent  western  blot  analysis.  The
remaining pellet was resuspended in benzonase buffer (50 mM Tris pH 8.0, 1 mM MgCl2) and 1
µl of benzonase (Novagen) was added and tubes were incubated for 30 min at 37ºC. Supernatant
(SOL)  and  chromatin  (CHR)  fractions  were  loaded  onto  SDS-PAGE  gels  for  western  blot
analysis with 4H8 and anti-MYC antibodies. 
ChIP assay
The ChIP assay was done as previously described  [142]. Primers are available  upon request.
ACT1 was used as an endogenous control and relative quantity was calculated using the CT
method  (Applied  Biosystems).  IP’s  were  normalized  to  the  respective  input.   Untreated  IP
samples were given an arbitrary unit 1 and increase or decrease folds were calculated. At least
three independent experiments were done for each gene and Student T test was used to calculate
the p-value.
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RESULTS
Rrd1 is associated with the chromatin and interacts with Rpb1
We previously  demonstrated that Rrd1 is  required to modulate  the expression of a subset  of
rapamycin-regulated genes independently of Sit4 [113].  To corroborate our earlier findings that
Rrd1 acts separately from the Sit4-Gln3 signaling  pathway,  we deleted the  RRD1 gene in the
gln3 background (known also to be resistant to rapamycin) and examined the resulting  gln3∆
rrd1∆ double mutant for the level of resistance to the drug [143].  This genetic analysis revealed
that the gln3∆ rrd1∆ double mutant was significantly more resistant to rapamycin than either of
the single mutants (Fig. 1), suggesting that Rrd1 performs a distinct role to regulate response to
the drug.  
To investigate this potentially novel role of Rrd1, we first checked whether Rrd1 binds to
chromatin in light of its involvement in gene regulation [113].  Chromatin fractions were derived
from strains  expressing  MYC-tagged Rrd1, as well  as the control proteins  Swe1, Rad52 and
Apn1 from the endogenous loci and subjected to Western blot analysis  probed with anti-MYC
antibody.  As shown in Fig. 2A, a significant amount of Rrd1-MYC was found in the chromatin
fraction (lane 3), suggesting that Rrd1 is  associated with the chromatin and consistent with an
earlier  study showing that Rrd1 is  also present  in  the nucleus [114].  In contrast, the control
protein  Swe1-MYC was only found  in  the soluble  fraction (lane  2),  while  Rad52-MYC and
Apn1-MYC, two DNA repair proteins known to bind chromatin, were present in the chromatin
fraction (lane 3) [144, 145].  
Since Rrd1 is bound to the chromatin and is involved in regulating gene expression, we
tested if it  is  associated with RNA pol II by performing co-immunoprecipitation analysis.   For
this experiment, we used total extracts derived from cells expressing either Rrd1-MYC or Swe1-
MYC  and  checked  for  the  pull-down  with  anti-Rpb1  (8WG16).   Rrd1-MYC  was  co-
immunoprecipitated with Rpb1, but not the control protein Swe1-MYC (Fig. 2B).  Since only a
small  amount  of  Rrd1-MYC  was  co-immunoprecipitated  with  anti-Rpb1,  the  association
between Rrd1 and RNA pol II may be weak or transient.  There was no alteration in the amount
of Rrd1 co-immunoprecipitated by anti-Rpb1 when cells were treated with rapamycin (200 ng/ml
for 30 min) (Fig. 2B).  
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Anti-Rpb1  also  co-immunoprecipitated  Rrd1  from  parent  cells  carrying  a  plasmid
expressing GFP-tagged Rrd1 (Fig. 2C).  In addition, the Sit4 phosphatase known to physically
interact  with  Rrd1  [114]  co-immunoprecipitated with  Rpb1  from parent  cells  expressing  this
protein  as GFP fusion (Fig.  2C).  Two additional GFP fusion proteins,  GFP-Imp2 and GFP-
Rad52,  which  do  not  interact  with  Rrd1,  were  not  co-immunoprecipitated  with  anti-Rpb1
antibody,  although a minute amount of GFP-Rad52 non-specifically  interacted with the beads
used  for  immunoprecipitation  (Fig.  2C,  and  data  not  shown).   Thus,  Rpb1  associates  with
proteins known to bind Rrd1, suggesting that Rrd1 could exist in a complex with Rpb1.  We note
that the reverse co-immunoprecipitation with Rrd1-MYC did not pull down Rpb1 under the same
reaction conditions, raising the possibility that the size of the RNA pol II complex might impede
the  pull  down  although  we  cannot  exclude  other  alternatives  such  as  a  weak  or  indirect
interaction via another protein.  
Rrd1 associates with the CTD of Rpb1 and alters its structure in response to rapamycin
Since the C-terminal domain (CTD) of Rpb1 is a repeated sequence (YSPTSPS) rich in proline
residues, and has previously been shown to bind the isomerases Ess1 and Pin1 [95, 108, 146], we
reasoned that Rrd1 could function to isomerize the CTD.  As such, we assessed whether the CTD
is a substrate for the PPIase activity of Rrd1 in vivo.  The CTD was expressed as a GST fusion
protein from a previously described plasmid (see Materials and Methods) and has been shown to
undergo  post-translational  modifications  including  Ser-5  and  Ser-2  phosphorylation,
isomerization and ubiquitylation [44, 137, 147, 148].  Introduction of this plasmid into the parent
and rrd1Δ strains directed the expression of the GST-CTD fusion protein with the expected size
(95-kDa) as determined by Western blot analysis probed with anti-GST antibodies (Fig. 3A, see
also Supple. Fig. S1).  The GST-CTD contained both phosphorylated Ser-5 and Ser-2 as detected
by  anti-H14  and  anti-H5  antibodies,  which  specifically  recognize  Ser-5  and  Ser-2
phosphorylation, respectively (Fig. 3A), consistent with previous studies that the GST-CTD can
be  functionally  modified  in  vivo [137,  147-149].   From  these  analyses,  we  observed  no
differences in the (i)  size,  (ii)  level of expression,  and (iii)  phosphorylation of the GST-CTD
whether it  was derived from the parent or the rrd1Δ mutant or from cells  that were pretreated
with rapamycin (Fig. 3A. Supple. Fig. S1).  
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We next  prepared GST-CTD affinity  beads from parent  cells  and determined  whether
these could pull down Rrd1.  Total extract derived from the parent strain expressing Rrd1-MYC
(Fig. 3B, lane 2) was incubated with the GST-CTD affinity beads.  The beads were recovered,
washed  and  an aliquot  examined  for  retention of Rrd1-MYC by Western blot  analysis.   As
shown in  Fig.  3C and  D, Rrd1-MYC was pulled  down by the GST-CTD affinity  beads.   In
contrast, the GST-CTD affinity beads did not pull down the transcriptional activator Yap8, also
tagged with MYC (Fig. 3B, C and D).  As expected, the empty beads did not pull down Rrd1-
MYC from the total extract  nor  did  the control beads  carrying  GST-Apn1  (Fig.  3C and D).
These data support the notion that Rrd1 associates with the CTD of Rpb1, consistent with the
above observation that Rpb1 co-immunoprecipitated Rrd1.        
We next  investigated whether Rrd1 could induce conformational  changes in  the GST-
CTD fusion  protein  by  using  circular  dichroism  (CD)  spectroscopy,  a  method  that  is  very
sensitive to changes in the secondary structure of proteins [141].  We first purified the GST-CTD
from the parent and the rrd1Δ mutant, as well as GST from the parent to be used as the control.
Silver stain analysis of the purified GST-CTD revealed that there was no difference in the size of
this protein, whether it was derived from the parent or the rrd1Δ mutant (Fig. 4A, lane 3 vs. 5) or
when the cells were treated with rapamycin (lane 3 vs. 4 or 5 vs.6).  As observed for total extract,
the purified  GST-CTD showed no alteration in  either Ser-5 or Ser-2 phosphorylation (Supple
Fig.  S1A).  To ensure that the observed phosphorylation status of the GST-CTD is similar  to
Rpb1 CTD phosphorylation, we purified Rpb1 from the TAP tagged strains and monitored this
protein for its phosphorylation. Like the GST-CTD, Rpb1-TAP showed no differences in either
Ser-5 or Ser-2 phosphorylation following rapamycin treatment (see Supple Fig. S1B).  However,
this approach may not distinguish  between subtle  phosphorylation differences  that may occur
amongst  the  heptad  repeats  [150].  Since  the  GST-CTD is  similarly  phosphorylated  as  the
endogenous Rpb1, we used it as a tool for further analysis. 
CD spectra obtained for the purified GST-CTD derived from either the untreated parent
or  rrd1Δ  mutant were indistinguishable,  and displayed  a minimum at 202 nm (Fig.  4B).   In
contrast, GST-CTD derived from the parent cells  treated with rapamycin exhibited a spectrum
with a minimum at 208 nm and shoulder at ~225 nm (Fig. 4B), suggesting that the GST-CTD
underwent a detectable change in its secondary structure.  Remarkably,  rapamycin treatment of
the  rrd1Δ  mutant failed  to induce this  conformational  change onto the GST-CTD (Fig.  4B).
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Introduction of a single copy plasmid expressing functional Rrd1 in the  rrd1Δ mutant restored
the change in the spectral pattern of the GST-CTD (Fig.  4C)[74].  Additionally,  purified GST
alone  derived from untreated or rapamycin  treated parent  cells  did  not exhibit  any structural
differences,  suggesting that it  is  the CTD portion of the fusion protein that is  undergoing the
rapamycin-induced changes (Fig. 4D).  We further confirmed the structural change of the GST-
CTD as observed by CD using  limited  proteolysis  with  chymotrypsin,  which can distinguish
proteins with different secondary structures and exclusively cleaves peptides in the trans-proline
conformation  [151].  As shown in  Fig.  4E, the GST-CTD purified from the rapamycin-treated
parent cells  was more resistant to limited chymotrypsin digestion, as opposed to the GST-CTD
derived from the untreated cells, suggesting that indeed the GST-CTD went through a structural
reorganization in response to rapamycin.  On the basis of these findings, it would appear that the
CTD of Rpb1 changes its structure  in vivo following exposure to rapamycin,  and that Rrd1 is
essential for this alteration.  
Rrd1 alters the GST-CTD structure in response to 4-NQO, but not MMS
We next checked if isomerization of the CTD is specific for rapamycin.  Since the rrd1Δ mutant
was previously shown to be sensitive to the DNA damaging agent 4-NQO [74], which induces
oxidative  stress  as  well  as  creating  bulky  lesions  onto  the  DNA  [152],   we  examined  for
isomerization of the GST- CTD in the parent and the mutant following treatment with this drug.
We observed that the structure of the GST-CTD was altered in the parent, but not in the rrd1Δ
mutant following  4-NQO treatment  (Fig.  5A).   We also tested another DNA damaging  agent,
methyl methane sulfonate (MMS), to which the rrd1Δ mutant displays parental sensitivity [74].
MMS creates apurinic/apyrimidinic sites in the genome, and for this experiment it was used at a
concentration that  kills  ~70% of the cells.   Under  this  condition,  the GST-CTD showed  no
structural alteration following the MMS treatment (Fig. 5B).  On the basis of these findings, it
would appear that this phenomenon might  occur for other stress conditions besides exposure to
rapamycin.    
Rrd1 directly alters the structure of the CTD in vitro
We next examined whether purified Rrd1 can induce structural changes onto the CTD in vitro.
To do this, we incubated equimolar amounts of recombinant HIS-Rrd1 purified from E. coli with
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affinity purified GST-CTD derived from the rrd1Δ mutant at 30oC for 30 min, then recovered the
GST-CTD for CD analysis.   As shown in Fig. 6, purified HIS-Rrd1 significantly modified the
CTD  structure  under  the  standard  phosphate  buffer  reaction  conditions.   Since  the  Rrd1
isomerase activity has been shown to be stimulated by ATP and Mg2+ [133], we examined the
effect of these additions to the reaction mixture.  Inclusion of ATP and Mg2+ in the buffer caused
no structural alteration to the CTD in the absence of Rrd1 (Fig. 6).  However, addition of purified
HIS-Rrd1 to the complete ATP/Mg2+ phosphate buffer introduced a more dramatic change to the
CTD structure, as compared to the mixture lacking ATP/Mg2+ (Fig. 6).  Moreover, the purified
HIS-Rrd1 did not confer any structural changes onto another purified GST fusion protein, GST-
Apn1 (data not shown).  These findings suggest that Rrd1 can directly isomerize the CTD.   
Comparison of RNA pol II occupancy at rapamycin-responsive genes
Since Rrd1 associates with and isomerizes the CTD, and that  rrd1Δ  mutant  did not affect the
phosphorylation  status of Rpb1, we asked  whether  it  would  alter  RNA pol II  occupancy on
rapamycin responsive genes  in vivo.  To do this, we performed chromatin immunoprecipitation
(ChIP) analysis of Rpb1 on two known RNA pol II-responsive genes, RPS26A and CPA2 [153].
Since both genes are known to be rapidly downregulated and upregulated, respectively,  within
30 min,  we treated cells  for this time  period with rapamycin  [113, 128].   In parent  cells,  the
Rpb1-ChIP  signal  from  the  RPS26A gene  was  reduced  by  nearly  8-fold  upon  rapamycin
treatment (Fig. 7A).  In contrast, Rpb1 remained associated with  RPS26A in the rrd1∆  mutant
(Fig.  7A).   In the case of the upregulated gene  CPA2, we observed an increase in Rpb1-ChIP
signal in the parent upon rapamycin, whereas in the mutant there was only a modest increase in
the signal (Fig. 7B).  The occupancy of RNA pol II on these genes is consistent with the mRNA
expression levels [113, 128].  These data raise the possibility that Rrd1 might displace Rpb1 in
order to optimize rapid transcriptional changes caused by rapamycin.   
Purified Rrd1 stimulates the release of chromatin-bound RNA pol II in vitro
To explore the above possibility, we examined if purified Rrd1 would displace RNA pol II from
the chromatin.   Briefly,  we isolated chromatin containing RNA pol II derived from the  rrd1Δ
mutant, the chromatin was washed and resuspended in the standard phosphate buffer containing
ATP and Mg2+.  To this reaction, increasing amounts of purified Rrd1 was added and following
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incubation the levels of chromatin-bound and soluble Rpb1 were monitored by Western blot. As
shown in Fig. 8, increasing concentration of Rrd1 caused a loss of chromatin-bound Rpb1, while
there was a correlating gain in the soluble fraction.  In contrast, Rrd1 concentration did not affect
the level of the control protein Apn1-MYC.  Collectively,  our data indicate that Rrd1 possesses
the  ability  to  isomerize  the  CTD  of  Rpb1  thereby  promoting  its  displacement  from  the
chromatin.  
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DISCUSSION  
In the present study, we show that Rrd1 is a chromatin bound protein, which associates
with the RNA pol II, presumably through the CTD of Rpb1. We believe that this association
allows isomerization of the CTD in response to specific stress such as that caused by rapamycin
and 4-NQO but not MMS.  In addition, we show that in vitro purified Rrd1 (i) can directly alter
the structure of the CTD and (ii)  dissociate Rpb1 from the chromatin.   On the basis of these
observations, we propose the following model whereby in response to specific stress conditions
the  RNA pol  II  associated  Rrd1  isomerizes  the  CTD of Rpb1  such  that  the  polymerase  is
dissociated from the chromatin.  Once the RNA pol II is released it would be recruited to stress-
responsive genes.  
There is supporting evidence that elongating RNA pol II is in excess on ribosomal protein
genes,  surprisingly  associated with a low transcriptional rate under glucose grown conditions
[154].  However, once these cells are submitted to a metabolic change, e.g., a switch to galactose
growth  conditions,  the  level  of  RNA  pol  II  decreased  on  these  ribosomal  genes  and  the
transcriptional  rate  increased [154].   This  shift  also  simultaneously  caused an enrichment  of
RNA pol II onto mitochondrial genes [154].  This suggests a mechanism where excessive RNA
pol II is  removed from the ribosomal genes and recruited to mitochondrial genes to increase
expression.  Therefore, metabolic  switches would stimulate re-localization of elongating RNA
pol  II  from one  regulon  to  the  other.    As  it  is  known  that  rapamycin  mimics  starvation
conditions and represses ribosomal biogenesis, we suspect a similar  mechanism as the glucose-
galactose  shift  is  operational  to  rapidly  change  transcription.   Besides  Rrd1,  another  well
characterized  peptidyl  prolyl  isomerase  Pin1  can  trigger  the  release  of  RNA  pol  II  from
transcribing  genes  in  human  cells  [95].   Under  normal  conditions,  Pin1  interacts  with  the
phosphorylated  CTD  of  RNA  pol  II  and  this  association  is  retained  along  the  length  of
transcribed genes [95].  However, when Pin1 is overexpressed it promotes hyperphosphorylation
of the CTD during the transition from initiation to elongation, thereby causing RNA pol II to
dissociate  from active  genes  and  leading  to  the  inhibition  of  transcription  [95,  106].   The
dissociated  RNA  pol  II  accumulates  in  enlarged  speckle-associated  structures  enriched  for
transcription and RNA processing factors [95, 155].      
51
Because Rrd1 intersects with the biological functions of Pin1,  it  is  possible  that Rrd1
could modulate the phosphorylation status of the CTD.  Recent  studies showed that the yeast
homologue of Pin1, Ess1, binds and catalyzes the cis/trans isomerization of the CTD such that
Ser-5 phosphorylation can be dephosphorylated by the Ssu72 phosphatase  [44].  Moreover, a
variant  of Ess1  (Cys120Arg)  caused  accumulation  of  Ser-5  phosphorylation,  and  not  Ser-2
phosphorylation, both of which were monitored using the same set of antibodies (anti-H5, -H14
and  -8WG16)  as in  this  study [44].   We  found  no  alteration in  the  global  Ser-2 and  Ser-5
phosphorylation status upon rapamycin treatment, as well as between the parent and the rrd1Δ
mutant using the same set of antibodies (Fig. 3A and Supple Fig. S1).  As such, it  would seem
that  Rrd1  uses  a  novel  mechanism  independent  of  phosphorylation  to  isomerize  the  CTD,
although we cannot exclude the possibility that there are unique Ser-2 and Ser-5 phosphorylation
differences which can be masked by neighboring phosphorylations.   For example,  where one
heptad is  phosphorylated,  but  not  the adjacent  [150].   However,  since  RNA pol II  exists  in
different  phosphorylation forms  throughout the transcription cycle,  it  seems logical  to have a
mechanism that triggers RNA pol II release independent of its phosphorylation status. 
In yeast,  the CTD consists of 26 repeats of the heptad sequence  YSPTPS.  It  exists
largely in  a disordered structure, but adopts a static conformation upon interaction with target
proteins such as  the mediator complex that regulates transcription initiation and enzymes  that
modify  the  5’  and  3’ends  of  mRNA [156,  157].   Binding  of these  proteins  to  the CTD is
modulated by serine  phosphorylation and proline  isomerization [150].   Thus,  a given  heptad
repeat  could  give  rise  to  many  different  conformations  with  the  various  combinations  of
phosphorylated Ser-2, -5 and -7, as well as the cis/trans isomerization of the two prolines, Pro-3
and Pro-6, to generate a broad range of binding  sites to allow precise association with several
factors [7, 156, 157].  At least three CTD interacting proteins (Pcf1, Pin1, and Ctg-1 from C.
albicans) have been shown to bind exclusively the all-trans conformation, providing support for
the hypothesis that proline isomerization of the CTD plays a critical regulatory role [7].  This
strongly suggests that multiple  conformations of the CTD exist  in vivo.   Consistent  with this
notion, we observed by CD analysis two conformations of the CTD that remained stable through
out its purification (Lisa Miller,  Brookhaven National Laboratories, personal communications)
from untreated and rapamycin-treated cells (Fig. 4).  These different conformations could be the
result  of proline  isomerization,  as  prolines  are known to be  stable  in  either  the  cis or  trans
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conformation when the protein is in a folded form [158].  Only peptidyl prolyl isomerases such
as Pin1/Ess1 are known to trigger a switch between the cis and trans conformations of the CTD
[96], and that in the absence of these enzymes the conformational switch is slow [159].  Because
Rrd1 possesses peptidyl  prolyl isomerase activity and it  associates with RNA pol II, it  seems
likely  that  this  function  is  responsible  for  inducing  structural  changes  to  the  CTD  upon
rapamycin exposure.  In support of this, Rrd1 directly alters the CTD structure in vitro (Fig. 6),
and we therefore predict that Rrd1 might act in a similar manner onto the CTD in vivo.
In addition to rapamycin,  we also observed that the DNA damaging agent 4-NQO, but
not MMS, triggered alteration of the CTD structure (Fig. 5).  We examined the effect of 4-NQO,
as we had previously shown that  rrd1∆ mutants were sensitive  to this agent and not to MMS
[74].  The distinct difference between 4-NQO and MMS is that the former agent potently induces
the production of reactive oxygen species such as superoxide anions [152].  Both starvation and
oxidative  stress  are  known  to  mediate  similar  transcriptional  programs,  also  termed  as  the
environmental stress response, for example, where ribosome biogenesis is turned off [71].  This
would explain  why the  rrd1∆ mutants are sensitive  to 4-NQO, but  resistant  to rapamycin;  (i)
genes  required  for  counteracting  the  4-NQO-induced  oxidative  stress  are  not  turned  on
efficiently  and  as  a  result  the  cells  accumulate  genotoxic  lesions,  and  (ii)  under  rapamycin
condition  nutrients  are  still  available  and  the  failure  to  alter  gene  expression  allows  rrd1∆
mutants to grow.  Taken together, our data suggest that Rrd1 participates in a novel mechanism
that  allows  redistribution  of RNA pol II  for  transcriptional  regulation of genes  involved  in
specific stress conditions.  
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FIGURE LEGENDS 
Figure 1.  gln3∆ rrd1∆ double mutant is more resistant to rapamycin than either
single mutant.  Cells were serially diluted and spotted onto YPD plates without and with
rapamycin (Rap).  Photos were taken after two days of growth at 30oC.
Figure 2.  Rrd1 is associated with the chromatin and interacts with Rpb1. A) Rrd1 is
bound  to chromatin.  Whole  cell  extract  (WCE), soluble  (SOL) and  chromatin  (CHR)
fractions were derived  from the parent cells  expressing either Rrd1-MYC, Swe1-MYC,
Rad52-MYC  or  Apn1-MYC  and  the  distribution  of  the  MYC-tagged  proteins  was
examined by Western blots.  The data is representative of two independent analyses.  B)
Rpb1  pull-down  of  Rrd1.  The  8WG16  antibodies  were  used  to  immunoprecipitate
extracts  from untreated  (-)  and  rapamycin-treated  (+)  (200  ng/ml  for  30  min)  cells
expressing  either  Rrd1-MYC  or  Swe1-MYC.   The  presence  of  Rrd1  in  the
immunoprecipitates was determined by Western blotting.  C) Specificity  of Rpb1 pull-
down of GFP tagged proteins.  The 8WG16 antibodies were used to immunoprecipitate
extracts from cells  expressing either of the following GFP tagged proteins: Imp2, Rrd1,
Rad52 or Sit4.  The presence of the GFP-tagged proteins in the immunoprecipitates was
detected by Western blotting.
Figure 3. Analysis of the GST-CTD and its interaction with Rrd1.  A) Comparison of
the expression and phosphorylation status of the GST-CTD between parent and  rrd1∆
mutant cells  following rapamycin exposure.   The  indicated cells  expressing GST-CTD
were treated with (+) and without (-) rapamycin (200 ng/ml for 30 min) and total protein
extracts were probed for Ser-2 phosphorylation (H5) or Ser-5 phosphorylation (H14). The
membranes were stripped and reprobed with anti-GST antibody. B-D) Retention of Rrd1-
MYC by GST-CTD affinity beads.   B) The input of parent cells expressing Yap8-MYC
and Rrd1-MYC from the endogenous locus.  C) Empty beads and beads containing either
GST-CTD or GST-Apn1.  D)  Total protein extracts derived from the parent or parent
expressing  either  Yap8-MYC or Rrd1-MYC were incubated with the empty beads or
beads containing either GST-CTD or GST-Apn1.  The beads were then washed and an
aliquot examined for retention of the MYC tagged proteins using anti-MYC antibodies.
Results shown are representative of two independent experiments.   
Figure 4.  rrd1∆ mutants are unable to induce conformational changes to the GST-
CTD in response to rapamycin. A) Silver stained gel of purified GST and GST-CTD.
The indicated strains carrying either the GST (lanes 1 and 2) or GST-CTD expressing
plasmid (lanes 3-6) were untreated (-) or treated (+) with rapamycin  (RAP)  (200 ng/ml
for 30 min).  B and C) Far-UV circular  dichroism spectral (CD) analysis  of purified
GST-CTD.  The purified GST-CTD (0.45 µM) was derived from the indicated strains (A)
carrying the empty vector or pRRD1 (B) that were untreated or treated with rapamycin.
D) CD analysis of purified GST (0.76 µM) derived from untreated and rapamycin treated
parent cells as above.  Results shown are the averages of two independent experiments.
E) Limited  proteolysis  of purified  GST-CTD derived  from parent  cells  untreated  or
treated with rapamycin.  The purified GST-CTD was subjected to partial chymotrypsin
digestion  and  analyzed  by  silver  staining.   Results  shown  are  representative  of  two
independent experiments.
Figure 5. 4-NQO, but not MMS, induces structural changes onto the GST-CTD.  A
and B, CD analysis of the purified GST-CTD derived from exponentially growing Apn1-
MYC tagged parent and rrd1Δ mutant were treated with either 4-NQO (2 µg/ml 30 min)
or MMS (1% for 60 min).  
Figure 6. Purified recombinant Rrd1 alters the structure of the GST-CTD in vitro.
Equimolar amounts (4.5 µM) of purified GST-CTD derived from the rrd1Δ mutant and
the purified recombinant  HIS-Rrd1 were incubated at 30oC in  phosphate buffer  in  the
absence and presence of Mg2+/ATP.  The resulting GST-CTD was re-purified free of the
recombinant  HIS-Rrd1 and  subjected to  CD analysis  as in  Fig.  4.   The result  is  the
average of two independent experiments.
Figure 7. Comparison of RNA pol II occupancy at the indicated target genes in the
parent and rrd1∆ mutant in response to rapamycin treatment.  Cells were untreated
or treated with 200 ng/ml rapamycin for 30 min and Rpb1 localization was analyzed by
ChIP  assay  (see  Materials  and  Methods).   Primer  locations  are  indicated  below  the
diagram.   The respective input  normalized  IP amounts were quantified  relative  to the
ACT1 gene  using  the  CT  method.   Results  are  shown  as  the  average  of  three
independent  experiments.   Error  bars  represent  standard  deviation  and  the  P-values
compare untreated vs. treated.  
Figure 8.  Purified recombinant Rrd1 dissociates Rpb1 from the chromatin in vitro.
Increasing amounts of purified HIS-Rrd1 were added to the chromatin fraction isolated
from  rrd1Δ  mutant  strain  expressing  Apn1-MYC  and  incubated  at  30oC for  1  h  in
phosphate buffer.   Chromatin  was recovered from the buffer  and both fractions were
analyzed by Western blotting probed with 4H8 (against Rpb1) and anti-MYC antibodies.
Apn1-MYC was used as loading control.  Result shown is representative of at least three
experiments.
 
Figure S1.  Analysis of the phosphorylation status of purified GST-CTD and Rpb1-
TAP.  A)  Comparison of the phosphorylation status of the purified GST-CTD derived
from the parent and rrd1∆ mutant following rapamycin exposure (200 ng/ml for 30 min).
The purified  GST-CTD was subjected to Western blot  analysis  and  probed for  Ser-2
phosphorylation  (H5)  or  Ser-5  phosphorylation  (H14).   To  measure  equal  loading
membranes were stripped and reprobed with anti-GST antibody.  B)  Comparison of the
phosphorylation status of purified Rpb1-TAP derived from the parent and rrd1∆ mutant
cells  following  rapamycin  treatment,  as  in  panel  B.   Rpb1-TAP  was  purified  by
calmodulin affinity column and then probed with the indicated antibodies.  To control for
equal  protein  loading  the  membranes  were  stripped  and  reprobed  with  the  anti-PAP
antibody. Results shown are representative of three independent experiments. 
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2.2 The yeast peptidyl prolyl isomerase Rrd1 is an elongation factor required for
transcriptional stress responses
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Abstract 
Rapamycin is an anticancer molecule and immunosuppressant that acts by inhibiting the
TOR  signaling  pathway.  In  yeast,  rapamycin  mediates  a  profound  transcriptional
response,  for  which  the  RRD1 gene  is  required.  This  gene encodes  a  peptidyl  prolyl
isomerase  that  associates  with  RNA  polymerase  II  (RNAPII)  and  isomerizes  its  C-
terminal domain (CTD) in response to rapamycin.  To further investigate this biological
connection,  we  performed  genome  wide  association  studies  of RNAPII  and  Rrd1  in
response to rapamycin  to demonstrate that Rrd1 co-localizes  with RNAPII on actively
transcribed genes and that both are recruited to rapamycin responsive genes. Strikingly,
when Rrd1 is lacking, RNAPII fails to dissociate from a large set of ribosomal genes and
is  recruited to a  set  of rapamycin  responsive  genes;  this  occurs independently  of the
TATA  box  binding  protein  recruitment.  We  further  show  that  Rrd1  modulates  the
phosphorylation  status  of  RNAPII  CTD,  and  finally  provide  evidence  that  Rrd1  is
required for the transcriptional response to various stresses. We propose a model whereby
Rrd1 acts as an elongation factor to optimize the transcriptional stress response.  
Introduction
Rapamycin is an immunosuppressant and an anticancer molecule that acts through
inhibition of the TOR (target of rapamycin)  signaling pathway [160, 161]. In the yeast
Saccharomyces cerevisiae, TOR1 and  TOR2 genes encode two serine/threonine kinases
whereby each forms  the core of the rapamycin  sensitive  (TORC1)  and the rapamycin
insensitive  TORC2 complex,  respectively  [58,  162-164].  TORC1 positively  regulates
anabolic  processes,  by promoting mRNA translation and the transcription of ribosome
biogenesis  genes  [58, 162-164]. Upon nutrient  starvation, or rapamycin  treatment,  the
TORC1 complex  becomes inactivated,  with the consequence of a  severe reduction of
anabolic  processes,  cell  cycle  progression  and  growth,  as  well  as  the  induction  of
catabolic  processes and stress responsive  factors  [58, 162-164].  This  drastic  change is
mediated  by  alteration  of  gene  transcription  and  is  regulated  through  the
phosphorylation/dephosphorylation and translocation of transcription factors between the
cytoplasm and the nucleus.  Ribosomal gene transcription is regulated by the ribosomal
gene repressor Crf1, which is sequestered in the cytoplasm when TORC1 is active. Upon
TORC1 inactivation, Crf1 is  phosphorylated by the Yak1 kinase,  translocates into  the
nucleus and competes with the co-activator Ifh1 for binding to the ribosomal transcription
factor Fhl1, thereby repressing transcription [67]. Further, upon TORC1 inactivation, the
downstream TORC1 regulator Tap42 activates PP2A and Sit4 phosphatases, which then
in turn dephosphorylate the transcription factors Rtg1/2 and Gln3 causing these factors to
move into the nucleus and induce the expression of retrograde signaling genes (RTG) and
nitrogen discrimination genes (NDG), respectively  [60, 118, 162, 163]. In addition, the
expression of stress responsive genes is  stimulated via activation of Tap42, enhancing
nuclear retention of the transcription factors Msn2/4 [58, 60, 163, 164]. Once translocated
to the nucleus, these transcription factors bind to specific  DNA elements, alter the local
chromatin state and recruit the general transcription machinery to mediate assembly of
the pre-initiation complex (PIC) and transcription by RNA polymerase II (RNAPII) [16,
165].
The exact mechanisms  of these regulatory circuits are not fully  understood but
genome wide deletion screens in  S.cerevisae have been a useful tool to identify  novel
factors that are required to mediate an efficient  response to rapamycin  [110, 124, 166,
167]. One of these factors is the peptidyl prolyl isomerase Rrd1 (Resistant to rapamycin
deletion 1) that was originally identified to play a role in the cellular  protection against
the carcinogen 4-nitroquinoline-1-oxide, as well as to UVA radiation [74]. rrd1Δ mutants
exhibit  multiple  phenotypes,  but  the  most  prominent  is  its  extreme  resistance  to
rapamycin [110]. Rrd1 is evolutionally conserved and it shares 35% amino acid sequence
identity with the human homologue PTPA [87, 88, 93].  PTPA was first characterized to
be  an activator of the phospho-tyrosyl  phosphatase  activity  of PP2A phosphatases  in
vitro  [85, 86]. However, an  in vivo role of this activity has not been described yet  and
subsequent studies revealed that PTPA/Rrd1 is required for PP2A substrate specificity,
complex formation and the reactivation of inactive PP2A complexes [89, 90]. It turns out
that PTPA/Rrd1 has intrinsic  peptidyl prolyl isomerase activity and is  able  to catalyze
proline isomerization on a specific  peptide sequence of PP2A [93]. Consistent with this
function, we and others found that in yeast Rrd1 interacts with the PP2A like phosphatase
Sit4 [111, 112, 114, 117]. Sit4 and Rrd1 form a ternary complex with the Tor signaling
mediator Tap42 [117]. As mentioned above, upon TORC1 inactivation Tap42 dissociates
from Sit4-Rrd1 which then dephosphorylates and activates the transcription factor Gln3
[113, 118]. Interestingly,  gln3Δ mutant cells  are resistant to rapamycin and therefore it
was postulated that rrd1Δ mutants are rapamycin resistant since they are involved in the
Gln3 pathway [117]. However, we found that the Gln3 target gene MEP2 was activated
independently of RRD1, suggesting that  RRD1 has an additional role in the response to
rapamycin  [113].  Consistent  with  this,  we  found  that  Rrd1  exerts  an  effect  at  the
transcriptional level: genes known to be upregulated (e.g., the diauxic shift  genes CPA2
and  PYC1)  and  down-regulated (e.g.,  the ribosomal  protein  genes  including  RPS26A,
RPL30, and RPL9) following rapamycin exposure showed an altered transcription pattern
in rrd1 mutants [113]. Subsequently, we demonstrated that Rrd1 interacts with RNAPII
and that it directly isomerizes the CTD of the large subunit (Rpb1) of RNAPII (Jouvet et
al., 2010 NAR in revision). In addition, we provided evidence that Rrd1 releases RNAPII
from the chromatin, which could be a new mechanism of RNAPII regulation (Jouvet et
al., 2010 NAR in revision). It would appear that Rrd1 exerts its role during transcription
elongation as this was similarly shown for another peptidyl prolyl isomerase, Pin1, and
its yeast homologue Ess1  [44, 45, 95, 106, 168]. Pin1/Ess1 is  thought to isomerize the
CTD of RNAPII  and regulate  elongation  [95, 106].  In yeast,  the CTD consists of 26
repeats of the  YS2PTS5PS7 heptad sequence which  is  differentially  phosphorylated on
serine  2,  serine  5  and  serine  7  [7-9,  42,  169,  170].  These  different  phosphorylation
patterns  act  as  a  recruitment  platform  for  multiple  factors  involved  in  chromatin
remodelling,  mRNA  processing  and  transcription  termination  [7-9,  170].  The  yeast
homologue of Pin1, Ess1 has been shown to stimulate the dephosphorylation of Ser-5 to
efficiently terminate transcription of a subset of genes [44].    
In this study, we further analyzed how Rrd1 regulates transcription by RNAPII.
We mapped the genome wide association of Rrd1 and RNAPII using ChIP-chip analysis
under control and rapamycin treated conditions and demonstrate that Rrd1 co-localizes
with RNAPII  on actively  transcribed  genes  in  both conditions.  We further  show that
rrd1Δ deletion affects RNAPII occupancy on a large set of rapamycin responsive genes.
This happens independently of Spt15 recruitment to the promoter suggesting that Rrd1
acts downstream of PIC formation during transcriptional initiation and elongation. This is
further  confirmed  by  the  fact  that  Rrd1  modulates  serine  5  phosphorylation  of  the
RNAPII CTD. Finally,  we demonstrate that Rrd1 is generally required to regulate gene
expression in response to a variety of environmental stresses thus establishing Rrd1 as a
new elongation factor required for effective transcriptional responses.
Results
Rrd1 localization correlates with RNAPII along actively transcribed genes.
We recently reported that Rrd1 is associated with chromatin and directly interacts with
RNAPII (Jouvet et al., 2010 NAR in revision). To analyze if Rrd1 interacts with RNAPII
along transcribed genes and whether  this  is  relevant  to the transcriptional  response to
rapamycin,  we used ChIP-chip analysis  to address this question. We first examined the
genome-wide RNAPII occupancy under exponential growth conditions without and with
30 minutes of rapamycin treatment, where the rapamycin transcriptional response is most
prominent  based on mRNA expression analysis  [128]. In Fig.  1A, we took the median
RNAPII  occupancy  of  approximately  5000  ORFs,  where  RNAPII  enrichment  was
expressed  as  a  log  2  ratio  of  the  immunoprecipitated  DNA  compared  to  the
corresponding  input  DNA ( enrichment  is  negative  when the IP amount  is  below the
Input amount).  Similarly enriched genes were clustered into groups using self organizing
maps (SOM) with cluster 3.0. SOM creates distinct clusters of similar performing genes
within different conditions and allows for the distinction of subgroups [171]. To facilitate
the  identification  of  the  genes  that  were  affected  by  rapamycin,  we  subtracted  the
rapamycin treated data from the untreated (Fig. 1A row 3). The resulting clusters (W1-
W6)  were  then  analyzed  for   gene  ontology  (GO)  category  enrichment   with
funcassociate 2.0 [172] (Suppl. Fig. S1). Upon rapamycin treatment RNAPII occupancy
was sharply reduced on metabolic genes including ribosome biogenesis (see cluster W1,
W6 and Suppl. Fig. S1). In contrast, RNAPII was strongly enriched on genes belonging
to nitrogen discrimination,  Krebs  cycle,  stress  response  and  catabolic  processes  after
rapamycin treatment (W3, W4 and Suppl.  Fig.  S1). These data are consistent  with the
transcriptional  changes reported for  rapamycin  treatment  and the environmental  stress
response [63, 71, 128]. 
We next  performed  ChIP-chip  analysis  on an endogenous MYC tagged RRD1
strain  (Jouvet  et  al.,  2010 NAR in  revision)  to  determine  if  Rrd1 is  associated with
actively  transcribed  genes.  We  mapped  RNAPII  and  Rrd1-MYC on groups of genes
sorted according  to  their  level  of  RNAPII  occupancy  (Fig.1B)  and  found  that  Rrd1
association correlated with RNAPII on actively transcribed genes (Fig. 1B and C).  The
distribution of Rrd1 peaks after the promoter and remained constant throughout the ORF
(Fig. 1C). Interestingly, when the same analysis was performed in rapamycin treated cells
we  observed  a  similar  binding  pattern,  which  suggests  that  Rrd1,  like  RNAPII,  is
recruited to rapamycin  induced genes (Suppl.  Fig.  S2A). In addition,  linear  regression
revealed that Rrd1 localization correlated with that of RNAPII (Suppl.  Fig.  S2B)  [19].
This  comparison  resulted  in  a  correlation  coefficient  (R2)  of  0.61  under  exponential
growth  conditions,  and  which  did  not  alter  when  the  cells  were  challenged  with
rapamycin (R2 = 0.62) (Suppl. Fig. S2B). 
To  further  analyze  the  genes  that  were  bound  by  Rrd1-MYC,  we  clustered
RNAPII gene occupancy,  as well as the difference  between untreated and rapamycin-
treated gene occupancy for RNAPII and Rrd1-MYC (Fig. 1D). GO analyses performed as
above revealed that similar  genes as RNAPII were enriched or depleted for Rrd1-MYC
upon rapamycin  treatment,  (Fig.  1D and for GO Suppl.  Fig.  S3A). We also  analyzed
single genes which are representative of each of the four clusters from the SOM in Fig.
1D (see Suppl. Fig. S3B).  These data suggest that Rrd1 and RNAPII co-localize within
the body of most of the actively transcribed genes, even after transcriptional changes such
as the one caused by rapamycin treatment, except for Cluster R2 where Rrd1 binding was
slightly different from RNAPII binding, which could be because of variability between
experiments or that Rrd1 might perform additional roles on the chromatin. However, for
most genes these observations are consistent with a model whereby Rrd1 interacts with
RNAPII (Jouvet et al.,  2010 NAR in revision),  and suggests that Rrd1 might  act as a
transcriptional  elongation  factor  to  directly  influence  the  polymerase  activity  (see
discussion).  
RRD1 deletion affects RNAPII localization in response to rapamycin 
Since Rrd1 presence correlates with RNAPII on actively transcribed genes and it
was previously shown to be required to modulate the expression of some genes when
cells  are challenged  with rapamycin  (Jouvet  et  al.,  2010 NAR in revision)  [113],  we
mapped  the  genome-wide  location  of  RNAPII  in  a  rrd1Δ mutant  using  the  same
conditions  as above.  First,  we  plotted RNAPII  gene  occupancy of the  rrd1Δ mutant
against the WT and calculated the correlation coefficient  (R2 = 0.87) under exponential
growth conditions and after rapamycin treatment (R2 = 0.75). This R2 alteration suggests
that RNAPII gene association might  diverge between the  rrd1Δ mutant and WT upon
rapamycin  treatment  (Fig.  2A).  The ribosomal  biogenesis  genes  (Ribi)  and  ribosomal
protein genes (RP) were labeled in different colors (Fig. 2A, red and green, respectively).
The data revealed  that  Ribi  and RP genes were similarly  occupied  in  WT and  rrd1Δ
mutant  cells  under  normal  growth conditions,  but  when treated with  rapamycin  these
genes  were  more  occupied  in  an  rrd1Δ mutant  (Fig.  2A),  suggesting  a  defect  in
transcriptional  regulation of these  genes.   We  next  compared the RNAPII  occupancy
difference (i.e., before and after rapamycin treatment) in the WT with that obtained from
the rrd1Δ mutant (as obtained from Suppl. Fig. S4). We used the untreated RNAPII gene
occupancy as a reference (Fig. 2B). This comparison revealed that RNAPII distribution
was different in the rrd1Δ mutant when compared to the corresponding WT in response
to rapamycin for most genes (Fig. 2B). However cluster P2, which was strongly depleted
by RNAPII from WT cells in response to rapamycin, was not altered in the rrd1Δ mutant,
indicating  that  Rrd1  is  required  to  downregulate  this  group  of  genes  in  response  to
rapamycin. GO analysis revealed that this cluster was highly enriched for metabolic and
ribosomal  biogenesis  genes  as  well  as  for  genes  with  metabolic  regulatory functions
(Suppl.  Fig.  S5).  Cluster  P5  was  strongly  enriched  by  RNAPII  from WT  cells  but
substantially less in the rrd1Δ mutant, suggesting that the recruitment of RNAPII to this
group of genes also depends on Rrd1 presence.  GO revealed that cluster P5 is  highly
enriched  with  catabolic  and  stress  response  genes,  which  are  a  major  part  of  the
transcriptional  response  to  rapamycin  and  other  environmental  stresses  [63,  71].  The
clusters (P1 and P4) that were not dependent upon Rrd1 function were also analyzed by
GO: cluster P1, which was depleted for RNAPII after treatment, was highly enriched in
ribosome biogenesis  genes and cluster P4, which was enriched for RNAPII, contained
genes involved in catabolic processes suggesting that not all genes that are regulated by
rapamycin treatment are affected by rrd1Δ deletion (Suppl. Fig. S5).
Taken together, the data suggest that cells devoid of Rrd1 display altered RNAPII
occupancy on specific  groups of genes in  response to rapamycin.  This  is  the case for
genes that are downregulated or upregulated by rapamycin  treatment  [128]. Rrd1 was
only required to dissociate RNAPII from a fraction of ribosomal genes (compare P1 and
P2), notably ribosomal regulatory genes,  and similarly,  Rrd1 was required to populate
RNAPII only on some catabolic  genes (P5 but not P4).  This suggests that Rrd1 might
regulate transcription, not by altering the recruitment of transcription factors, but likely
through its association with RNAPII on actively transcribed genes.
To confirm our genome wide findings, we performed independent ChIP analysis
followed by Q-PCR on selected genes  from our ChIP-chip  data.  Fig.  3 revealed  that
genes upregulated by rapamycin,  such as  PUT4,  encoding the proline  transporter, and
HSP104, encoding a heat shock protein,  were significantly enriched for RNAPII in the
WT (panel A) but only slightly enriched for RNAPII in the rrd1Δ mutant (Fig. 3B).  In
the  case  of genes  downregulated  by  rapamycin,  such  as  RPL32 and  RPS2  encoding
ribosomal proteins, they were depleted for RNAPII in the WT, while  the  rrd1Δ mutant
still retained substantial levels (Fig.3A and B). Analysis of a gene that was unaffected by
rapamycin treatment, such as the actin coding gene  ACT1, showed that RNAPII levels
were not altered in the WT or the rrd1Δ mutant (Fig. 3A and B). The same set of genes
was also monitored for Rrd1-MYC occupancy (Fig. 3C). As observed for RNAPII, Rrd1-
MYC was enriched  on  PUT4 and  HSP104,  but  was depleted on  RPL32 and  RPS2 in
response to rapamycin whereas Rrd1 levels did not change on the ACT1 gene (Fig. 3C).
It is noteworthy that the amount of Rrd1-MYC immunoprecipitated was low as compared
to RNAPII (see discussion).  Nonetheless, these data are consistent with the genome-wide
distribution of RNAPII and Rrd1, and validate the co-localization of RNAPII and Rrd1-
MYC.  
Rrd1 regulates RNAPII occupancy independently of TBP binding
To distinguish if Rrd1 influences RNAPII occupancy upstream or downstream of
pre-initiation complex (PIC) formation, we examined the genome wide association of the
yeast  TATA box binding  protein  (Spt15),  using  ChIP-chip  assay as above.   If  rrd1Δ
mutants affect  transcription at the level  or upstream of PIC formation,  we predict  that
upon rapamycin treatment the occupancy of Spt15-MYC would be similarly  altered as
RNAPII and Rrd1-MYC. We clustered the binding differences (treated minus untreated)
from WT cells for RNAPII, Rrd1-MYC and Spt15-MYC (Fig. 4A). We observed that all
three proteins were decreased in cluster S1, whereas in cluster S2, both RNAPII and Rrd1
were  decreased,  but  Spt15-MYC  remained  unchanged.  This  suggests  that  RNAPII
occupancy is regulated by two distinct mechanisms, one of which is independent of Spt15
binding.  GO analysis  of cluster  S1 shows that  the genes  are enriched  for  ribosomal
biogenesis,  while  cluster S2 is  enriched for genes in  functions of metabolic  regulation
(Suppl. Fig. S6 for GO analysis). We note that the occupancy of Rrd1-MYC for clusters
S3, S4 and S6 was different from RNAPII and Spt15 suggesting that Rrd1 might perform
additional roles besides its association with RNAPII as was also observed in Fig 1D. 
We  next  checked  if  Spt15 binding  correlates  with  RNAPII  occupancy  in  the
absence  of Rrd1 by mapping  RNAPII and  Spt15-MYC in  the WT and  rrd1Δ mutant
strains for the clusters S1 and S2 as well as cluster S5 (Fig. 4B). In cluster S1, Spt15-
MYC  was  strongly  reduced  in  the  WT  and  to  a  lesser  extent  in  the  rrd1Δ mutant,
correlating with the reduction of RNAPII association within these genes. The observation
that in the rrd1Δ mutant, Spt15 and RNAPII association were less reduced compared to
the WT suggests that Rrd1 might influence to a minor extent Spt15 binding and RNAPII
recruitment,  probably  by  affecting  the  signaling  cascade  upstream of  Spt15  binding
[117]. In the case of cluster S2, we observed no difference in Spt15 binding between the
WT and the rrd1Δ mutant. However, there was a substantial difference between WT and
mutant in the level of RNAPII in response to rapamycin,  suggesting that for these genes
Rrd1 is required to regulate RNAPII association downstream of TBP (Fig. 4B). Cluster
S5 was  similarly  enriched  for  Spt15 binding  after  rapamycin  treatment,  but  RNAPII
occupancy  in  the  rrd1Δ mutant  failed  to  reach WT  levels,  suggesting  that  a  similar
mechanism is functioning for these genes. 
The above data suggests that Rrd1 regulates some genes independently of Spt15
promoter binding. If this would be true we would expect to see the same pattern of Spt15
binding in the SOM of Fig 2B and therefore mapped Spt15 on the rapamycin regulated
clusters  (Suppl.  Fig.  S7).  Cluster  P1  showed  a  similar  Spt15  reduction  following
rapamycin treatment as seen in cluster S1 from Fig. 4A, which occurred in both WT and
rrd1Δ mutant, indicating that these genes are regulated by Spt15 binding (Suppl. Fig. S7).
In contrast cluster P2 resembled cluster S2 from Fig.  4A, where Spt15-MYC was not
altered, but RNAPII binding was dependent on Rrd1 presence (Suppl. Fig. S7). Cluster
P4 was similarly enriched for Spt15 in response to rapamycin as cluster S5, and  rrd1Δ
mutants failed to efficiently recruit RNAPII (Suppl. Fig. S7). Taken together these data
suggest that specific groups of genes are regulated additionally to Spt15 promoter binding
and this depends on Rrd1 presence. 
rrd1Δ mutants  exhibit  phenotypes  associated  with  a  defect  in  transcriptional
elongation—The above data suggest that Rrd1 regulates transcription independently of
TBP and therefore might act on elongating RNAPII.  Mutants defective in elongation are
known to  be  sensitive  to  6-azauracil  (6-AU),  an  inhibitor  of  the IMP dehydrogenase
(IMDPH), which decreases GTP pools and thereby causing transcriptional arrest [22, 48,
173]. As a positive control we used the TFIIS elongation factor mutant (dst1∆), a well
characterized transcription elongation factor  [22, 174].  Using this drug, we found that
rrd1∆ mutants were sensitive to 6-AU, as compared to the WT, but less sensitive than the
dst1∆ mutant  (Fig.5A)  suggesting  that  Rrd1 might  indeed play a role  in  transcription
elongation. 
To further investigate this possibility, and since we previously have demonstrated
that  Rrd1 isomerizes  the CTD of RNAPII  (Jouvet  et  al.,  2010 NAR  in  revision)  we
examined whether Rrd1 might influence elongation by altering the phosphorylation status
of  the  RNAPII  C-terminal  domain  (CTD).  The  CTD  consist  of  26  repeats  of  a
heptapeptide YSPTSPS in yeast which is differentially phosphorylated on serine 2 (Ser2-
P) and serine 5 (Ser5-P). The different phosphorylation states of RNAPII are thought to
be hallmarks of elongation,  whereby RNAPII is  highly  phosphorylated on Ser5 at the
promoter  and  the  early  elongation  phase,  whereas  Ser2-P  progressively  increases
throughout the ORF until it  culminates at the 3’ end of the gene  [7-9, 170]. These two
phosphorylations  are  recruitment  platforms  for  chromatin  modifying  enzymes,
transcription  elongation  factors,  mRNA  processing  factors  and  mRNA  termination
factors  [3,  7-9,  14,  170,  175].  These  differential  phosphorylations  can  be  used  as  a
surrogate for transcription elongation efficiency,  as was the case for the peptidyl prolyl
isomerase Pin1.  It was shown that over-expression of Pin1 leads to increased Ser5-P of
RNAPII and its dissociation from the chromatin [95].  In addition, the yeast homologue
of Pin1, Ess1, was shown to regulate Ser5-P of RNAPII  [44]. We performed ChIP-chip
analysis of Ser5-P and Ser2-P in WT and rrd1Δ mutant strains under the same conditions
as above. Since RNAPII occupancy was different in WT and rrd1Δ mutant cells (see Fig.
2B),  we normalized  the complete data set  of both phosphorylations with the RNAPII
occupancy of the WT and the rrd1Δ mutant. This allowed for an unbiased representation
of the phosphorylations independently of RNAPII occupancy. Next we generated SOM
of the differences for Ser5-P and Ser2-P (between rrd1Δ mutant and WT) in untreated
and rapamycin treated conditions (Fig. 5B). We observed no striking difference in Ser2-P
between the WT and  rrd1Δ mutant  in  untreated or rapamycin  treated conditions  (Fig.
5B). However, there were pronounced differences in Ser5-P; all four clusters displayed
diminished  or  increased  Ser5-P  within  both  conditions  (Fig.  5B),  suggesting  that  in
general Ser5-P is  altered in  rrd1Δ mutants.  GO analysis  revealed that some metabolic
genes are decreased in  Ser5-P (cluster F2)  upon rapamycin  treatment  but  others were
increased for Ser5-P (cluster F3) under normal growth conditions (Fig. S8 for GO). Thus,
under both growth conditions, Rrd1 may affect Ser5-P of most genes, which could in turn
affect  RNAPII  occupancy.  This  is  consistent  with  the  altered  RNAPII  occupancy  of
rrd1Δ mutants under rapamycin treated conditions (see Fig. 2B).  
Taken together the above data suggests that rrd1Δ mutants display phenotypes consistent
with a transcriptional elongation defect of RNAPII. 
 
Rrd1 is required to mediate efficient transcriptional stress responses 
The above data clearly indicate that Rrd1 is required for an optimal transcriptional
response  following  rapamycin  exposure.  As  such,  we  predict  that  this  mechanism  is
implicated  in  other  environmental  stress  responses.  Consistent  with  this,  the  rrd1Δ
mutant  exhibits  multiple  phenotypes  including  resistance  to  caffeine,  but  sensitivity
towards vanadate, 4-NQO and calcium [74, 110]. Both, vanadate and 4-NQO are known
to  cause  oxidative  stress  and  thus,  we  expect  the  rrd1Δ mutant  to  be  sensitive  to
additional  oxidants.  To  test  this,  we  challenged  the  mutant  cells  with  the  chemical
oxidant  H2O2 as well as sodium arsenite (NaAs) and found that the  rrd1Δ mutant was
indeed sensitive to these agents as compared to the WT (Fig. 6A and B).  To ensure that
the  sensitivity  was  a  result  of  a  defect  in  gene  regulation,  we  introduced  a  known
arsenite-response reporter that bears the promoter of the ACR3 gene fused to lacZ [136].
ACR3 encodes  a  plasma  membrane  efflux  pump  that  is  upregulated  via the  Yap8
transcriptional activator in response to arsenite [136]. While there was a strong induction
of the  ACR3-lacZ reporter in the WT, it  was hardly induced in the  rrd1Δ mutant (Fig.
6C).  This  data suggests that in  response to NaAs the transcriptional response is  also
affected in the rrd1Δ mutant.
We therefore monitored gene expression of 9 stress responsive genes using the
multiplex PCR GeXP expression technique in response to rapamyin,  H2O2, Na Arsenite
and  heat  shock (see  Materials  and  Methods).  We  chose  genes  that  are  known to be
upregulated  (PRX1,  ARR3,  HSP12,  HXK1,  TSL1)  or  downregulated  (RPL3,  RPL32,
RPS2, and PRS1) in response to environmental stresses as well as control genes which
are not significantly altered (  ACT1, GAL1)  [71]. First, we compared the untreated and
rapamycin  treated expression  data to the  RNAPII  median  enrichment  on these  ORFs
(Suppl. Fig. S11). This analysis revealed that for the both conditions RNAPII correlated
with mRNA expression  for  most  of the genes,  except  the  ribosomal  genes.  We next
compared  the  gene-expression  from  WT  and  the  rrd1Δ mutant  for  the  different
conditions (Fig. 7). Genes that are known to be induced such as (PRX1, ARR3, HSP12,
HXK1, TSL1) in the WT upon stress were indeed upregulated in the WT, but only slightly
in the  rrd1Δ mutant (Fig. 7A). Genes that are known to be downregulated, such as the
ribosomal genes RPL32, RPS2 and RPL3, displayed a similar expression pattern between
WT  and  the  rrd1Δ mutant  (Fig.  7B).  It  might  be  possible  that  for  these genes  other
regulatory mechanisms  are active including  mRNA stability  and translation efficiency
(see Discussion).   In the case of the  PRS1  gene, it  was repressed for some treatments.
Finally,  the control genes  ACT1 and  GAL1 remained  similar  between WT  and  rrd1Δ
throughout  the various treatment  conditions  (Fig.  7C).  Taken together,  the expression
analysis  and the multiple  phenotypes of  rrd1Δ mutants towards environmental stresses
suggest that Rrd1 plays a more generally role in transcriptional stress responses. 
Discussion 
Using  ChIP-chip  analysis  we  demonstrated  that  rapamycin  induces  a  strong
reorganization of the genome-wide RNAPII occupancy.  RNAPII drastically  reduces its
association with anabolic genes (e.g. Ribi and RP genes) and is recruited to catabolic and
stress response genes. These changes are in a qualitatively and timely relationship with
total mRNA expression analyses from rapamycin treated cells [128]. 
We analyzed the genome-wide association of Rrd1 and found that it  co-localizes
with RNAPII on actively transcribed genes. Interestingly, Rrd1 remained associated with
actively transcribed RNAPII genes independently of rapamycin treatment, suggesting that
like  RNAPII, Rrd1 is  at  low levels  on repressed genes but  highly  enriched on newly
transcribed  genes.  The  data obtained  was  comparable  to  another  report  where  TFIIS
occupancy  was  matched  to  RNAPII  [19].  Using  the  same  assay,  we  found  that  the
correlation between RNAPII and Rrd1 (0.61) was similar  to TFIIS and RNAPII (0.64)
(Suppl.  Fig.  S2B)  [19].  This  clearly  indicates,  that like  TFIIS, Rrd1 co-localizes  with
RNAPII.  In fact,  of all  the RNAPII actively  transcribed  genes  (based on ChIP ratio);
Rrd1 was present on 75% (2044 genes) of these genes under normal growth conditions.
However, when cells were treated with rapamycin Rrd1 was still recruited to 72% of the
RNAPII bound genes (2160 genes).  
With the help of gene mapping studies we now can precisely monitor Rrd1 within
the genes:  The Rrd1 gene-association coincides with the reduction of Ser5-P after the
promoter,  and  remains  throughout  the  ORFs.  At  the  end  of  the  gene  Rrd1  binding
gradually  decreases before Ser2-P peaks (see Suppl.  Fig.  S9). This suggests that Rrd1
might exert its function during transcription elongation events. 
Analysis  of RNAPII occupancy in the  rrd1Δ deletion strain revealed that under
normal growth conditions most genes are similarly occupied by RNAPII as in WT cells
(only a small subset of genes was altered, that contains nucleotide biosynthetic pathway
genes  (Suppl.  Fig.  S10)).  However,  in  response  to  rapamycin,  Rrd1  was  needed  to
decrease RNAPII occupancy on a large set  of genes including  the Ribi and RP genes
(Fig.  2A and 2B).  In addition,  Rrd1 was required to efficiently  populate  RNAPII  on
catabolic and stress response genes (Fig. 2B). Interestingly, some anabolic and catabolic
genes  were more  affected  than others,  suggesting  that  Rrd1  does not  generally  alter
transcription, but rather influences genes with variable intensity. 
Further analysis revealed that Rrd1 acts independently of the TATA box binding
protein Spt15 (TBP).  The premise is that upon rapamycin treatment, transcription factors
such  Gln3,  Rtg1/2,  Msn2/4  and  Crf1  are  translocated  to  the  nucleus,  recruited  to
promoters  and  then  stimulate  or  repress  transcription  by  regulating  TBP  and  PIC
assembly [59, 60, 65-67, 165].  If this process is not affected then clearly Rrd1 must act
downstream of the PIC.  For genes that are upregulated in  response to rapamycin,  we
found that TBP is similarly  recruited to the promoter in the WT and the rrd1Δ mutant.
However, our data showed that RNAPII was less recruited in a rrd1 mutant, suggesting
that Rrd1 regulates transcription independently of TBP recruitment. This, and given that
Rrd1 is  associated within the ORF of most genes we believe that it  acts at the level of
initiation and/or elongation.  
In  the  case  of  the  rapamycin  repressed  genes,  we  found  two  modes  of TBP
regulation.  First, for a group of genes TBP binding was depleted and in a second group
TBP remained bound in response to rapamycin.   For the first group, we observed minor
differences between WT and rrd1Δ mutant for TBP binding (see Fig. 4).  This suggests
that Rrd1 influences processes upstream of the PIC.  At the moment, we do not know
how Rrd1 operates upstream of TBP, although it could be through its ability to activate
phosphatases  [89, 90,  176].  For the second group, although TBP remained  the same,
RNAPII  occupancy  decreased  in  the  WT  but  remained  higher  in  the  rrd1Δ mutant,
suggesting  that  Rrd1 function is  downstream of TBP.   This  observation is  similar  as
observed  for  the  upregulated  genes,  again  suggesting  a  role  for  Rrd1  in
initiation/elongation.  
We note that our data also reveal a novel observation showing that TBP remained
promoter-bound onto a subset of anabolic genes while RNAPII decreased in response to
rapamycin and partially dependent on Rrd1 (Fig. 4 and Suppl. Fig. S7).  We suspect that
this might  be a  mechanism to temporarily  turn down transcription,  but  rapidly  restart
gene expression once the stress is over.  
Since  all  the  data  so  far  pointed  towards  a  role  for  Rrd1  in  transcription
initiation/elongation, we tested and found that  rrd1Δ mutants displayed hypersensitivity
against the agent 6-AU, which has been widely used to identify elongation mutants [22,
23, 48, 174, 177]. Although this is not a direct proof, this phenotype is in accordance with
a potential role of Rrd1 in  transcription elongation.  Furthermore,  we found that  rrd1Δ
mutants display an altered Ser5-P but not Ser2-P form of RNAPII on a lot of genes and
this pattern changes upon rapamycin  treatment (Fig.5B). We note that for some genes
Ser5-P  was  increased  whereas  for  others  it  was  decreased,  suggesting  that  Rrd1  is
required to regulate both states (hyper- and hypophosphorylation status).  
It  could  be  that  Rrd1  regulates  the  Ser5-P and  thereby influences  the  rate of
transcription of RNAPII. In the case of downregulated genes that are not regulated by
TBP,  Rrd1  increases  Ser5-P  and  this  causes  RNAPII  to  slow  down  initiation  and
elongation until the stress is over. Indeed, we observe a cluster where Ser-5P is low on
anabolic  genes upon rapamycin treatment in  the  rrd1Δ mutant (Fig.  5B cluster F2). In
contrast, for genes that are upregulated in  response to rapamycin,  Rrd1 favours a low
Ser5-P form of RNAPII, thereby increasing initiation and elongation efficiency.  
 It  is  known  that  RNAPII  occupancy  is  regulated  during  transcription
elongation, for example,  it  was previously reported that the  Ser5-P form of RNAPII is
enriched on ribosomal genes, and this is associated with a slow transcriptional rate [154].
Interestingly,  when  these  cells  were  transferred  from glucose  to  galactose  containing
medium,  the  level  of  RNAPII  decreased  on  these  ribosomal  genes  and  their
transcriptional  rate  increased.  Simultaneously,  RNAPII  was  recruited  to  other  genes
including mitochondrial genes [154]. This suggests a mechanism where RNAPII can alter
its  transcriptional rate in  order to fine-tune gene expression  [154]. Similar  to a switch
from glucose to galactose, rapamycin induces a transcriptional response which requires
some genes to be turned off and others to be induced. We propose that this is regulated
through  TBP  binding,  but  additionally  Rrd1  might  influence  the  Ser5-P  of  RNAPII
thereby fine-tuning the elongation efficiency for up- and downregulated genes. 
Although we previously postulated that the phosphorylation status of RNAPII is
not altered in rrd1Δ mutants when analyzing total cell extract by Western blot (Jouvet et
al., 2010 NAR in revision), here we show that Rrd1 influences  Ser5-P, but not  Ser2-P
phosphorylation, using the ChIP-chip assay. Indeed, since some genes contained a higher
amount  of  Ser5-P  RNAPII,  while  others  had  less,  the Western blot  assay  might  not
identify such subtle changes. 
Based on the above findings, we expect Rrd1 to have a much broader role in stress
response situations, notably the environmental stress responses as they display a similar
pattern of gene expression as rapamycin [63, 71]. Indeed, we found rrd1Δ mutants to be
sensitive  towards agents causing oxidative stress which are known to induce a drastic
transcriptional response (see Fig. 6) [63, 71].  Although these phenotypes are opposite of
the one observed for rapamycin, it is clearly consistent with Rrd1 function.  When rrd1Δ
mutant  cells  are  challenged  with  rapamycin  they  do  no  respond  adequately  to  the
starvation signal  but  the environment  is  nutrient  rich and they are able  to continue to
grow. However,  if  that is  the case during an increase in reactive oxygen species,  their
deleterious effects will be amplified and cause cell death.  Consistent with this, we show
for the first time that Rrd1 is required to adequately induce gene expression on a subset of
stress responsive genes upon various stress conditions (Fig. 7).  Surprisingly,  ribosomal
genes were not strongly altered in  the WT or in the mutant  as was predicted from the
ChIP-chip data.  We suspect that other mechanisms such as mRNA stability maintain a
high amount of mRNA although RNAPII is not transcribing these genes anymore. 
Taken together  we have  shown that  Rrd1 regulates transcription elongation of
RNAPII in response to stress. Further, the multiple phenotypes of rrd1Δ mutants and its
inability  to adequately respond to transcriptional changes support that Rrd1 is  required
for transcriptional stress responses. As such, we propose that Rrd1 is a novel transcription
elongation factor required to modulate gene expression in response to stresses.
Materials and Methods 
Strains, Cell Growth and Crosslinking Conditions
All strains used in this study were from the BY4741 background (Mat a, his3-1, leu2-0,
met15-0, ura3-0). All strains used for ChIP analysis were grown in 50 mL of YPD to an
OD600  of 0.6-0.8 before crosslinking.  For ChIP-chip,  strains  were crosslinked with 1%
formaldehyde for 30 min at room temperature on a rotator. 
Chromatin Immunoprecipitation and Antibodies
ChIP  experiments  were  performed  as  per  (Ren  et  al.,  2000)  [178],  with  minor
modifications.For myc-tag ChIP, we used 5g of 9E11 antibody coupled to 2x107 pan-
mouse IgG DynaBeads (Invitrogen) per sample. RNAPII ChIPs were done using 2L of
8WG16 antibody coupled to 2x107  panmouse IgG DynaBeads per sample. For S2P and
S5P ChIP, we used 100L of rat serum (3E8 and 3E10 respectively)  coupled to 2x107
protein G DynaBeads per sample  [40]. The microarrays used for location analysis were
purchased from Agilent Technologies (Palo Alto, California, United States) and contain a
total of 44,290 Tm-adjusted 60-mer probes covering the entire  genome for an average
density  of  one  probe  every  275  bp  (±100  bp)  within  the  probed  regions  (catalog  #
G4486A and G4493A).  Myc-tag ChIPs were hybridized  against  ChIPs from isogenic
strains  that  did  not  contain  the  tag as  controls.  RNAPII  ChIPs  hybridized  against  a
sample  derived  from  400ng  of  input  (non-immunoprecipitated)  DNA.  Q-PCR  ChIP
experiments were performed as above, only that after phenol chloroform extraction; the
DNA  was  quantified  with  quantitative  real-time  PCR  analysis,  using  the  ABI  7000
machine  (Applied biosciences) and Sybr  green PCR mastermix ( Applied biosystems).
The % IP ORF/ % IP no ORF ratio was determined using the relative efficiency method
and calculated as in Lloyd et al.  [179]. Briefly,  the % IP was calculated with respect to
the Input for the target region (ORF) and the control region (no ORF) and then expressed
as  a  ratio  [179].  Primers  were  designed  using  the primer  express  software  (Applied
biosciences) with a total amplification length of maximum 150bp, exclusively matching
the ORF of the indicated genes (listed in table S2). 
Data Analysis
The data was normalized and replicates were combined using a weighted average method
as described previously [178]. The log2 ratio of each spot of combined datasets was then
converted to Z-score, similar to Hogan et al. [180] to circumvent the large differences in
the immunoprecipitation efficiencies of the different factors. Visual inspection of the Z-
scores was carried out on the UCSC Genome Browser (http://genome.ucsc.edu/). All data
analyses described here were done using data from protein-coding genes longer than 500
bp. Median Z-score values for promoter and gene coding sequences were calculated and
used in our clustering analyses. Promoters are defined as the shortest of either 250bp or
half  the intergenic  region (half-IG) relative  to the reference gene’s 5’ boundary.  Self-
organizing  map  (SOM)  clustering  was  done  with  the  Cluster  software  [171] and
visualized with Java Treeview  [181]. Only genes with no missing  value were used for
clustering. Gene mapping was performed as in Rufiange et al. [182] on selected groups of
genes described in the text. Briefly, data were mapped onto the 5’ and 3’ boundaries in 50
bp windows for each half-gene and adjacent half-IG regions. A sliding window of 300 bp
was then applied to the Z-scores to smooth the curve.
GO analyses on clusters were performed with funcassociate 2.0. For this, an association
file for the entire gene set was generated and used for all analyses [172].
Regression analysis  was plotted using excel, where the x-axis and y-axis contained the
whole data set of the average ORF enrichments of the indicated ChIP. A trend line was
plotted and the R2 was calculated. The regression analysis of Suppl. Fig. S2B was plotted
as in Ghavi-Helm et al., except that RNAPIII genes were excluded [19].
 
Phenotype analysis of rrd1Δ mutants
The  H2O2 survival  curves  were  performed  as  described  previously  [183],  briefly
exponentially growing cells were washed once in 50mM KPO4 (p H7.5) and treated with
the indicated concentration of H2O2 (Bio basic Inc) in 50mM KPO4 (pH7.5) buffer for
one  hour.  Cells  were then washed  and  plated  onto YPD agar  and  scored for  colony
formation after three days at 30C.
Spottest with Na arsenite (Sigma) analysis  was performed as described previously  [73].
For spottests with 6-azauracil (Sigma), strains were transformed with and empty vector
bearing the URA3 gene (pTW423) and spotted onto synthetic media agar plates lacking
uracil, with the indicated concentrations of 6AU. 
β-gal assay 
For  lacZ expression  the  plasmid  bearing  the  ACR3  fusion  with  LacZ [136] was
transformed  into  indicated  strains  and  exponentially  growing  cells  were  treated with
1mM Na Arsenite  (Sigma),  aliquots were taken and the  β-gal assay was performed as
described in [184].
Legends 
Figure 1:  Rrd1 localization correlates with RNAPII along actively transcribed
genes
(A) Self-organizing  map (SOM) clustering  of RNAPII from WT strain  binding  at
ORFs.  Red  colour  indicates  enriched  (bound)  regions  and  blue  colour  represents
depleted regions.  The difference (diff)  was calculated by subtracting  the complete
untreated (- Rap) RNAPII data set from the treated (+Rap) RNAPII data set. (Rap=
rapamycin 100ng/ml for 30 min) The brackets (W1-W6) indicate clusters that were
analyzed by gene ontology (GO) (see Suppl. Fig.S1)
(B) RNAPII occupancy mapped on four groups of genes that are distinguished by
their  amount  of bound  RNAPII.  (red),  genes  are  very highly  bound  by  RNAPII;
(orange) genes are highly bound by RNAPII; (light  blue)  and (dark blue)  low and
very low RNAPII bound, respectively. 
(C) Rrd1-MYC occupancy was mapped on the same groups of genes from panel (B)
(D) SOM clustering of RNAPII WT (-Rap), RNAPII WT difference and Rrd1-MYC
difference  calculated  as  in  panel  (A).  Brackets indicate  clusters  R1-R4 that  were
analyzed by GO (see Suppl.Fig.3)
Figure 2: rrd1Δ deletion affects RNAPII localization in response to rapamycin 
(A) Linear regression of RNAPII enrichment  on ORFs from WT (x-axis) and rrd1Δ
mutant (y-axis). Each circle represents a RNAPII ORF. The trend line and the R2 is
indicated  (0.87).  The  second  regression  shows the  same  under  rapamycin  treated
condition;  R2 (0.75).  Circles  in  red  represent  ribosomal  biogenesis  genes  (Ribi)
whereas green circles represent  ribosomal protein genes (RP). 
 (B)  Self-organizing  map  (SOM)  clustering  of  the  difference  from WT  RNAPII
(obtained from panel A), the difference from rrd1Δ mutant RNAPII (obtained from
Suppl.  Fig.S4)  and the difference  from both (subtraction of the  rrd1Δ mutant  diff
from WT diff).  WT RNAPII (-Rap) was separately added as a reference. The clusters
P1- P6 were analyzed by GO (see Suppl. Fig. S5.)
Figure 3: Validation of the genome-wide analysis
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(A) ChIP of Rpb1 from WT cells followed by Q-PCR on the indicated genes. Dashed
bars indicate rapamycin treatment (100ng/ml for 30 min). The data is represented as a
ratio % IP over Input on the ORF compared to % IP over Input in a non transcribed
region (noORF). 
(B) ChIP of Rpb1 (8WG16 antibodies) from rrd1Δ mutant cells performed as in panel
A. 
(C) ChIP of Rrd1-MYC (Myc antibodies) performed as in panel A.
 Results  for  all  panels  are  shown  as  an  average  of  at  least  three  independent
experiments, error bars indicate the standard deviation and the asterix (*) indicates if
the  Pvalue  is  below  0.05  between  the  untreated  and  treated  condition  using  the
Student T test.
Figure  4:  Rrd1  is  required  for  RNAPII  association  independently  of  TBP
recruitment 
(A) SOM of RNAPII,  Rrd1-MYC and Spt15-MYC difference (+/-) (treated minus
untreated) from the ORF,  ORF and promoter respectively.  RNAPII  occupancy of
corresponding genes from untreated cells  was added separately. Cluster S1-S6 were
analyzed by GO (see Suppl. Fig.S6)
(B) Mapping of Spt15-MYC occupancy on genes contained within clusters S1, S2, S4
and S5, from WT (blue) and from rrd1Δ  mutant  (orange). The same clusters were
also  mapped  for  RNAPII  occupancy  from WT  (green)  and  rrd1Δ  mutant  (red).
Dashed lines indicate rapamycin treatment and solid lines the untreated.
Figure  5:  rrd1Δ mutants  exhibit  phenotypes  consistent  with  a  defect  in
transcriptional elongation
(A)  Spottest  analysis  of WT,  rrd1Δ  and  dst1Δ mutant  strains  on agar  containing
selective  media  lacking  uracil  (-URA),  containing  6-azauracil  (6AU)  with  the
indicated concentration. 
(B) SOM clustering of the difference of serine 5 (median enrichment at the promoter)
and serine 2 (median enrichment at the ORF) phosphorylated form of RNAPII (rrd1Δ
mutant  minus  WT),  as  well  as  RNAPII  from WT  (-Rap)  and  the  difference  of
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RNAPII  (rrd1Δ mutant  minus  WT).  RNAPII  ORF  enrichment  was  added  as  a
reference ( - and + rapamycin). GO analysis data from the genes within cluster SP1-
SP4 are found in Suppl. Fig. S8.
(C) Mapping of serine 5 (full line) and serine 2 (dashed line) phosphorylated form of
RNAPII  on genes contained within  clusters F1 to F4, from WT (green)  and from
rrd1Δ mutant (red). 
Figure 6 rrd1Δ mutants display hypersensitivity to agents causing oxidative
stress. 
(A) Survival curve of WT (open circle) and rrd1Δ mutant strains (closed circle) upon
H2O2 treatment. H2O2 concentrations are indicated below; result shown is an average
of three independent experiments and error bars indicate the standard deviation.
(B) Spottest analysis of WT and rrd1Δ mutant strain with indicated Na Arsenite
treatment (1mM) 
(C) LacZ reporter expression analysis from the ACR3-lacZ fusion plasmid, expressed
in Miller units. WT (open circle) and rrd1Δ mutant (closed circle) show the ACR3-
lacZ expression over time in response to 1mM Na Arsenite treatment.
Figure 7 mRNA expression analyses in response to different stress conditions 
GeXP multiplex Q-PCR analysis of 11 genes under untreated, rapamycin treated
(100ng/ml for 30 min), 0.6mM H2O2 for 30 min, 1mM NaArs for 30 min, heat shock
at 37C for 30 min. The data is expressed in log 2 ratio and is calculated relative to an
internal PCR control.  (A) Five upregulated genes. (B) Four downregulated genes (C)
Two control genes.
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Michael Newmarch, Francois Robert, and Dindial Ramotar
SUPPLEMENTAL EXPERIMENTAL PROCEDURE
Table S1: A list of all primers used for the Q-PCR analysis
Figure S1, S3-S6, S8, S10: GO analysis of figures 1-5 
File S1 contains GO analysis of cluster W1-W6 from figure 1A
File S3A contains GO analysis of cluster R1-R4 from figure 1D
 from figure 1D
File S4 contains SOM clustering and GO analysis of rrd1Δ mutant (-/+)
rapamycin
File S5 contains GO analysis of cluster P1-P6 of figure 2B
File S6 contains GO analysis of cluster S1-S6 of figure 4A
File S8 contains GO analysis of cluster SP1-SP4 of figure 5B
Figure S2: (A) A complement to Figure 1B, same experiment besides that the data
was obtained from rapamycin treated cells. (B) Linear regression of all enriched
ORFs x-axis Rrd1-MYC and y-axis RNAPII (-) and (+) rapamycin
Figure S3B genome browser analysis of 4 genes representative of each group R1-R4
(WT stands for RNAPII)
Figure S4: contains SOM clustering and GO analysis of rrd1Δ mutant (-/+)
rapamycin
Figure S7: Spt15 and RNAPII mapping of cluster P1, P2 P3, P4 of fig 2B
Figure S9: Mapping of serine 5, serine 2, RNAPII and Rrd1-MYC on transcribed
genes
Figure S10: (A) SOM clustering and GO analysis of WT, rrd1Δ mutant as well as
the difference (rrd1Δ minus WT) without rapamycin treatment. 
Figure S11: Comparison of GeXP mRNA expression and RNAPII median average
ChIP data of the corresponding gene for untreated and rapamycin treated conditions.
Both are expressed in log2 ratio.  
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ACCATCTGGAAGTTCGTAGGATTTAct1R
AAACTATGTTACGTCGCCTTGGAAct1F 
GAAGCCGCACATTTCCAATTTel1R (noORF)
TTGTAGAAAAAACGTGGACGGTAATel1F (noORF)
GGAACCCATCCCTTTTCTTCArps2R
AACAGAGGCCGTCCAAACAGrps2F
AGCGCCACGAGAGTCAATTChsp104R
TTGAGGCCATCAAGCAACAAhsp104F
AGCGCGATCAGTTGCACATput4R
AGCGAGCCGCACAAACTAAput4F
CTTAGCTCTAGCCAAAATGACAACTCrpl32R
GCCGCTGAAATTGCTCACArpl32F
Q-PCR primers used in this study 
Table S1 Supplementary information Poschmann J. et al.,
Supplemental tabe S1 Poschmann J. et al., 2010
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3 DISCUSSION 
From its discovery in 1998 until today, our laboratory has studied the role of
Rrd1  to  identify  its  cellular  function  [74].  Since  rrd1Δ deletion  was  found  to
contribute to oxidative stress and DNA damage induced by the carcinogen 4NQO, we
were interested in identifying the role of Rrd1 in DNA response pathways [74, 114].
A breakthrough was made when we found that Rrd1 is required for the transcriptional
response towards rapamycin and its PPIase function was published in 2006 [93, 113].
This project started with the hypothesis that Rrd1 is  involved in the transcriptional
regulation of RNAPII. From here we were able to make several discoveries that led to
a  model  for  Rrd1  regulating  RNAPII  in  response  to  various  stresses.  These
discoveries  are  listed  and  discussed  below,  followed  by  a  proposed  model  of
regulation. 
3.1 Rrd1 acts independently of the Sit4-Tap42 complex 
As known from the literature, rrd1Δ mutants are highly resistant to rapamycin
and the Rrd1 protein interacts with the PP2A-like phosphatase Sit4 [111-113]. Sit4
and Rrd1 interact  with Tap42 and are thought to dephosphorylate  and activate the
transcription factor Gln3 in response to rapamycin or nutrient starvation. This results
in the activation of nitrogen discrimination genes, including the MEP2 gene which is
required for ammonium intake [113]. Therefore, it  was postulated that Rrd1 acts in
conjunction with Sit4-Tap42 in response to rapamycin and that this function accounts
for the high resistance of rrd1Δ mutants [117]. However, our lab found that the Gln3
target  gene  MEP2 is  induced  independently  of Rrd1 [113].  This  suggests that the
Gln3 signaling pathway might not require the function of Rrd1 and that Rrd1 might
be  functioning  elsewhere  in  the response to rapamycin.  To further  investigate the
possibility  this  possibility,  we  created a  double  deletion  rrd1Δ-gln3Δ strain.  This
strain displayed an additive phenotype respective to the single mutants in response to
rapamycin  (article  1  figure  1).  This  genetic  evidence  supports  that  Rrd1  has
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additional roles in the response to rapamycin.  However, we cannot exclude that this
new role of Rrd1 is independent of its association with Sit4 (see below). 
3.2 Rrd1 interacts with RNAPII 
This  novel  function for Rrd1 was confirmed  when we showed that Rrd1 is
associated  with  chromatin.  This  suggests  a  role  in  DNA metabolism  and  indeed,
using different assays we identified that the major subunit of RNAPII interacts with
Rrd1.  In  addition to co-immunopreciptiation and pull-down assays,  ChIP analysis
showed that  both proteins  co-localize  on actively  transcribed  genes,  and  that  this
association remains during transcriptional changes induced by rapamycin.  Actually,
we found that Rrd1 was bound to 75 % of genes (approx. 2000) that were occupied
by RNAPII. More precisely, Rrd1 localizes within the body of the gene, suggesting a
role  during  transcription  elongation  (article  2  Supplemental  figure  S9).  Indeed,
multiple  elongation  factors  associate  with  RNAPII  once  it  dissociates  from  the
promoter and initiates elongation. For example, using the same type of assay, TFIIS
was shown to have  a similar  association with RNAPII as did  Rrd1 [19] (article  2
supplemental  figure  S2B).  Similar  to  Rrd1,  another  peptidyl  prolyl  isomerase,
Pin1/Ess1, is known to interact with RNAPII during elongation [44, 95, 106]. 
When  Rrd1  was  immunoprecipitated  with  RNAPII,  we  were  also  able  to
immunoprecipitate the PP2A-like  phosphatase Sit4.  It  is  very likely  that Rrd1 and
Sit4 interact together when associated with RNAPII.  Our data did  not  allow us to
exclude  a  role  for  Sit4  in  Rrd1  function;  therefore,  this  would  be  interesting  to
investigate further.
Interestingly,  we found that Rrd1 did associate with the CTD of Rpb1. This
association points towards a regulatory role of Rrd1, since the CTD is a recruitment
platform for multiple  factors during elongation and is  strongly modified throughout
these steps. More interestingly, the CTD has been previously shown to be isomerized
by the PPIase Pin1/Ess1 [95, 106, 159]. Taken together our data reveal for the first
time  that  Rrd1  interacts  directly  with  the  transcriptional  machinery  on  actively
transcribed  genes.  The  interaction  is  at  least  partially  mediated  via  the  CTD  of
RNAPII and this interaction takes place when RNAPII is moving along the ORFs. 
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3.3 Rrd1 isomerizes the CTD of RNAPII 
Since Rrd1 is  a peptidyl  prolyl isomerase and it  interacts with RNAPII,  we
addressed  the  question of whether  RNAPII  would  be  a  substrate  of Rrd1.  Using
circular dichroism, we showed that Rrd1 isomerizes the CTD of RNAPII  in vivo in
response to rapamycin and also directly in vitro when both are purified. In addition,
we  confirmed  a  structural change  of the  CTD in  response  to  rapamycin  using  a
limited proteolysis assay. 
To analyze proline isomerization, one can make use of four different assays, namely
circular  dichroism,  limited  proteolysis,  limited  proteolysis  coupled to fluorescence
and  NMR analysis.  The  first  two allow the use of the complete protein  with  the
disadvantage that one will not determine the precise proline that is isomerized. The
latter  two will  allow for  identification  of the exact  proline,  but  requires  that  the
protein be segmented into peptides. We used CD analysis since it allowed us to purify
two different stable conformations of the CTD from cells (see chapter 2.1 figure 4).
Instead of purifying  the whole  RNAPII complex,  which  contains  at  least  12 large
proteins,  we generated a GST-CTD fusion protein that is  easily  purified from cells
and was also shown to be functional in vivo (e.g. phosphorylation status) (see chapter
2.1 supplemental figure S1). The advantage of the fusion protein (GST-CTD) is that
it retained its structural conformation throughout the purification steps. This is not the
case with peptides as they are known to spontaneously and slowly alter their proline
configuration over time [159]. In addition, using a CTD that can be phosphorylated
(see chapter 2.1 figure 3A and supplemental figure S1) was helpful since the exact
substrate specificity of Rrd1 is  not known. Using  peptides,  we would first  have to
determine  the exact  phosphorylation status of the substrate  peptide.  However,  the
disadvantage of using the CD technique is that we could not determine exactly where
Rrd1  isomerizes  the  CTD  or  in  which  configuration  it  needs  to  be  (e.g.
phosphorylation status). Also, albeit that we demonstrated that purified Rrd1 can alter
purified  GST-CTD structure,  we have  no direct  proof that  this  is  through proline
isomerization, although this is the most probable explanation. Future work is required
to directly demonstrate that Rrd1 isomerizes the CTD of Rpb1. Experiments should
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include  a catalytically  inactive  mutant  of Rrd1 and the use of peptides coupled to
NMR  or  limited  proteolysis  with  fluorescence  in  order  to  determine  the  exact
substrate configuration of the CTD. Another interesting alternative would be to co-
crystallize Rrd1 with the CTD of Rpb1 as this would provide structural cues of its
interaction and substrate binding. 
It is noteworthy that we showed for the first time that a PPIase isomerizes the
CTD of Rpb1  in  vivo  using  CD analysis.  Although  it  is  widely  accepted  in  the
literature that Pin1/Ess1 is  a CTD isomerase,  a direct  demonstration that the CTD
isomerization happens  in vivo is  not available  yet.  The only direct proof that Ess1
isomerizes the CTD of Rpb1 was shown in vitro using small peptides as substrates for
the protease assay and NMR [159]. 
3.4 Rrd1 modulates transcription in response to rapamycin
The consequences of CTD isomerization can be multiple. For example, it may
interfere with recruitment of CTD binding proteins or alter the phosphorylation status
of the CTD as was shown for Ess1 [44]. However, our previous studies revealed that
Rrd1 is  required  to  modulate  the  expression of a  subset  of genes  in  response  to
rapamycin.  In addition, we found that although RNAPII is  degraded in response to
rapamycin after a long period of treatment, this degradation is strongly reduced in the
rrd1Δ mutant [113]. 
The observation that RNAPII is degraded in response to rapamycin might be due to a
mechanism that occurs after a long period of hunger. We observed an inhibition of
this degradation in the  rrd1Δ mutant but this was not specific  to Rrd1. In fact, this
degradation was also diminished when other rapamycin resistant mutant were tested
[113] (unpublished  data).  One  could  imagine  that  when  nutrient  limitation  (or
rapamycin treatment) persists, cells  catabolise excessive protein in  order to survive
longer.  It  is  noteworthy that  the  degradation only  starts  after  45  min  to  1  hour,
whereas the most drastic transcriptional changes occur at 30 min, which then decrease
within the next hour [128]. This suggests a timely response where gene expression of
stress response genes are turned on before and while excessive RNAPII is degraded
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and  explains  why  genes are enriched  for  RNAPII,  but  the overall  RNAPII  levels
eventually decrease.  
 Since Rrd1 interacts with  RNAPII  and  modulates its  expression,  we used
ChIP on chip analysis to determine how many genes are affected by the deletion of
RRD1. Although this question could have been addressed by performing expression
analysis and quantifying the mRNA using microarrays, we chose to use ChIP on chip
technology as this gives additional information on the localization of RNAPII and its
association with  Rrd1.  We  found  that  Rrd1  plays  a  major  role  in  transcriptional
regulation of genes that are repressed or induced in response to rapamycin. Our gene
ontology analysis  revealed  that  Rrd1  is  especially  required  for  the  repression  of
regulatory  metabolic  genes,  including  genes  involved  in  regulatory  functions  of
transcription,  translation  and  ribosome  biogenesis  (see  chapter  2.2  figure  2B and
supplemental figure S5). We suspect that Rrd1 might be part of a specific regulatory
mechanism.  For example,  the expression of regulatory genes needs to be modulated
rapidly  in  order  to  alter  the  expression  of other  metabolic  genes  (e.g.  ribosomal
structural genes). Results obtained until now don’t allow us to prove this hypothesis,
which  would  require  additional  expression  analysis  after  shorter  periods  of  drug
treatment  of  the  regulatory  metabolic  genes  and  compare  them  with  structural
ribosomal  genes. However,  using  our  assay,  we  have  demonstrated  that  Rrd1
regulates transcription independently of its Tap42- Sit4-Gln3 signaling activity since
this  branch  does  not  regulate  ribosome  biogenesis  [60].  In  addition,  we  found
catabolic and stress genes to be regulated by Rrd1, which are part of the Msn2/Msn4
signalling  branch thought to be regulated only partially  through Tor signaling  (see
section 1.1.8.1.1) [63].
Taken together, results indicate that Rrd1 regulates a large set of genes in response to
rapamycin in an unknown fashion. The next question to be addressed was how Rrd1
regulates transcription.
3.5 Rrd1 is a transcription elongation factor 
We  have  obtained  several  data  that  point  towards  a  role  of  Rrd1  in
transcription elongation, where it  regulates RNAPII association with the gene. First,
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as  already  discussed  above,  Rrd1  isomerizes  the  CTD  of  RNAPII,  the  CTD
occupying a central role during transcriptional regulation [7-9, 14, 26]. Second, using
a new assay developed by our team, we found that purified Rrd1 was able to release
RNAPII from the chromatin in vitro (see chapter 2.1 figure 8). We conclude from this
experiment  that Rrd1 enables RNAPII dissociation from genes, presumably through
its interaction with and isomerization of Rpb1. Third, with our in vivo data from ChIP
on chip  analyses,  we showed an opposite effect  when  RRD1 was absent: RNAPII
remained on ribosomal genes as well as regulatory metabolic  genes involved in the
response to rapamycin. Thus, in vivo Rrd1 also promotes the release of RNAPII from
specific genes. 
A similar  observation  was found with  Pin1. When Pin1 is  overexpressed it
promotes RNAPII dissociation from active genes,  followed by the accumulation of
the dissociated RNAPII in enlarged structures [95, 155]. Although these assays are
different,  it  seems  that  PPiases  are  capable  of  releasing  RNAPII  from  genes.
Consistent with this  data, it  was previously published that a slow transcribing  and
highly serine 5 phosphorylated form of elongating RNAPII is present on a group of
ribosomal  genes  under  glucose  grown  conditions[154].  When  these  cells  were
stressed  by  a  switch  from glucose  to  galactose  containing  medium,  this  form of
RNAPII  disappeared on the ribosomal  genes  and RNAPII was recruited to newly
activated genes [154].  The authors concluded that under normal growth conditions,
RNAPII  is  enriched  on  ribosomal  genes  [154],  which  could  be  a  ‘storage’
mechanism. Thus, in response to metabolic changes, this excessive RNAPII would be
rapidly recruited to other genes. As demonstrated for rapamycin treatment, a similar
situation  occurs  where  RNAPII  needs  to  be  released  from  genes  that  are
downregulated and be recruited to newly activated genes.
Fourth, from our ChIP on chip data, we find that rrd1Δ mutants display in general an
altered serine-5-phosphorylated form of RNAPII on most genes under normal growth
or rapamycin  treated conditions.  This  suggests that Rrd1 is  required is  required to
modulate  serine  5  phosphorylation  of  RNAPII  population,  for  example  during  a
transcriptional stress where RNAPII needs to be redistributed.
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3.6 Rrd1 is required for a broad range of stresses
The litterature confirms  that  rrd1Δ mutants display  multiple  phenotypes  in
response to a broad range of drugs (see section 1.2.2). One common aspect shared by
many of these drugs is that they all cause oxidative stress. Our study also identified
drugs that generate ROS and cause  rrd1Δ mutant  sensitivity (see chapter 2.2 figure
6). We further note that Rrd1 might be required for the osmotic stress response. Our
unpublished data shows that rrd1Δ mutants display sensitivity towards osmotic stress
induced by NaCl in a specific  yeast background (W303). Another study has shown
that  this  response  occurs  in  response  to  Ca2+ [110].  These  findings  bring  up the
question of what is common between oxidative stress, osmotic stress and rapamycin.
The answer to this question is  that they all induce similar  transcriptional responses
[71]. To equivalent extents all induce stress, causing the induction of the expression
of catabolic  genes  and  the inhibition  of ribosome biogenesis;  these  responses  all
being  mediated  by  the  same  transcription  factors  [63].  Since  rrd1Δ mutants  are
sensitive  to  all  three  conditions  we  believe  that  Rrd1  is  required  for  the  same
mechanism of transcriptional regulation that has been demonstrated for rapamycin.
We have already obtained initial data, that Rrd1 is required for the transcription of the
ACR3-LacZ  reporter  gene  in  response  to  Na  Arsenite  treatment  (see  chapter  2.2
figure 6C). ACR3 encodes an efflux pump that is highly upregulated in response to
Na Arsenite and is crucial for its cellular detoxification [136].
To confirm the lacZ reporter assay and to test if  rrd1Δ mutants are also required for
other stresses, we used the GeXP multiplex PCR system to simultaneously quantify
several  mRNAs  (see  chapter  2.2  fig.  7).  The  GeXP  system  was  developed  by
Beckman and the principles  are similar  to those in  quantitative  real-time PCR. To
distinguish  between  different  genes  within  the  same  sample,  LM-PCR  adds  a
different fragment to each target gene, so that each can be distinguished by a different
length.  This  analysis  is  performed  by  a  fluorescence  sensitive  capillary  system,
simultaneously  measuring  the intensity  (quantity)  and  size  (gene  specificity).  The
Kanamycin  resistance marker  is  added as an internal  control and  as a  control for
normalization in between different conditions. 
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The results presented clearly indicate that Rrd1 is  not only required for the
expression of rapamycin regulated genes, but also, in response to other environmental
stresses  such  as  oxidative  stress  and  heat  shock  (see  chapter  2.2  figure  7).  It  is
noteworthy that all chosen genes do not respond to the various treatments in a similar
manner. A striking example is the ACR3 gene which is only upregulated in response
to Na arsenite but not to the other stresses. This is  also true for the oxidative stress
gene PRX1 which is not induced in response to rapamycin or heat shock. Independent
of this, Rrd1 is clearly required to regulate expression of these genes as most of them
fail to reach WT expression levels in response to the various stresses.
Interestingly, the ribosomal genes were not strikingly downregulated as would
been suggested by the ChIP on chip data (see chapter 2.2 figure 7) and was shown in
[71]. This might be due to different strain backgrounds used (By4741 as opposed to
DBY7286).  In  the  By4741  background  it  might  be  the  case  that  the  ribosomal
mRNAs are additionally regulated by their stability and that they have a longer half-
life  then the other  genes  analyzed  and  therefore do not  show a big  difference  in
response to the various stresses. However, this was not the case for all downregulated
genes since Prs1 also showed a repression in response to various stresses (see chapter
2.2 fig. 7). Here one can also observe that rrd1Δ mutants failed to adequately inhibit
transcription for most conditions.
 Taken  together,  our  data  suggests that  Rrd1  modulates  the environmental  stress
response (ESR) by regulating transcription of RNAPII. 
3.7 Model of RNAPII regulation 
From  the  above  considerations,  we  propose  the  following  model:  under
normal  growth conditions,  Rrd1  is  associated  with  RNAPII  complex  on actively
transcribed genes (figure 8A). While associated to these genes, Rrd1 may promote the
transition from the serine 5 phosphorylated form to the serine 2 phosphorylated form
of RNAPII. This would occur on specific  genes including the ribosomal genes and
could be done by isomerizing the CTD of Rpb1, thereby recruiting a phosphatase that
would  dephosphorylate  serine  5  and  increase  the RNAPII  transcription  rate,  thus
releasing it from the gene. These genes contain a relatively high amount of RNAPII,
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which is  associated with a low transcription rate. Upon stress, two mechanisms  of
transcriptional  inhibition  are  activated.  First,  genes  that  are  required  to  regulate
metabolic processes are downregulated rapidly via Rrd1 using the above mechanism
(figure 8B). In this group of genes, the PIC remains assembled, allowing RNAPII to
be rapidly recruited to restart transcription once the stress is resolved. Second, genes
encoding  structural  factors  involved  in  metabolism,  such  as  ribosome  biogenesis
genes, are downregulated due to a rapid release of RNAPII via Rrd1 in addition to the
PIC being disassembled at the promoter (figure 8B). RNAPII remains associated with
Rrd1 and this complex along with the GTFs, can then be recruited to newly activated
genes such as those needed for catabolism and stress responses. The role of Rrd1 in
these situations would be similar  to what was described above, which would be to
assist  RNAPII  elongation  and,  if  necessary,  to  stimulate  the  release  of  RNAPII
(figure 8A).
Our model is  based on our experimental data presented in  the  two articles.
However, two statements in this model are based on an assumption that has not been
tested: (i) although it was shown that ribosomal genes that contain a high amount of
the serine 5 phosphorylated form of RNAPII are associated with a low transcriptional
rate [154] we can only assume that Rrd1 is required to stimulate the transcriptional
rate by decreasing serine 5 phosphorylation. This assumption needs to be tested and
involves a complicated assay that to date, has only been published by the same group
[185]. A possible alternative is that in response to rapamycin Rrd1 increases serine 5
phosphorylation  of  RNAPII  on  these  genes,  thereby  slowing  down  even  more
transcription. This would happen on the set of genes where TBP remains bound and
once the stress is over these genes can then be rapidly re-activated.  (ii)  Second, we
postulated that this might  be the mechanism by which Rrd1 releases RNAPII from
genes.  Although this  is  a  logical  interpretation of the data,  we cannot  exclude  an
alternative  mechanism  of RNAPII  release  by  Rrd1.  For  example,  in  response  to
stress, Rrd1 can be activated by post-translational modifications and thus may alter its
activity causing it to isomerize RNAPII in such a way that it  is released in a more
drastic fashion. We have analyzed the post-translation modifications  of Rrd1 using
mass  spectrometry and  found  a  putative  ubiquitylation  site  (K236)  (unpublished
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data).  Therefore,  it  could  very  well  be  that  under  certain  circumstances,  Rrd1  is
regulated by a signaling pathway that leads to the ubiquitylation and modification of
Rrd1 activity.  Further  investigation of this  putative  ubiquitylation site  is  required,
such as the generation of site directed mutants of this specific lysine (R236K).    
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Figure 8 Model of RNAPII regulation
GTFs represent the PIC localized on the promoter. RNAPII (light blue) is the initiating RNAPII which
is highly phosphorylated on serine 5 of its CTD, as indicated by the black line and the number 5. The
darker blue RNAPII is the elongating RNAPII that has increased serine 2 phosphorylation. 
3.8 The catalytic activity of Rrd1 
Rrd1 has been extensively characterized as a peptidyl prolyl  isomerase [87,
88,  93].  We,  so  far,  have  analyzed  the  rrd1Δ mutant  phenotypes,  the  Rrd1
associations  with  RNAPII,  its  genome  wide  localization  and  shown  from  a
biochemical point of view that Rrd1 is able to release RNAPII from the chromatin in
vitro. Another critical experiment would be to demonstrate that the catalytic PPIase
activity of Rrd1 is really involved in the isomerization of the CTD. To do this, site
directed mutagenesis can be used to alter critical residues in the catalytic center of the
PPIase domain. Such residues have already been characterized, including a mutation
which results in the conversion of the glycine into an aspartate at site 205 (G200D in
S.cerevisiae) which was shown to impair the isomerase activity of Rrd1 (see figure 7)
[87, 88]. We now have designed a plasmid that expresses the RRD1 gene containing
the G200D mutation to purify  sufficient  amounts of the protein for use in  in vitro
assays. We would like to address two critical questions with this mutant: first, is this
mutant  able  to  isomerize  the  CTD-GST  fusion  protein  using  the  CD  analysis?
Second, does this mutant release RNAPII from the chromatin? 
The first question is still in the process as it requires several purification steps and it
is  currently being performed by Nathalie  Jouvet. However, for the second question
we can now show that the catalytic D200G mutant is not able to release RNAPII from
the chromatin (see figure 9). This clearly indicates that the isomerase activity of Rrd1
is required for this step. This experiment does not directly support the hypothesis that
Rrd1 isomerizes the CTD of RNAPII, but it does confirm that Rrd1 is able to release
RNAPII form the chromatin in vitro, and that this activity requires the PPIase domain
of Rrd1. It is still possible that besides the CTD of RNAPII, other PPIase substrates
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of Rrd1 are required for the release of RNAPII from the chromatin (discussed in the
next section). 
Figure 9 The Rrd1 catalytic mutant (D200G) does not release RNAPII from the chromatin.
Experiments were performed as in chapter 1 figure 8, only that Mock (no protein added), D200G
(Rrd1 catalytic mutant protein added) RRD1 (native protein added). 
3.9 Alternative targets of Rrd1
To date, only two substrates of Rrd1 isomerase activity have been discovered.
The first  substrate to be identified  was a  peptide matching  a specific  sequence of
PP2A (186LQEVPHEGAMCDL198) [93].  Rrd1 does not share the same substrate
specificity  as Pin1/Ess1, which targets phosphorylated threonine  or serine  residues
that precede the proline residue [93]. This suggests a precise substrate specificity of
Rrd1  but  it  does  not  exclude  that  Rrd1  might  isomerize  other  targets  of  the
transcriptional machinery besides the CTD of RNAPII. One can imagine that Rrd1
might isomerize a phosphatase that would then dephosphorylate serine 5 of the CTD
of RNAPII. Also, depending on whether a cell is under ‘normal growth conditions’ or
‘stress conditions’,  Rrd1 substrate specificity  could be altered by post-translational
modifications, therefore drastically alter RNAPII gene association. 
As it  is  known, Pin1 has multiple  cellular  targets involving  a pleiotropy of cellular
events  [94-96,  186].  The  same  could  be  true  for  Rrd1,  since  we  have  already
identified a novel function of Rrd1. In addition, our genome-wide Rrd1 association
  Mock    D200G    RRD1CHR SOL Mock   D200G     RRD1
RNAPII
Apn1-MYC
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study showed that Rrd1 associates with a group of genes independently of RNAPII
(article 2 figure 1D and 4A), suggesting that it might perform additional roles to the
one described here. 
Very recently,  a new role of Rrd1 was found in the regulation of telomere healing
[187].  It  is  thought  that  Rrd1  regulates  the  Pph3  phosphatase,  which  in  turn  is
recruited to double strand breaks (DSB) where it promotes the recruitment of Cdc13
by dephosphorylating its residue S306. Rrd1 seems to play a role here similar  to its
previously described function as a phosphatase activator [90]. If Rrd1 is lacking Pph3
does  not  adequately  dephosphorylate  Cdc13  and  its  recruitment  to  DSB  sites  is
prevented by its phosphorylation [187]. This new mechanism supports a model where
Rrd1 as a  peptidyl  prolyl  isomerase has  multiple  functions  within various cellular
conditions. 
3.10 Involvement of Rrd1 in regulatory pathways
As stated above, Rrd1 is required for the regulation of some (though not all)
ribosomal and metabolic regulatory genes. In addition, it is required for some stress
responsive  genes  (See  chapter  2  Figure  2B).  This  is  quite  surprising  since  the
ribosomal genes and the stress responsive genes are orchestrated as regulons which
are in turn controlled by the recruitment of transcription factors [63]. The ribosomal
genes are controlled by Fhl1 and Crf1 and the stress responsive genes are controlled
by Gln3, Msn2/4 and Rtg1/2 [59-61, 63, 65-67]. If Rrd1 is somehow involved in the
transition of these transcription factors from the cytoplasm to the nucleus, one would
expect that all genes would be similarly regulated by Rrd1. This, however, is not the
case, so we expect Rrd1 to function elsewhere. 
It is largely accepted that ribosome biogenesis is regulated in such a way that
all components are transcribed in a coordinated manner (from RNAPI, II and III) so
that the right amount of structural parts are produced [121]. So why does Rrd1 only
regulate a fraction of ribosomal genes expressed by RNAPII?  
First of all,  the above described model proposes that Rrd1 regulates RNAPII during
transcription elongation, thus eliminating any upstream regulatory mechanisms. 
Second, several hypotheses could explain this phenomenon: 
124
Rrd1  functions  as  a  molecular  timer  to  regulate  specific  subclasses  of
ribosomal genes in response to stress. For example, the mechanism of transcriptional
regulation of Rrd1 is  required to rapidly  remove RNAPII from a specific  type of
ribosomal genes that are not of structural but rather regulatory nature (see chapter 2.2
Suppl. Fig. S5). Since we only look at a specific  time point (30 min after treatment)
we do not know if these genes are eventually repressed in an rrd1Δ mutant. Indeed
ribosomal genes have been separated in ribosomal protein (RP) genes which are the
structural  proteins  of the  ribosome  as  well  as  ribosomal  biogenesis  (Ribi)  genes,
which  are  necessary  for  proper  transcription,  assembly  and  maintenance  of  the
ribosomes [121]. In chapter 2.2 Figure 2A we have already observed that most Ribi
and RP genes are affected in an rrd1Δ mutant in response to rapamycin.  To further
test whether Rrd1 affects RP and/or Ribi genes, RP genes and Ribi genes were added
to figure 2D of chapter 2.2 (see figure 10, below).
Figure 10 Rrd1 regulates Ribi genes and RP genes. Each line (red) acounts for a Ribi or RP genes
depending on the row. This figure is modified from chapter 2.2 figure 2B.
It turns out that  rrd1Δ deletion does affect  Ribi  genes much more strongly
then RP genes  (compare  cluster  P1, P2 and P6).  Rrd1 affects  about  37 % of the
rapamycin downregulated regulated Ribi genes (cluster P2). Most of the other Ribi
genes (59 %) are found in cluster P1, which is only mildly affected by rrd1Δ deletion.
Also, 90% of the RP genes are found in cluster P1 and only 5% are found in cluster
P2.  This suggests that Rrd1 does not specifically  regulate the RP or the Ribi genes
but rather affects both groups of genes with variable intensity.  It is noteworthy that
  RNAPII  rrd1Δ diff (+/-)
RNAPII WT diff (+/-)
rrd1Δ diff -  WT diff
P1 P3 P4P2 P6P5
Ribi genes
RP genes
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that some factors affect gene expression of Ribi genes but not RP genes. For example,
Dot6 and Tod6 have been shown to be specifically required to inhibit  the expression
of Ribi  genes  but  not  RP genes  [188].  Another  example  is  that  Med20 (Srb2),  a
component of the mediator complex, is required to exclusively repress RP genes in
response to rapamycin  treatment  [189].  It  is  known that  RP genes and Ribi  genes
contain  different  transcription  factor  binding  sites  within  their  promoters  and
therefore,  the different  activities  of Med20,  Dot6 and  Tod6 on Rp and Ribi  gene
expression can be explained [188, 189]. However, for Rrd1, this is not the case since
it affects both the Ribi and the RP genes. 
So far the only common feature of the Rrd1 regulated genes is that TBP (Spt15) did
not alter its promoter association (See chapter 2.2 figure 4). In response to rapamycin
TBP remained similarly  associated to the promoter but RNAPII decreased on these
genes.  In  the  rrd1Δ mutants,  TBP  also  similarly  remained  at  the  promoter  but
RNAPII occupancy was higher as compared to WT cells.
How and why does this group retain TBP (and probably the rest of the PIC) at these
promoters  is  not  clear.  However,  TBP  binding  at  these  genes  resembles  a
phenomenon that has been discovered thanks to genome wide association studies and
is  called  a  poised  state.  It  is  postulated  that  RNAPII  can  remain  poised  at  the
promoter  within  the  PIC,  for  example  in  yeast  during  stationary phase  [190].  In
higher eukaryotes, this poised complex is often found within developmental genes or
heat  shock  protein  genes,  and  then  once  the  signal  is  given,  RNAPII  starts
transcribing  [190].  We  could  observe  a  similar  mechanism  here,  where  the  PIC
remains assembled  at these promoters, and once the starvation period is  over, it  is
likely  that  transcription  can  rapidly  resume  by  recruiting  RNAPII.  We  did  not
observe an accumulation of RNAPII at these promoters, suggesting that only the PIC
remains poised. RNAPII might be recruited to other genes for transcription of stress
response genes, or for degradation of excess proteins. Taken together, we propose a
new  mechanism  of  RNAPII  transcriptional  regulation  that  does  not  fit  with  any
known regulatory mechanism, but resembles a poised form of RNAPII. 
This  might  explain  why only some ribosomal  genes  are downregulated by
Rrd1.  However,  this  mechanism  does  not  explain  why  only  some  genes  are
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upregulated by Rrd1 and this again, is independent of TBP recruitment (see chapter
2.2  figure 4).  One common link  between the upregulation and downregulation by
Rrd1 is  that  both are independent  of TBP binding  and  (probably)  PIC assembly.
Instead,  the  transcription  changes  occur  during  transcription  elongation,  which  is
further  indicated by the fact  that serine  5 phosphorylation of the RNAPII  CTD is
strongly  altered  in  rrd1Δ  mutants.  Therefore,  we  believe  that  whether  it  is
upregulation or downregulation, Rrd1 influences the transcription elongation process
through a so far unknown mechanism which involves serine 5 phosphorylation. The
big question remains, why are some genes affected strongly by Rrd1 but not others?
Here again one can propose the hypothesis, that Rrd1 as a peptidyl prolyl isomerase
acts as a molecular timer to timely optimize the transcriptional response. 
3.11  S.cerevisiae as a model
Throughout the entire project, S.cerevisiae was used as a model. Although it is
largely  accepted that  yeast  is  a  good model  to  study complex  molecular  biology
processes such as transcription, DNA replication or cell cycle, herein, we demonstrate
again that S.cerevisiae is a powerful research tool. Had genome-wide deletion arrays
not been available, the role of Rrd1 in response to rapamycin would probably not yet
have been elucidated. Our unpublished data (Nathalie Jouvet) from experiments with
mammalian  cells  using either siRNA or shRNA directed against  PTPA has not yet
allowed  us  to  determine  whether  PTPA  is  required  for  the  cellular  response  to
rapamycin.  Several  variables  might  explain  the  discrepancy,  such  as  the  longer
rapamycin treatment used in mammalian cells compared to yeast, the % knockdown
as well as the variability obtained in each experiment and in the different cell lines.
Therefore, the generation of a PTPA-knockout mouse would be a necessary step to
further analyze  the role  of PTPA in mammalian  cells.  However,  the generation of
transgenic mice is known to be a costly and lengthy procedure. 
Our  study has  used  multiple  ChIP  on chip  analyses  on a  genome-wide  scale  in
S.cerevisiae. In order to perform such an analysis  in  mammalian  cells,  one would
need  to  use  a  sequencing  technique  since  the  human  genome  only  contains
approximately  2% of coding  regions,  compared to  S.cerevisiae which  has a  much
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higher % of coding regions  [191]. Although ChiP-Seq is more precise,  the problem
lies in the cost of performing such experiments. Another major advantage to working
with yeast is  that genes can be endogenously tagged (e.g.  RRD1-MYC and  SPT15-
MYC), allowing the expression to be driven by their  endogenous promoter, giving
rise  to  the  expression  levels  that  aren’t  artificial  as  would  be  the  case  for  over-
expression plasmids.  This can be very useful for ChIP analyses,  in cases where the
antibody  directed  against  the  protein  of  interest  is  not  available.  However,  the
distance  of evolution between yeasts  and humans  is  significant;  therefore,  not  all
mechanisms are conserved. Thus, yeast is a great model to be used in research, but its
use  is  limited  to  initial  discoveries  and  analysis  of  basic  to  highly  complex
mechanisms,  which then need to be confirmed in  higher  eukaryotes.  Especially,  if
one takes into account the fact that yeast is a unicellular organism: It does not require
the integration of multiple  signalling  pathways-- such as those from neighbouring
cells,  multiple  (growth) hormonal signaling  pathways,  developmental processes and
cellular  differentiation  into  specialized  tissues.  Furthermore,  cancer  preventing
mechanisms  such  as  apoptosis,  although  known  to  be  present  in  yeast,  are  not
required to be highly controlled and regulated [192]. All these mechanisms add levels
of complexity  for  the integration of multiple  signalling  pathways  in  multicellular
eukaryotes which cannot be studied in yeast. 
3.12 Is the TORC1 complex regulated by superoxide anions? 
During  the progress of our work, a paper  was published  by another  group
proposing that the binding of Tor to the rapamycin-Fpr1 complex is inhibited by ROS
[124]. In this publication, the authors performed a genome wide mutant  sensitivity
screen in  response to rapamycin  [124].  Similarly  to other  published  screens,  they
identified  mutants highly  resistant  to rapamycin,  including  rrd1Δ and  gln3Δ [166,
167].  Since 2 of the 15 highly resistant mutants they identified were involved in the
oxidative  stress  response,  they investigated  whether  all  mutants  were  rapamycin-
resistant due to elevated levels of ROS. Their results showed indeed, all rapamycin-
resistant  mutants  displayed  elevated  ROS  levels,  when  compared  to  the  WT.
Furthermore,  they  showed  that  Tor  binding  to  the  Fpr1-rapamycin  complex  was
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inhibited when cells  had elevated levels of ROS. Therefore, they concluded that the
mutants were resistant to rapamycin not due to their function, but rather because they
displayed  elevated  levels  of  ROS.  We  disagree  with  their  conclusion  for  several
reasons. First, their experimental data is not conclusive. For example, they compared
total mRNA expression in gln3Δ and sod1Δ mutants to the expression in the WT and
concluded  that  expression  levels  were  different.  However,  if  this  difference  was
caused  by  the  elevated  levels  of  ROS,  one  would  expect  that  gln3Δ and  sod1Δ
mutants would display the same expression levels;  however, their expression levels
were strikingly different.  In addition, although the authors showed that all mutants
displayed elevated levels of ROS, they did not show a conclusive experiment where
elevated ROS levels  (e.g. induced by  H2O2) cause rapamycin-resistance in  the WT
strain. 
Also, besides showing that Tor does not seem to bind to the Fpr1 kinase, they never
demonstrated whether crucial downstream targets of the Tor signaling  pathway are
affected by elevated ROS levels (e.g. gene expression of Tor target genes). 
Second, if their hypothesis is true and strains bearing elevated levels of ROS
are  rapamycin-resistant,  theirs  and  other  genome  wide  drug  screens  would  have
identified multiple  resistant mutants bearing elevated ROS levels [166, 167], which
could  include  every  factor  involved  in  ROS  catabolism.  Surprisingly,  only  two
factors, a superoxide dismutase and its chaperone, render cells resistant to rapamycin,
when deleted. 
Third,  our  data  clearly  indicates  that  Rrd1  has  a  function  in  transcription
elongation, which does not exclude a role for Rrd1 in ROS metabolism. In contrast,
since  ROS is  a  form of stress,  transcription of genes would  be affected by Rrd1.
However, our data clearly reject the hypothesis that the  rrd1Δ mutant phenotype is
only  due  to  elevated  ROS  levels.  In  the  rrd1Δ mutant,  only  certain  groups  of
rapamycin-responsive  genes are affected,  which means  that despite  the absence of
Rrd1,  Tor  was  inactivated  by  rapamycin.  Furthermore,  TBP  recruitment  to  gene
promoters was similarly  affected in  the WT and the  rrd1Δ mutant, suggesting that
Tor signaling is functional in the rrd1Δ mutant. 
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As such, we only partially agree with the conclusions presented in Neklesa and Davis
(PNAS, 2008) and still  believe that most of the rapamycin-resistant mutants are so
because their gene products are somehow functionally involved in the Tor signaling
pathway. 
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4 CONCLUSION 
Transcriptional  regulation  in  response  to  environmental  changes  is  essential  for
survival  of  cells  and  allows  them  to  live  within  most  conditions.  Yeast  cells
constantly sense the environment and alter their transcription profile and metabolism
in response to the current condition. These pathways are conserved during evolution
and they allow us to adapt to multiple environmental conditions, including living in
hot or cold environments,  under strong sun exposure, under exposure to pollutants
such  as  cigarette  smoke,  food  restriction  or  excess.  Whether  these  pathways  are
perturbed in yeast cells or in humans they both cause an inability to adapt to stress
conditions  and  which  will  eventually  lead  to  disease  and  cell  death.  Therefore,
understanding  and  knowing  how  these  pathways  function  is  crucial  for  disease
treatment and prevention. We have used yeast as a model to identify a new factor that
is  involved  in  the response to stresses and from this  study we have  made several
conclusions which will be listed in a point form below:
 
4.1 Rrd1 is a transcription elongation factor required for the ESR in yeast
We have analyzed the role of the peptidyl prolyl isomerase Rrd1 in response
to  rapamycin  and  to  other  environmental  stresses.  Our  results  demonstrate  a
completely  new  role  for  Rrd1:  Rrd1  is  a  transcription  elongation  factor  that  is
required to regulate RNAPII gene transcription in response to environmental stresses
including, starvation, oxidative stress, and temperature stress. The precise mechanism
of  transcriptional  regulation  in  response  to  stresses  is  as  followed.  Rrd1  is  a
transcription  elongation  factor  that  isomerizes  the  CTD  of  RNAPII  and  this
interaction regulates RNAPII association with the gene.  So far this mechanism only
becomes prominent when cells are challenged with stresses that mediate a profound
transcriptional response. In this case, Rrd1 is  required to redistribute RNAPII. This
mechanism  is  additional  to  general  transcription  regulation  and  it  is  required  to
optimize  the  transcriptional  response.  It  is  likely  that  this  mechanism  acts  as  a
molecular timer for an optimal response to the environmental changes. It is not part
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of  the  fundamental  regulatory  mechanism  of  transcriptional  regulation  which
involves  the  transcription  factors  and  recruitment  of the  RNAPII  machinery,  but
rather,  an  additional  mechanism  of  regulation  that  allows  the  fine-tuning  of  the
transcriptional  response.  This  fine-tuning  seems  to  be  required  for  the  ESR  in
particular  since  although the ESR is  activated in  response to various stresses,  it  is
specific  for every stress [63]. Notably for oxidative stresses, most, but not all genes
are activated as in the heat shock or starvation stress response.  Therefore, multiple
steps of transcriptional regulatory circuits are necessary to precisely express the right
genes for the right condition. 
Herein  we  have  discovered  a  new  regulatory  mechanism,  which  regulates
transcription during the elongation phase after assembly of the pre-initiation complex
and recruitment of RNAPII.
4.2 The reason why rrd1Δ mutants have pleiotropic phenotypes
rrd1Δ  mutants  have  been  found  by  multiple  labs  to  have  a  variety  of
phenotypes. These mutants are resistant to rapamycin and caffeine but hypersensitive
to 4NQO, H2O2, NaAs, UVA, Vanadate, Ca2+, ketokonazole and cycloheximide. This
always  begged  the  question  why  rrd1Δ mutants  are  resistant  to  some  agents  but
sensitive to others.  We are the first  to be able to provide a logical answer. Rrd is
required  for  an  optimal  transcriptional  response  to  environmental  stresses.  Since,
most  of  these  drugs  stimulate  the  ESR  response  (besides  cycloheximide  and
ketokonazole),  it  is  likely  that  rrd1Δ mutants  are  hypersensitive  to  these  agents
because the transcriptional response is not adequate and cells will eventually die out
because of the cellular  toxicity.  However, for rapamycin  and caffeine  (which only
mimic starvation and oxidative stress respectively (see 1.1.8.1 and 1.2.2)), but do not
actually  cause a nutrient  depletion or ROS,  rrd1Δ mutants become resistant  as no
adequate stress response is  activated and there is  no cellular  toxicity and sufficient
nutrients  are  available  for  continued  growth.  WT  cells  will  activate  the  ESR  in
response to both agents with the consequence of growth inhibition. 
We note that the drug ketokonazole, which is known to inhibit  ergosterol synthesis,
might also cause a sort of ESR. This is probably because of a lack of ergosterol. This
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lack  could  be  regarded  as  a  form of starvation that  activates  an ESR to increase
uptake of components required for  ergosterol synthesis.  Finally,  the sensitivity  to
cycloheximide  could  be explained  by the fact  that  since  translation is  inhibited,  a
transcriptional stress response is activated to increase ribosome gene expression, and
rrd1Δ mutants might not be able to adequately mediate this response. 
4.3 Rrd1 is the second PPIase that isomerizes the CTD of RNAPII
We  demonstrate  that  a  second  peptidyl  prolyl  isomerase  is  required  to
isomerize the CTD of RNAPII besides Pin1/Ess1. Ess1 is  thought to isomerize the
CTD of RNAPII to alter its phosphorylation status, thus allowing the recruitment of
transcription  termination factors (Nrd complex)  in  order  to  arrest  transcription  of
snoRNA  [44].  Rrd1  also  isomerizes  the  CTD  of  RNAPII  and  alters  the
phosphorylation status of the CTD. In both cases,  when  RRD1 or  ESS1 genes are
mutated, serine 5 phosphorylation is  altered. However, the outcome is different for
rrd1Δ mutants as one only observes a transcriptional defect under stress conditions.
Furthermore, we exclude the possibility  that Rrd1 may be involved in  transcription
termination as we would have observed an accumulation of RNAPII on the 3’ end of
the  gene  in  an  rrd1Δ  mutant  as  was  observed  for  the  ess1-TS   mutation  [44].
Therefore, we suspect that Rrd1 is likely to act on serine 5 phosphorylation within the
5’ region of the gene, regulating the elongation of RNAPII. This is  also consistent
with  the fact  that  under  stress  conditions,  the Rrd1 regulated  genes  are less  well
transcribed  in  an  rrd1Δ mutant.  However  it  would be interesting to determine  the
phenotypes of an ESS1-RRD1 double deletion strain. Ess1 is essential,  but there are
thermosensitive mutants which could be used for that. 
It  is  not  surprising  that  another  PPIase  that  isomerizes  the CTD has  been
discovered, since the highly conserved structure of the CTD (YSPTSPS)n, contains 2
prolines per heptapeptide.  The CTD is seen as a recruitment  platform for multiple
elongation factors and needs to be highly modifiable so that different factors can be
ejected and  recruited  during  the  transcription cycle  [7-9,  193].  This  can  be  done
through  phosphorylation  of  serine  2,  serine  5  and  serine  7,  as  well  as  through
isomerisation by Ess1  and  Rrd1.  Thus,  one  can only imagine  the  possibilities  of
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different conformations that may arise when one takes into account that in yeast there
are only 26 repeats of the heptapeptide as compared to up to 52 repeats in mammals
[193]. 
4.4 The new role of Rrd1 might be conserved during evolution
Pin1  is  evolutionally  conserved  and  in  humans  it  plays  multiple  roles
including immunological responses, cancer and diseases such as Alzheimer’s  [186].
Since  Rrd1  is  also  evolutionary  conserved,  its  human  homologue  PTPA  might
perform a similar  function as does Rrd1 in yeast. Preliminary data already suggests
that this might be the case since PTPA was also capable of isomerising the CTD in
vitro (unpublished  data).  In  addition  we  and  others  have  shown  that  the
overexpression of PTPA can complement  for the lack of  RRD1 gene in yeast  [74].
We predict here that if its role in transcription elongation is conserved it would play a
role in many biological processes and thus might be important to prevent disease and
cancer. Mammalian cells also need to respond to environmental stresses such as heat
shock, starvation and oxidative stresses.  Therefore,  it  would not be surprising  that
similar  mechanisms of transcriptional regulation are present as the one we found in
yeast. 
A simple strategy would be to use rapamycin,  since it is used in clinics as an
immunosuppressant as well as for kidney carcinoma [160, 161]. So far, knockdown
strategies have not been supportive, which could be because we are yet  to obtain a
strong  knockdown  of  the  protein.  The  other  alternative  to  studying  PTPA  is  to
produce knockout cell lines and we are currently generating a PTPA knockout mouse
which will allow us to better study the function of this protein. Besides these efforts,
it would also be interesting to investigate the role of Rrd1 in other yeast species such
as  S.pombe or  C. albicans, in  order to know if this  function is  conserved in  these
yeast species as well. So far no publications are available in this regards.
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4.5 Rrd1 as a potential drug target 
 Pin1/Ess1 was found to be inhibited by the molecule juglone, and this could
be used in clinics for disease treatment [194]. It turns out that the unique structure and
the high substrate specificity of these PPIases makes them interesting drug targets.
Similarly, the unique structure of PTPA and its substrate specificity might also allow
for the generation of specific  inhibitors of this protein [93]. This would be another
reason to continue the investigation of the function of Rrd1/PTPA in other organisms.
4.6 Rrd1 has multiple cellular roles 
Rrd1 was first  described to be a phosphatase activator required to stimulate
the  in  vitro phospho-tyrosyl  phosphatise  activity  of  serine/threonine  PP2A
phosphatases. Subsequently, it was shown that it is a peptidyl prolyl isomerase that is
required for phosphatase assembly and substrate specificity in vivo. Rrd1 associates
with at least three phosphatases and multiple  roles have now been discovered: Rrd1
associates with Sit4 and Tap42 to dephosphorylate Gln3 upon Tor signaling, although
this function is controversial (see 1.2.8). We have now shown that Rrd1 interacts with
RNAPII on actively transcribed genes. We also have the first indication that Rrd1 is
indeed acting through isomerisation as the catalytic  inactive Rrd1 (D200G) protein
was unable to release RNAPII from the chromatin  in vitro (see section 3.8). Finally,
during the writing of the thesis,  new research was published showing  that  Rrd1 is
involved in telomere healing as it was found to activate the Pph3 phosphatase [187]f.
Thus, Rrd1 is involved in different  cellular mechanisms  and more roles may yet be
discovered for  it.  It  is  noteworthy that  Pin1  has  over 30 cellular  targets and it  is
involved in various cellular pathways (see 1.2.5). 
This clearly shows that contrary to the previously held belief, PPIases have additional
roles  besides  their  function  in  protein  folding.  As  was  shown  for  FKBPs  and
cyclophilins,  the parvulins  and the PTPA family,  PPIases are likely  to continue to
surprise investigators. 
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With  the  help  of  modern  molecular  biology  techniques  we  were  able  to
describe a so far uncharacterized regulatory mechanism of transcriptional regulation
which involves the PPIase Rrd1. However, this was only the ground work description
of  a  novel  mechanism.  There  are  still  a  lot  of  open  questions  that  need  to  be
answered: How is  Rrd1 regulated by itself?  What  are the other factors required to
mediate RNAPII release? What is the exact function of Rrd1 under normal growth
conditions?  But  the main  question we would  like  to address is  if  this  function is
evolutionary conserved. Future work should shed light on these questions.  
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5 PERSPECTIVES 
As  mentioned  above  this  study  has  presented  the  groundwork  of  a  new
mechanism of transcriptional regulation. Although we now have a model which is
supported by extensive experimental data, we do not know all the answers and further
experiments are required in order to fully elucidate this mechanism. In addition, many
questions arise from our proposed model, which will be addressed in this section in a
point form: 
 How does Rrd1 choose which gene to regulate?
The data from our genome-wide analyses  allowed us to make the observation that
Rrd1 is associated with RNAPII on a large subset of genes (see chapter 2.2 figure 1).
However, in response to rapamycin,  Rrd1 did not have an effect on every gene, but
rather on a specific  group of genes that are downregulated and a group of genes that
are upregulated. Therefore, it  would be interesting to investigate how Rrd1 is active
on these specific genes but not on the others, although they are regulated by the same
transcription factors. 
Proteins  with  regulatory functions  are often regulated by  post-translational
modifications  and as  a  starting  point  it  would  be  interesting  to analyze  the post-
translational modification of Rrd1 found using mass spectrometry. A close example is
Pin1,  which  has  been  shown  to  be  phosphorylated  and  also  oxidised,  two  post-
translation  modifications  which  alter  the  isomerase  activity  of  Pin1  [109].   As
previously stated, we have found a potential ubiquitylation site of Rrd1 on the K236.
Ubiquitylation is  not only known to target degradation of the ubiquitylated protein
but  also  to  regulate  localization,  protein-protein  interactions  and  protein  activity.
Therefore this ubiquitylation site might  provide cues on how Rrd1 is  regulated and
how it chooses specific  genes on which to regulate RNAPII. To test this, a K236R
mutation  could  be  introduced  into  the  RRD1 gene  in  order  to  express  an
ubiquitylation deficient mutant protein. With this, we then can test the isomerisation
of the CTD using CD, or test whether this mutant is able to release RNAPII from the
chromatin as we have shown for the catalytic  mutant (see figure 9). There are two
further  questions:  does Rrd1 become ubiquitylated upon rapamycin  treatment,  and
does it  interact with  RNAPII when it  is  in  its  ubiquitylated form. These could be
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tested  by  co-immunoprecipitation  experiments  with  RNAPII  and  then  with  an
ubiquitylation specific  antibody to see if Rrd1 is ubiquitylated when pulled down by
RNAPII.  Initial  experiments  have  already  been  conducted  but  the  ubiquitylation
specific  antibody was of poor quality  and therefore,  the results  were inconclusive
(data not shown). The hypothesis of ubiquitylation of Rrd1 could also be addressed in
a genetic way. For example by testing whether the deletion of ubiquitin ligases affect
the phenotypes of rrd1Δ mutants. There are multiple ubiquitin ligases, but one (Rsp5)
would be of special interest as it  has been shown to ubiquitylate RNAPII  and its
vicinity within the elongation machinery makes it a possible ubiquitin ligase of Rrd1
[195].  Nathalie  Jouvet  has  performed  complementation  assays  showing  that
overexpression of RRD1 from a plasmid abolishes the hypersensitivity of an rsp5-TS
mutant towards rapamycin thereby supporting a potential genetic interaction between
Rsp5 and Rrd1. 
A second way to investigate how Rrd1 regulates gene expression is to analyze
whether recruitment of proteins to the CTD of RNAPII are affected by the action of
Rrd1. We have shown that the isomerization of RNAP’s CTD by Rrd1 engenders a
profound  alteration  of  the  secondary  structure.  In  addition,  we  know  that  the
phosphorylation status of RNAPII is also altered in an rrd1Δ mutant, especially  for
serine  5  phosphorylation.  As  it  is  widely  accepted that  the CTD of RNAPII  is  a
recruitment platform for several elongation factors during the transcription cycle, and
that the phosphorylation status and the conformation of the CTD are crucial for the
timely coordinated recruitment  and exchange  of these factors,  Rrd1 could use this
mechanism to recruit other factors that then regulate transcription. To test this, one
could develop an in vitro CTD binding assay where total cell extracts are added either
before or after isomerization of the CTD by Rrd1 (similar to [196]). We would expect
then that depending of the CTD configuration, different factors might associate with
it. The identity of the factors associated would then be determined by silver staining
and subsequent  mass spectrometry analysis.  An alternative experiment  would be to
monitor the recruitment of known transcription elongation factors including Paf1, the
CTD phosphatases,  FACT  or  Spt4/5  to  a  model  gene  (e.g.  PUT4 or  RPL32)  in
response to rapamycin. This can be done in a similar manner as our demonstration of
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the recruitment  of RNAPII and Rrd1-MYC to these genes,  using ChIP-QPCR (see
chapter 2.2 Figure 3).
 How is RNAPII released from transcribed genes?
rrd1Δ mutants  display  an  elevated  level  of  the  serine  5  phosphorylated  form of
RNAPII on certain genes. This suggests that RNAPII might be slowly transcribing on
these genes, meaning that it maintains a slow transcriptional rate [154]. Therefore, it
would  be  interesting  to  test  whether  Rrd1  influences  transcription  elongation  by
regulating the transcriptional rate of RNAPII. As mentioned previously (see section
3.7) [185], another group has developed a transcriptional run-on assay that measures
the transcriptional rate of RNAPII. It would be of significant interest to run this assay
in an rrd1Δ mutant as our model of transcriptional regulation by Rrd1 is based on this
principle.   
An alternative would be to test factors that associate with the Rrd1-isomerized
CTD in an in vitro RNAPII transcription assay. For example,  does the transcription
change when Rrd1 is added to the in vitro assay?  If this is the case, which factors are
required  to  mediate  the  effects  of  Rrd1?  We  have  already  performed  intitial
experiments  where  addition  of  Rrd1  increases  the  transcription  of  RNAPII
(unpublished data, collaboration with Luc Gudreau USherbrooke). Now to find which
factor is required to mediate the effects of Rrd1 we could use cell extracts that lack
specific  factors  (e.g.  the  above  mentioned  transcription  elongation  factors)  and
monitor  if  Rrd1  still  enhances  transcription.  This  would  determine  which  factors
mediate the regulatory effects of Rrd1 in vitro.  This could then be further tested in
vivo using genetics and ChIP assays.  
 Identification of additional Rrd1 substrates
As  mentioned  previously,  it  would  be  interesting  to  determine  whether  Rrd1
isomerizes other factors than PP2A and the CTD of RNAPII. This is not an easy task
since  it  is  not  easy  to  measure  proline  isomerization  as  it  is  to  monitor
phosphorylation or ubiquitylation.  A more complex  strategy is  necessary to study
proline  isomerization.  The  first  step  would  be  to  exactly  identify  the  CTD
configuration (phosphorylation status) that  is  necessary for it  to be isomerized by
Rrd1. Next, the exact sequence surrounding the proline isomerized by Rrd1 needs to
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be  identified.  From this  information,  one  can use  sequence  similarity  to  identify
potential other substrates of Rrd1. 
An alternative way to identify potential Rrd1 substrates would be to use a co-
purification  assay.  Although  protein-protein  interactions  have  been  performed  on
virtually  every protein in  yeast, none of these studies have identified RNAPII as a
partner of Rrd1  [197, 198]. Therefore, one would need to optimize  the conditions
necessary to  identify  novel  partners  of Rrd1.  Our  unpublished  data  from tandem
affinity purification assays of Rrd1 suggests that Rrd1 interacts with components of
the mediator complex as well as the Swi/Snf chromatin remodeling complex. These
complexes, which are also involved in transcription, might be potential targets of the
isomerases activity of Rrd1.
Furthermore,  the  fact  that  Rrd1  influences  serine  5  phosphorylation  of
RNAP’s CTD suggests that a phosphatase or kinase might be a target of Rrd1. Since
only a limited set of kinases (Kin28) and phosphatases (Ssu72 and Rtr1) are known to
influence  serine  5  phosporylation,  it  would  be  worthwhile  to  test  whether  these
enzymes are actually isomerized by Rrd1 [199, 200]. This could be done similarly to
what was shown for the CTD of RNAPII in vitro.
  Is the role of Rrd1 conserved throughout evolution?
This  is  the  most  exciting  question  to  investigate  since  it  could  be  of  medical
importance. This question should be addressed not only in mammalian  systems but
also  in  other yeast  species  such as  S.pombe and  C.albicans.  For  investigations  in
other yeast species, the strategy would be to first analyze if the phenotypes of rrd1Δ
mutants  that  were  observed  in  S.cerevisiae also  occur  in  these  other  yeasts.
Furthermore, it would be of interest to test whether Rrd1 interacts with and regulates
RNAPII in these yeast species.  
To test the role of PTPA in mammalian cells, multiple strategies can be used.
First a knockdown of PTPA expression using siRNA or shRNA might  allow us to
study its  response  to  rapamycin  (in  progress).  Second,  the generation of a  PTPA
knockout  mouse  to  better  analyze  the  multiple  roles  of  PTPA  in  vivo, such  as
development would most definitely provide some answers. 
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Third, the analysis of protein-interactions in mammalian cell extracts using different
immunoprecipitation techniques  would  be  required  for  the validation of our yeast
model. We need to confirm whether PTPA interacts with RNAPII and whether PTPA
is recruited to chromatin.  
Fourth, it  would be interesting to verify if  PTPA is required for the rapamycin and
oxidative stress response: Since rapamycin inhibits B-cell and T-cell proliferation, it
would be interesting to investigate whether PTPA is required for this process [160]. 
Our group has  recently  published  that  the overexpression of PTPA stimulates  the
apoptosis of mammalian cells, clearly indicating that PTPA plays an important role in
cell viability [201]. Furthermore, in vitro analyses have shown that purified PTPA is
capable of isomerizing the CTD of RNAPII (unpublished data). These data encourage
further investigation into the cellular functions of PTPA in mammalian cells. 
Taken  together,  the  work  that  led  to  the  model  of  Rrd1  transcriptional
regulation in response to environmental stresses opens up a lot of questions that are of
interest to the scientific  community and of likely medical interest as well.  First, the
model needs to be further tested in the yeast S.cerevisiae, in order to establish Rrd1 as
a new transcription elongation factor. Then, it  needs to be determined whether this
mechanism occurs in other yeast species as well. Finally,  the main focus should be to
analyze the evolutionary conservation of this mechanism in higher eukaryotes such as
mammals, with relevance to development, cancer  and various other diseases.  
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